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Thesis summary   
 
Age related macular degeneration (AMD) is a major cause of blindness in human 
beings. AMD negatively impacts on the quality of life of patients and has severe economic 
implications because of impaired or loss of sight. Globally, eye diseases cost the health 
system about three trillion USD. In Australia the total economic cost of vision loss associated 
with AMD was in excess of 5 billion in 2010. In Australia, at the age of 50 and over, one in 
seven people are affected by AMD due to the influence of risk factors including aging, 
smoking, and family history. There are two stages of AMD, early and late. In the early stage, 
there are changes in retinal endothelial and retinal epithelial cells (RPE) which lead to the 
thickening of Bruch’s membrane (BM) and a loss of central vision. Understanding the 
processes and mechanisms involved in the regulation of proteoglycan (PG) expression is 
critical to understanding the various functions of endothelial and epithelial cells. BM 
constitutes the boundary between retina and choroid and the thickening of BM is associated 
with the deposition of PGs and glycosaminoglycan (GAG) in the tissue. Moreover, GAG 
can bind to lipids and form hyperelongated GAG. PGs with elongated GAG which are long 
molecules (Glycosaminoglycans are long unbranched polysaccharides consisting of 
repeating units of an amino sugar with a uronic sugar) that if too large (MW   15~27 kD) to 
pass through BM, can result in the accumulation of PG and elongated GAG and that may 
start to form drusen. 
The pathophysiology underlying the early AMD is not fully understood and there 
are currently no therapies targeting this stage. Early AMD is more prevalent than late AMD 
and early AMD. Therefore, the aim of this study was to investigate the role of selected 
growth factors on PG synthesis and GAG elongation in retinal endothelial and epithelial 
cells assessing their potential impacts on AMD.  
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The results obtained from this study showed that transforming growth factor beta 
(TGFβ), thrombin, platelet-derived growth factor (PDGF) and insulin-like growth factor 
(IGF) dose-dependently stimulated the retinal endothelial cells to synthesise PGs with 
elongated GAG chains. However, vascular endothelial growth factor (VEGF) did not 
stimulate PG synthesis nor GAG elongation which was surprising as anti VEGF is widely 
used in the treatment of late AMD. This study therefore investigated the effect of VEGF on 
both the phosphorylation of the poly functional ERK and ubiquitous serine/threonine protein 
kinase AKT. There are several pathways involving ERK to GAG hyper-elongation which 
are activated by VEGF. 
Investigations of the effects of these growth factors on the genes involved in mRNA 
expression of PGs synthesis and GAG elongation enzymes; xylosyltransferase-1 (XT-1), N-
acetylgalactosaminyltransferase-2 (ChGn-2), Chondroitin polymerizing factor (ChPF), 
Chondroitin sulfate synthase-1 (ChSy-1), Chondroitin 4-O-sulfotransferase-1 (C4ST-1) and 
Chondroitin 4-O-sulfotransferase-2 (C4ST-2) showed that TGFβ, thrombin and PDGF 
treatment stimulated the retinal endothelial cells to express the mRNA of enzymes required 
to synthesise elongated GAGs. These findings supported the study hypothesis; growth 
factors affect PG synthesis and GAG elongation, alter extracellular matrix (ECM) 
composition of RF/6A cells and consequently may impact on early changes in AMD. 
In the RPE cells, the observed effect of TGFβ, thrombin, PDGF, IGF and VEGF on 
RPE was unexpected as none of these growth factors except thrombin stimulated the 
synthesis of PGs. Indeed, there was no lipid binding PGs secreted by RPE cells. Thrombin 
treatment generated a PG band approximately 260-340 kDa on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel. This band was subjected to further 
investigations to determine its release mechanism. Through a series of experiments, it was 
determined that thrombin treatment resulted in cell surface PG shedding via thrombin 
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proteolytic activity rather than a protease-activated receptor (PAR-1) mediated shedding 
process. The cell surface shed PG could be playing vital roles in binding growth factors, 
influencing growth factor activities and transportation. The shed PGs could be of heparin 
sulphate (HS) which are highly sulphated soluble molecules that kept their HS moiety. These 
likely heparin sulfate moieties are potentially reactive for the ECM, where they would have 
subsequent effects on AMD.  
The roles of the growth factors were evaluated especially in regard to causing 
alterations in ECM composition. Changes in ECM composition have direct impact on 
cellular metabolism and waste accumulation which could lead to morphological changes to 
retinal endothelial and epithelial cells. These morphological alterations cause the gradual 
thickening of BM and accumulation of sulphated PGs which at a certain point, could trigger 
the secretion of growth factors. Associated with this secretion stage was the breakage 
(degenerative changes to the barrier-forming cells) of the blood-retinal barrier (BRB) and 
exposure of cell surface PGs to the direct effect of thrombin. This would result in excessive 
shedding of cell surface PGs and the accumulation of shed PGs. 
Growth factors can regulate the synthesis of PGs and GAG elongation in the retinal 
endothelial cells. This could directly affect waste accumulation and alter ECM composition 
causing BM thickening in early stage AMD. In the retinal epithelial cells, thrombin was 
observed to play a crucial role in the shedding of cell surface PGs which would allow the 
disease to progress to the late stage. 
Future research should explore the role of growth factors in regulating PG 
metabolism in the retina with an established role of GAG elongation and lipid binding. Our 
interesting finding of PG shedding plays a crucial role in retinal disease progression, requires 
investigation of the structure and role of shed PGs in AMD.  
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1. Chapter 1: Introduction  
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1.1 Overview  
The eye is an important part of the body as it is crucial for the provision of vision 
in many animals, including humans. Consequently, eye diseases which cause partial or total 
impairment of vision can have severe negative impacts on not only human health but also 
on the socio-economic lives of affected individuals [1]. Age-related macular degeneration 
(AMD) is a good example of an eye disease that often starts in patients aged 50 or over that 
eventually damages the centre of the retina. The initiation site of AMD is Bruch’s membrane 
(BM) with many changes occurring therein. These changes include the deposition of plasma 
derived lipids, accumulation of extracellular debris and structural changes in BM 
morphology. Morphological changes in BM can lead to the formation of the drusen and alter 
BM layers. Therefore, assessing changes in cell function in the different layers of BM and 
during the early stages of the AMD with special focus on retinal pigmented epithelial cells 
(RPE) and retinal endothelial choroid cells, is crucial to understanding the pathogenesis of 
AMD [2]. 
Proteoglycans (PGs) such as leucine-rich PGs decorin and biglycan are a type of 
complex carbohydrate molecule that affect lipid retention in different organs and tissues [3]. 
In the lipid deposition type diseases such as atherosclerosis, modified PGs retain and bind to 
apolipoproteins in the artery wall. These chemically modified trapped lipids are 
immunogenic and can initiate a chronic inflammatory process evident as atherosclerotic 
plaque leading to artery blockages, heart attacks or strokes [4-7]. In addition, plasma derived 
lipoprotein deposits are found in BM in early AMD and it is possible that lipoprotein 
resulting from a similar process occurs within the macula [7-12]. 
This chapter will review the current knowledge of the synthesis and behaviour of 
PGs in the retina and specifically in relation to AMD disease. The effects of selected growth 
factor signalling pathways associated with the retina (and the pathogenesis of AMD) will 
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also be reviewed. The positive and negative impacts of the ECM on BM layers in particular 
on retinal choroidal endothelial cells and epithelial cells will be assessed. The various genes 
involved in the mRNA expression of glycosaminoglycan (GAG) enzymes will be 
investigated in relation to AMD. Gene mRNA expression of these specific enzymes, XT-1, 
ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 will be studied. Other mechanisms and 
processes of the release of PGs involving RPE will also be reviewed in this chapter. These 
different investigations should allow for the evaluation of this thesis’ hypothesis which is 
that “growth factors impact PG synthesis and GAG elongation in retinal endothelial and 
epithelial cells [13]. 
1.2 Retinal disease 
The eye is responsible for vision and it is an extension of the neural system as it 
shares physiological and anatomical characteristics with the brain [14]. Eye diseases are very 
common and have the potential to impair the vision and affect daily activities. Examples of 
eye diseases include AMD, glaucoma, cataract, diabetic retinopathy, neuro-ophthalmic and 
refractive error [14, 15]. Globally, eye diseases cost the health system about three trillion 
USD with eye diseases in Australia costing the health system 9.85 billion AUD in 2004. In 
Australia the total economic cost of vision loss associated with AMD was in excess of 5 
billion in 2010 [16-18].  
The various tissues and components of the eye are designed to serve the function of 
forming clear images of an object that is transmitted to the brain through the optic nerve, as 
shown in Figure 1.1 [14]. The retina is located on the inner surface of the eye where it is 
involved in the processing of visual images [19]. The retina is light sensitive and has a very 
complex structure which likely contributes to its vulnerability in injury to alteration due to 
injury [19]. Therefore, retinal diseases are a major group of eye diseases that can cause 
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reversible and irreversible damage (blindness) [20]. Examples of retinal degenerative 
diseases include AMD, glaucoma, diabetic retinopathy and retinitis pigmentosa [16, 21].  
The retina consists of various highly interconnected cell types such as pigment 
epithelial, photoreceptors, outer limiting membrane, Muller cells, horizontal cells, bipolar 
cells, amacrine cells, ganglion cells, nerve fibre layer and inner limiting membrane [16, 22].  
The retina converts focused light from the lens into a form of neural signals which are sent 
to the brain for visual recognition [21, 23]. Diseases of the retina interfere with this process 
and consequently affect vision with AMD (a type of retina disease) affecting 8.7% of the 
world population [24]. AMD in particular causes thickening of BM (a thin layer of ECM 
between RPE and choriocapillaris), a vital part of the retina with the unique permeation 
properties important in the transfer of nutrients inside the cells and waste out of the cells [9]. 
Many changes occur during the development of AMD; these include formation of drusen 
(lesion in the macula), choroidal atrophy, oxidative stress, apoptosis, RPE dysfunction and 
BM alteration [25-27]. In addition, there are links between AMD and other retinal diseases 
such as retinopathy diseases which cause acute damage to the retina [28]. Inflammation and 
trauma, solar retinopathy, radiation retinopathy, purtsche retinopathy, hyper viscosity 
retinopathy, diabetic retinopathy, hypertensive retinopathy are associated with retina 
damage [29]. Although diabetic retinopathy, retinopathy of prematurity and AMD take place 
at different locations in the retina, they share a common element which is the growth of 
blood vessels and penetration of the retina [30-32]. 
There is a need for more research into AMD in order to address gaps in scientific 
knowledge especially with regard to clarifying its position in relation to other retinal disease 
[33]. This could be in terms of the mechanism and degree of damage associated with AMD, 
which is defined as any malfunction in any part of the retina [34].
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Figure 1-1 Basic structure of the eye 
 
 
Diagram showing the basic structure of the eye and the various components in the front of 
the eye: iris, cornea lens and pupil. The back of the eye is where the macula is located (black 
circle) and it is part of the retina; a key site for AMD.  
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1.3 Eye structure: Macula and BM 
The ocular fundus of the eye consists of five parts, namely the macula, retina, optic 
disc, fovea, and posterior pole and includes BM which is part of the choroid as illustrated in 
Figure 1.1 and 1.2 [9, 35, 36]. There are two types of photoreceptors in the eye; rod and cone 
cells [37]. Rod cells support vision at low light levels and are used in peripheral vision. On 
the other hand, the cone cells function best at bright light and are responsible for colour and 
central vision [38]. The macula contains comparatively more cones and photoreceptors than 
the rest of the retina, and thus it plays a vital role in the central vision and acuity enhancing 
the resolution of details. The macula is also the most affected part of the eye by AMD disease 
[39].  
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Figure 1-2 Retinal layers at the macula 
 
Retina consists of five parts: Macula, Fovea, Photoreceptor cells, RPE cells and BM. The 
macula is part of retina and the site for AMD disease. Choroid cells are of endothelial origin, 
and from this layer the nutrients pass via BM to the RPE cells, photoreceptors and all other 
eye tissues and through this layer, cellular wastes are disposed outside of the eye.  
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The outer retina consists of a multilayer network of interdependent cells and 
contains the BRB which is the highest oxygen consumer in the human body (weight to 
consumption ratio) [40]. This BRB is selectively permeable, immune privileged, and is 
important in maintaining homeostatis in the retina. Breakage in the BRB is a key milestone 
in the progression of AMD. 
BM is another important site in the retina and is the key site for AMD development 
[41, 42]. Defects, damage or disorders to BM can lead to loss of its functions and are 
especially dangerous if they affect key functions such as those involving the transit of waste 
from RPE cells and photo receptors to the choroidal vessels as explained in Figure 1.3. In 
AMD, early altered function can be identified as a thickening of BM [43]. 
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Figure 1-3 Function and structure of BM 
 
The unique permeability property of BM, is lost when BM starts thickening. BM consists of 
five layers of ECM; retinal pigmented epithelial (RPE) basement membrane, inner collagen, 
elastin, outer collagen and choroid basement membrane [41]. There is strong evidence that 
a strong relationship between Choroidal neovascularization (CNV) formation and RPE 
exists [34, 42, 44-47]. 
 
  
13 
 
Alteration to BM thickness as shown in Figure 1.4 could result from the increase in 
the levels of lipid deposition as a result of positively charged lipids and lipoproteins binding 
to negatively charged PG. Lipid deposition is a key event in early atherosclerosis and altered 
PG synthesis and structure. Increased GAG chain sulfation status and/or length, results in an 
increased lipoprotein to PG binding ratio and greater deleterious lipid deposition [5, 11, 47-
50]. The extent to which this process occurs in AMD is still not clear. 
Normal ageing is the strongest risk factor for AMD [24]. Ageing results in 
deposition of lipid, phospholipids, triglycerides, fatty acids and free cholesterol in BM [51]. 
However at some point, a lipid wall forms in BM which affects movement of molecules with 
consequences for RPE function [52, 53]. Major alterations in the composition of BM take 
place in the early stages of AMD [54]. The first marked effects of the disease appear in RPE 
cells, as abnormal cellular pigmentation occurs and  lipids and protein start to accumulate to 
form a yellowish deposit which is called drusen [55]. This project’s hypothesis is that these 
alterations to BM and RPE cells are consequences of other alterations such as altered PG 
synthesis,  structure, and sulfation and increased lipoprotein to PG binding ratio [5, 11, 47, 
48, 50, 56, 57].  
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Figure 1-4 Alteration to BM thickness 
 
Thickening of BM is due to accumulation of cell debris, lipids and protein. This alteration 
to BM thickness is the first clinical hallmark of early AMD [11, 54, 58]. 
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Non-focal AMD laminar deposits such as BLinD and BLamD are similar in content 
and site of deposition as drusen. However, they form thin layers which are associated with 
an early thickening of BM and along with soft drusen, are more commonly found in the 
central macula [59]. BLamD are found alongside BM, at the RPE basal laminar and contain 
cholesterol as well as other lipoproteins [11, 43]. 
Drusen formation is a main characteristic of early AMD. Drusen are focal deposits 
between the basal lamina of the RPE and the inner collagenous layer of BM. They contain 
proteins, lipoproteins, including apoB, apoE, and lipids such as cholesterol and 
phosphatidylcholine [60-62]. Drusen are multicomponent and heterogeneous structures that 
extend in their size externally and internally to the RPE. The formation of the drusen occurs 
over a period of years (sometimes up to 10 years) and eventually the formation of drusen 
can lead to the death of the RPE cells [11, 35, 39, 63]. In non-diseased aged macula, small 
drusen can exist without significant effects on cell function [64, 65] but numerous larger 
drusen are more commonly associated with AMD [66, 67].  
The other progressive features of AMD include BM thickening, geographic atrophy 
(GA), RPE atrophy, BM and RPE degeneration and Choroidal Neo Vascularization (CNV) 
[68, 69]. Although the CNV is the result of more than 40 diseases, it is also a diagnostic 
feature of the wet stage of AMD. The most influential factor that controls the process of 
CNV formation is BM which plays a vital role as a shield or barrier against the penetration 
of capillary blood vessels into the retina and the subsequent progression of CNV [42]. 
1.4 Age related macular degeneration 
AMD develops from the age of 50 [33] and damages the centre of the retina, 
specifically the macula as shown in Figure 1.5 leading to a gradual decline in vision [70, 71]. 
It causes blurring and distortion of the central vision and affecting its functionality such as 
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those associated with reading, driving, face and colour recognition [72, 73]. In developed 
countries, AMD is a common cause of blindness in the elderly and is responsible for 9% of 
blindness worldwide [46, 47, 74-80]. Moreover, AMD is ranked third globally after cataract 
and glaucoma as the main cause of blindness [52, 81-83]. In Australia at the age of 50 and 
over, one in seven people are affected by AMD due to the influence of risk factors such as 
ageing, smoking and family history [18, 35, 77, 84, 85]. 
The retina facilitates central vision and contains photoreceptors. Thus, any damage 
to the macula is identified by a black spot that causes loss of central vision as shown in 
Figure 1.5 [71, 84]. Understanding retinal structure and its components is important for a 
more detailed understanding of AMD pathogenesis [39, 41, 86, 87]. Several studies have 
reported the interrelationship between RPE, BM, photoreceptors and choriocapillaris [88, 
89]. RPE loss is reportedly associated with atrophy of choriocapillaris and choroid, which is 
the early detectable changes in AMD [88-90]. The key site for initial changes in AMD is 
BM, a structure located in the middle of the retina and choroidal circulation [91, 92]. BM 
plays crucial functional roles which includes forming a physical barrier against the invasion 
of new vessels into the retina, exchange of oxygen, nutrients and waste products between 
RPE and choriocapillaris, the mechanism of cell to cell communication, cellular 
differentiation, proliferation, migration and tissue remodelling [42, 43, 63]. The major 
changes to the BM in the early stages of AMD include abnormalities of the ECM component 
PGs, with these being potentially associated with an increase in lipoprotein to PG binding 
and consequently altered BM functionality [2, 13, 56, 92, 93]. 
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Figure 1-5 Effect of AMD on the central vision of objects 
The left side photo shows the vision of the normal eye while the right photo shows the effect of AMD on the central vision of objects. AMD causes 
big black spots in the centre of vision which affect the patient’s daily life practices by impairing central vision including recognition of hazards, 
reading, visualizing objects while driving and recognising facial features.
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The early pathological features of AMD have led to the hypothesis that it can be 
considered a disease similar in some aspects to atherosclerosis and glomerulosclerosis which 
involve lipid deposition. Previous research has focused on cell degeneration in AMD but our 
interest is in the role of growth factors and hormones on the synthesis and structure of PGs 
which are known to bind lipids in the ECM [4-7, 94, 95]. Research to date has generated 
some treatments for late stage AMD but there has been comparatively fewer investigations 
of potential treatments for the early stages of AMD such as early lipid deposition [5, 48, 95-
99]. 
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1.5 Classification of AMD 
Generally all AMD classifications aim at providing information about each stage 
of the disease, but to date there is no universally adopted staging of AMD [100] although a 
detailed classification is available from the age-related eye disease study (AREDS) [101-
104]. AMD is classified into 2 stages: The first stage is composed of 2 types, early AMD 
based on the presence of drusen and indicative of early stage pathology and dry AMD which 
is manifested by GA [105]. The second stage is late AMD based on the penetration of 
choroidal blood vessels into the retina, (Figure 1.6) [39, 72, 106]. Drusen are defined as sub 
RPE deposits and are characteristic of AMD but not necessarily associated only with AMD 
[43].  
Drusen are known as lipid and protein rich extracellular deposits and the RPE is 
known to produce many drusenoid materials [61, 105, 107]. Drusens are classified into two 
classes: large, soft drusen which are normally associated with early AMD, and small hard 
drusen evident with increasing age but not necessarily associated with the presence and 
development of AMD [106]. CNV starts from the choroidal vasculature with leaky blood 
vessels breaking through BM into the RPE cell layer. CNV can result in the leakage of blood 
and accumulation of serum in the eye leading to irreversible vision loss in a short period of 
time [32, 34, 39, 41, 107, 108].  
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Figure 1-6 Progression of AMD 
 
Stages of AMD disease: early dry AMD, intermediate dry AMD, late dry AMD and wet 
AMD. In the normal retina, the arrangements of the cells are still intact, BM is of normal 
shape and size and all layers and tissues are functioning correctly.  
(i) In the early dry stage of AMD, inflammation of tissues starts which leads to the 
thickening of BM due to accumulation of proteins and lipids.  
(ii) In the intermediate dry stage of AMD, the drusen starts to form as small hard and 
round objects.  
(iii) In the advanced dry stage, the drusen becomes bigger in size and softer which 
leads to atrophy and disorder.  
(iv) In the wet stage of AMD, cell atrophy starts to form in the RPE cells, the blood 
vessels start to grow and enter the macular through BM and finally the 
photoreceptors become disordered and start to degenerate. 
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1.5.1 First stage: early AMD (classification of AMD) 
The normal healthy retinal tissues in the macula are illustrated in Figure 1.7. There 
are two phases of dry AMD also known as non-CNV AMD and three distinctive 
characteristic features; thickening of BM, formation of small hard drusen which later 
transforms into large soft drusen and GA which is the characteristic of advanced dry AMD. 
The formation of drusen is a result of lipid, calcium and undigested RPE waste deposited 
outside the RPE [43]. AMD causes some visual deterioration that can progress to blindness 
[2, 39, 76, 82, 106]. 
 
 
Figure 1-7 Normal retina 
Photoreceptors ordered and organised, RPE cells normal, BM in the normal size and 
functioning perfectly, choroid with normal blood vessels. 
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The two phases of early AMD are: 
1.5.1.1 Early phase of dry AMD 
This phase is characterized by the thickening of BM. In this phase, the alteration of 
ECM components leads to an increased deposition of lipids and protein components in BM 
causing the thickening of BM as illustrated in Figure 1.8 [28, 55, 84, 87, 109]. 
 
 
Figure 1-8 Early dry AMD 
  
All layers are normal. Photoreceptors, RPE cells, choroid are normal except that the BM 
starts thickening and consequently loses its function.  
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1.5.1.2 Intermediate phase of dry AMD 
Intermediate dry AMD: At this stage the size of the drusen has been classed as 
medium (63 µm to 124 µm) which is intermediate to early and late stages, there are usually 
several drusen or one big drusen [43, 110]. The accumulation of insoluble extracellular 
substances occurs which later leads to the formation of round, yellow well demarcated small 
sized drusen with a diameter of less than 64 𝜇m. Thickening of BM when seen in conjunction 
with the presence of drusen is considered a clinical hallmark for AMD. Here, AMD is highly 
likely to progress into advanced AMD as explained in Figure 1.9 [43, 82, 111, 112]. 
 
 
Figure 1-9 Intermediate dry AMD 
Photoreceptors and choroid are normal, formation of deposits (drusen) around and between 
the basal lamina of the RPE and the inner collagenous layer of BM. 
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1.5.2 Second stage: Late AMD  
1.5.2.1 Dry AMD (Advanced Phase) 
Advanced dry AMD is also known as GA AMD or Non-CNV and this advanced 
phase is preceded by the formation of the hard drusen [113]. This phase is characterized by 
a big, soft drusen and GA. The important changes in the dry AMD (advanced phase) are a 
dramatic decrease in the numbers of photoreceptor cells and potential atrophy of RPE within 
the GA area of the macula [114]. Other important changes associated with this phase include 
some scattered area of degeneration in the RPE cells and the retinal photoreceptors [39]. The 
RPE becomes increasingly lipidized (more lipid deposition) and starts to degenerate. 
Breakage of light sensitive cells and the gradual blurring of the central vision is also known 
to occur at this stage and about 65% of the patients with advanced dry AMD can develop 
advanced wet AMD as illustrated in Figure 1.10 [82, 84, 107]. 
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Figure 1-10 Late dry AMD 
 
The drusen becomes large and soft, and atrophy occurs; with disordered photoreceptors and 
normal choroids. 
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1.5.2.2 Wet AMD 
This stage is also known as CNV. At this stage, the newly formed blood vessels 
start to grow towards the outer retina (where there has been fluid leakage from vessels). This 
process can cause the destruction of the macula. However, it must be noted that while this 
stage causes 85% of AMD related vision loss , it only accounts for 8% of total AMD cases 
[52, 115]. The wet phase is also known as the exudative, and a key feature of this stage is 
formation of CNV [115]. In clinical cases, the progression of AMD can vary widely among 
AMD patients and is characterised by many factors associated with the early signs of AMD. 
These signs include the extent of GA, RPE abnormalities, pigment changes, and the 
declining rate of the reading speed [116]. Wet AMD can quickly progress to blindness if 
untreated. It usually develops in the background of dry AMD which itself (dry AMD) is 
considered to be a risk factor for wet AMD as shown in Figure 1.11 [39, 117].  
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Figure 1-11 Wet AMD 
 
BM has lost its function in the transportation of wastes, nutrient and oxygen. The blood 
vessels start to grow towards BM and penetrate it leading to fluid leakage in the outer retina. 
Photoreceptors and RPE initially become disordered before degenerating. 
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1.6 Prevalence and trends of AMD  
AMD is a major cause of blindness in the developed world. It affects 7 million 
patients aged above 65 worldwide [39, 63, 118]. In Australia, AMD is the main cause of 
48% of cases with severe vision loss [18]. Wet AMD are estimated to be around 17,000 and 
a further breakdown was based mainly on age and showed that patients in their 60’s reached 
approximately 3500 in their 70s,  and 5600 patients in their 80’s accounted about 8600 new 
cases every year [18, 104, 119]. 
The prevalence of AMD increases with age and the reasons behind this are not 
properly understood. In fact, AMD is known to affect 2% of people age 40 years and 25% 
of people age 80 years [39, 42]. The number of blindness cases in 2002 was mainly caused 
by AMD and reached about 8.7% of the total blindness number [80]. The majority of acute 
vision loss cases (90%) were due to CNV related AMD with 10% being due to the GA or 
dry AMD [76, 82, 95]. 
Predictions based on statistical data have led to estimations of up to 3 million people 
being affected by AMD by 2020 in the United States. Taking into account a rapidly ageing 
population, AMD prevalence is likely to increase dramatically in the future [100]. In 
Australia, there are alarming figures for early dry AMD with 65% of people aged around 90 
years likely to develop AMD and 25% of this population estimated to be likely to lose their 
vision [85, 120]. In addition, there are reportedly 48,319 cases of AMD related blindness. In 
this population, around 70% of people have developed CNV AMD at least in one eye, and 
around 55% are likely to develop GA dry AMD in at least one eye. Other  studies reported 
AMD incidence of 200,000 AMD cases that were likely to have large drusen at least in one 
eye with half of that number being diagnosed to have bilateral large drusen [43, 84, 85]. 
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1.7 Risk factors for AMD 
 There are many risk factors for AMD which can be categorised into three main 
groups; strong, weak and emerging. In terms of strong factors, smoking is one of the most 
important factors for AMD [16]. Smokers have three times the risk of developing AMD with 
a large AMD case control study reportedly showing a strong association between AMD and 
smoking habits [72, 77, 84, 101, 109, 118, 121-124]. Ageing is also another strong risk factor 
with substantial increases in the prevalence and progression of AMD with age [124]; the 
older the patients, the later their stage of AMD. Genetic factors indicated by family history 
of AMD are also another strong risk factors. Individuals with a family history of AMD are 
thought to have a 50% chance of developing AMD with both ageing and genetic factors 
showing strong association with advanced AMD [2, 104, 118, 125]. 
The weak risk factors include body mass index (BMI), cardiovascular disease, 
hypertension and elevated plasma fibrinogen, gender (females are more susceptible than 
males), ethnicity (individuals with light skin colour are more prone to developing AMD), 
diabetes, serum lipid levels, and exposure to sun light (increases the risk of AMD twofold) 
[39, 77]. Notably, there is an association between AMD and serum lipid content but 
relatively not much attention has been given to this observation [126, 127]. 
Emerging risk factors for AMD include diet, obesity, and physical activities [123, 
128]. There is inconsistency in the relationships between cataract and AMD as some research 
findings support a relationship while others have found none. However, there is thought to 
be a relationship between AMD and hyperopia, as well as hormonal levels and AMD [77, 
124]. Relationship with other diseases has also been postulated. The most associated diseases 
with AMD which constitute a risk factor are the retinopathy diseases especially the ones that 
involve the formation of drusen and lead to a decline in central vision, namely diabetic 
retinopathy [28, 43, 72, 77, 119]. The development of AMD is related to other vascular 
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diseases including coronary heart disease (CHD), diabetes, hyperglycemia and blood 
pressure [77, 103, 118, 125]. 
1.8 Pathogenesis of AMD 
The pathogenesis of AMD remains relatively unclear as there are many factors 
contributing to AMD disease [129]. Progression of AMD to the advance stages is varied 
among AMD patients and is influenced by many factors [103]. The main factors that 
contribute to the progression of AMD include the size of the GA, RPE abnormalities, 
pigment changes and the declining rate of the reading speed [110, 116]. All these factors 
were extensively studied through ARED study [28, 84, 109]. The alteration of ECM leads to 
an increase deposition of lipids and proteins components on BM layers. Thickening of BM 
in conjunction with development of soft drusen are considered to be a clinical hallmark for 
intermediate dry AMD and pigments abnormalities quickly shift the disease to the stage of 
development of choroidal neovascular membrane [55, 112]. 
1.9 Current available therapies for AMD  
Current AMD treatment strategies aims to delay, prevent, arrest and reverse disease 
progression [16, 119]. Examples of these treatments are laser photocoagulation, 
photodynamic therapy and intravitreal injections with inhibitors of VEGF as in the case of 
treatment with ranibizumab [16, 130]. VEGF has been shown by large clinical trials to be of 
good benefit to patients with choroidal neovascularization and there is some recent research 
focusing on gene therapy and a number of other anti-VEGF agents [63, 95, 131, 132]. There 
is overlap between the various stages of AMD, and more research is needed on the process 
underlining wet and dry AMD which should enhance the chances of finding successful 
treatment regimes [11, 81, 133]. However, there are only small numbers of food and drug 
31 
 
administration (FDA) approved drugs and these only target end stages of AMD [16]. There 
is no approved treatment for early dry AMD and the finding of effective therapy remains a 
challenge in all stages and types of AMD in particular for dry stage. [39, 57, 85]. 
1.9.1 Drug therapy 
The introduction of anti-VEGF antibodies has revolutionized CNV AMD 
treatment, as injection with ranibizumab trials have shown significant improvements in CNV 
AMD patients visual acuity [46, 63, 94, 134]. Generally, anti-VEGF therapy halts vision loss 
in 90% of patients in trials group and improve vision in one third of the patients [76, 81, 95, 
135]. Unfortunately, Most AMD therapies have unfavourable effects such as tachyphylaxis, 
which is the reduction in body response to treatment after repeated use of the drug [136]. It 
has been reported that anti-VEGF therapies commonly used in the treatment of late stages 
of AMD, result in increasing intraocular pressure [137]. Other drug therapies include anti-
inflammatory agents and antioxidants [119, 138]. 
1.9.2 Non-drug therapies 
Non-drug AMD treatment therapies include radiation, cell replacement, bionic eye, 
the BRB treatment options, genetic and surgical therapies [44, 119, 139, 140]. Some of these 
techniques used in radiation therapy are the photon external beam radiation and argon laser 
photocoagulation, which cause iatrogenic vision loss in specific types of AMD patients [63, 
141]. One of the replacement methods is using stem cell transplantation and mobilization 
[16, 119]. 
Bionic eye is the restoration of vision in patients with AMD using retinal prostheses 
which are of two types. The first is an optoelectric system and the second type has a multi 
electrode array system [16, 142]. The RPE forms part of the outer BRB, serving a central 
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function of preserving the unique eye property of tolerance to foreign objects which makes 
it possible to replace the RPE cells and photoreceptors cells by stem cells derived from 
human induced pluripotent cells [27, 143]. Genetic therapy involves using vectors such as 
adeno associated viruses to express pigment derived epithelial factor (PDEF), which is 
similar to the other gene therapy known as anti-VEGF. in that both methods inhibit 
angiogenesis [16, 144].  
Laser surgery is another widely used surgical method for the treatment of AMD 
[145]. Several surgical techniques have been used in the treatment of AMD which can be 
put into two different categories: Full and limited macular translocation [146]. 
1.10 Limitations of AMD therapy 
Drug therapy using anti-VEGF showed variable outcomes from patient to patient 
and is very costly. One injection of Ranibizumab is estimated to cost thousands of dollars 
and this treatment costs 9 billion dollars per year in America [135]. Treatment is also 
demanding with patients needing to take their injections on a monthly basis [63, 119]. In 
fact, most patients stop taking the injection in the first few months as observed in two four 
year trials [46, 119].  
Radiation therapy, which can also be used in conjunction with injection therapy has 
the disadvantage of frequent injection and radiation [119]. The risk of retina radiation is one 
of the shortcomings of using the radiation-therapy [63, 133]. Currently there are no 
preventative measures or drug treatments for dry AMD [18, 138]. 
Treatment and therapy were only available for the wet stage of AMD although were 
not efficient [46, 63, 76, 95, 133]. 90% of AMD patients remained incurable and there was 
no approved treatment especially the early stages of dry AMD [39]. In the radiation therapy 
category for wet stage of AMD, recent studies have shown radiation therapy techniques to 
33 
 
be beneficial to the patients. A good example is the study by Amar and colleagues [63] which 
suggested that the usage of stereotactic radiation therapy, proton therapy, and brachytherapy 
was beneficial to patients [63, 95, 132]. Intervention therapy aimed at increasing the level of 
serum by supplementation with Lutein (L) and zeaxanthin (Z) has been shown to improve 
vision function in AMD patients [147]. These therapies target late stages of AMD and deal 
with damage caused by the disease, while effective therapy should focus on early stages of 
the disease and on the root causes of the disease. 
1.11 PGs and AMD 
1.11.1 PGs structure and alterations in AMD 
AMD like some other retinal diseases is affected by the dysfunction and death of 
RPE cells. Early changes of AMD can be manifested by the formation of sub-retinal pigment 
epithelial (SRPE) basal deposits that distort the morphology and function of the RPE. It 
forms an integral part of the structure and function of the retina and its unique location in 
the vertebrate eye between the neural retina and the choriocapillaris allows it to develop the 
outer BRB. This allows the RPE to perform biological functions responsible for the 
movement of nutrients, vitamin A, water, transfer of electrical signals and responses while 
also providing protection against photo-oxidation and light [247, 261, 376, 404-408]. 
PG constitutes the majority of the ECM within tissues and plays an important role 
in providing mechanical strength to tissues [148]. The other constituents of the ECM are 
collagens, elastin, and micro fibrillar proteins [149]. Hormones and growth factors stimulate 
cells to cause the elongation of GAG chains on PGs which leads to enhanced lipid binding 
and the trapping of materials in tissues [2, 13, 56, 150, 151]. The function of PGs varies 
greatly depending on the core protein family [56, 150]. The type, number, size and sulfation 
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of GAG chains are illustrated in Figure 1.12. Generally, PGs act as a binder for the ECM as 
well as a pool for growth factors and tissue hydration [150]. PGs are classified into four 
major families: heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), and 
keratin sulfate (KS) [12, 152-154]. GAG chains are linear polysaccharides that are attached 
in variable numbers to PG core proteins [49, 155]. 
There are four main classes of PG to which almost all the discovered PGs of the 
mammalian genome belong to [154, 156]. This classification is based on the following three 
main criteria. The first one is concerned with their location, whether cellular or subcellular. 
The second criteria is based on the overall gene/protein homology while the third criteria is 
dependent on the existence of the respective core protein in a specific protein model [154]. 
PGs can be present on the cell surface, inside the cell, and are also secreted into the ECM of 
mammalian tissues [150, 152]. Prominent PG species in the eye include the small leucine-
rich CSPGs decorin and biglycan. It is an established paradigm that tissue insult leads to 
their increased production and it could possibly be the same case in the eye [52, 117]. PGs 
are heavily sulfated and thus negatively charged which allows them to bind and retain 
positively charged molecules including apolipoproteins on the surface of lipids [96]. The 
specific role of PGs in the development and progression of AMD has not yet been fully 
determined despite their roles in (i) ECM deposition in the thickening of BM in early AMD 
and (ii) their facilitation of CNV in wet AMD [42, 157].  
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Figure 1-12 PGs structure 
 
The structure of PGs (biglycan) is shown. The main structural features are core protein and 
2 chains of GAG. The GAG chain is linked to specific serine residues on the core protein. 
The GAG chain starts with the linkage regions which is composed of xylose (Xyl) then 
galactose (Gal) and Gal and glucuronic acid (GlcA)/ idorunic acid (IdoA) followed by amino 
disaccharides (which are disaccharide derivatives having one or more substituted or 
unsubstituted amino groups in place of hydroxy groups) in a sequence of GlcA / IdoA and 
N-acetylgalactosamine (GalNAc). PGs carry negative charges that increase with the length 
of the chain and allow them to bind to positively charged molecules such as low-density 
lipoprotein (LDL). 
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Alteration to the PGs in BM of AMD include changes to the PG structure, shape and size 
leading to altered BM function as well as on its permeability properties [158]. Changes in 
the negative charge increase with increasing chain length with the ability to bind to positively 
charged molecules such as lipids [159]. The discontinuous nature of the elastic lamina of 
BM in the macula highlights the potential of choroidal cells including endothelial, fibroblast, 
and vascular smooth muscle cells to also contribute matrix components including PG [2]. 
Studies using whole eye organ cultures showed that the proportion of newly synthesized PGs 
remains consistent at 75% CS/DS and 25% HS [47]. CS/DS GAGs are associated with 
collagen fibrils in BM and HS is found near the basement membrane of RPE layer and 
choriocapillaris. GAGs chains are directly linked to AMD as their content is higher in AMD 
patients [39, 47, 53, 100].  
HSPGs play a vital role in AMD through regulation of the complement system and 
contribute to the pathogenesis of both dry and wet stages of AMD [160]. The eye is an 
immune privileged site and the main function of the complement system is to preserve it 
from exogenous and endogenous insult.  [161]. The complement system is evolutionarily 
conserved and is recognised as a key player in the pathogenesis of many diseases including 
AMD [162]. Accumulation of waste in AMD is correlated with inactivation of the 
complement systems in the inflammatory stage that is represented by thickening of BM. This 
process takes place in the outer and inner collagen layer, altering the ECM [163]. There are 
three stages; pre-inflammation, inflammation and post inflammation. The post inflammatory 
stage in AMD is when there is high accumulation of lipids, proteins and other materials in 
the BM and RPE cells. This takes a longer period to occur compared to the inflammatory 
stage. HS is a long unbranched polysaccharide GAG that is attached to ocular PG core 
proteins in the ECM of BM and macular tissues [150, 152]. 
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1.11.2 PG synthesis 
PGs and their GAG moieties are the major members of the ECM which are known 
to support, trigger and protect the activity of informatics molecules like growth factors [2, 
96, 164]. Understanding GAG structure and function at the molecular level represents a 
potential opportunity to gain knowledge that will have a positive impact on human diseases 
[165, 166]. GAG is group of polysaccharide molecules with affinity to bind to a range of 
proteins and signalling molecules such as growth factors (TGFβ, Thrombin, PDGF, IGF and 
VEGF. GAG may impact the activity and function of these factors [166-169]. 
There have been significant advancements in the understanding of signalling 
pathways that control GAG hyperelongation [49, 170]. Growth factors serve a vital role in 
mediating GAG hyperelongation [2, 48]. PGs have a basal or natural GAG chain length, 
which can change under the influence of growth factors. Growth factor mediated activation 
of GAG synthesizing enzymes can lead to the synthesis and secretion of PGs with elongated 
GAG chains which have increased binding to LDL [13, 171]. 
Lipids trapped in tissues undergo chemical modifications including oxidation that 
initiates an inflammatory cascade [2]. This can negatively impact on RPE and 
photoreceptors, to the extent that it may impair their function [10]. One of the most important 
lipids in AMD is cholesterol with high levels in the lipid-rich drusen being associated with 
AMD [10]. There is a gap in knowledge regarding the possibility that these deposits might 
arise from the trapping of lipids by PGs with elongated GAG chains and the impact such 
interactions may have on the pathogenesis of AMD [2, 62]. Deposition of lipid particles in 
BM creates a lipid wall to the outer RPE basal lamina impairing BM permeation function 
between choriocapillaris and the RPE. This is manifested in early dry stages of AMD [50, 
62, 172-174]. 
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1.11.3 Core protein biosynthesis 
Tissue injury can induce vascular smooth muscle (VSMC) cells to change their 
mode of action from a contractile to a synthetic state and to secrete different ECM 
components including PG [175]. PG synthesis involves a series of processes mainly in the 
Golgi apparatus [176]. 
The transcription of mRNA for GAGs synthesis enzymes involve interactions with 
endoplasmic reticulum (ER) for core protein synthesis [177]. Once out of ER, xylose 
becomes attached to the core protein. This step initiates the build-up of other linkages which 
occur inside a site for glycan modification called cisternae-Golgi. This is a cellular structure 
that is composed of layers of membrane-enclosed saccules. The synthesis of the repeated 
disaccharides however takes place in the trans-Golgi [176, 178]. 
1.11.4 GAGs biosynthesis 
GAGs serve many functions and are found in both cell membranes and extracellular 
spaces [179, 180]. GAGs have been reported to be involved in many biological process and 
important regulatory mechanisms [181, 182]. The Golgi compartment is the location for the 
sulfation of the GAGs [181, 182]. 
The genes in Tables 1.1, 1.2 and 1.3 are important in the synthesis of the enzymes 
involved in the process of GAGs elongation. 
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Table 1.1 Glycosyltransferase enzymes involved in CS/DS synthesis in 
human. Adapted from [170, 183]. 
Enzymes  
(activity) 
Enzymes 
Abbreviation 
Gene symbols 
   
I- Glycosyltransferases involved in synthesis of the tetrasaccharide linkage region 
   
Xylosyltransferase XT-1 XYLT1 
 XT-2 XYLT2 
β1,4-Galactosyltransferase-I GalT-1 B4GALT7 
β1,3-Galactosyltransferase-II GalT-2 B3GALT6 
β1,3-Glucuronyltransferase-I GlcAT-1 B3GAT3 
   
II- Glycosyltransferases involved in synthesis of the repeating disaccharide region of CS chains 
   
Chondroitin synthase (GalNAcT-II, GlcAT-II) ChSy-1 CHSY1 
 ChSy-2 CHSY2 (CSS3) 
 ChSy-3 CHSY3 (CHPF2) 
Chondroitin polymerizing factor (GalNAcT II, GlcAT II) 
ChPF CHPF (CSS2) 
Chondroitin GalNAc transferase (GalNAcT-I, 
GalNAcT-II) 
ChGn-1 CSGALNACT1 
 
ChGn-2 CSGALNACT2 
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Table 1.2 Sulfotransferase and epimerase enzymes involved in CS/DS 
synthesis in human. Adapted from [170, 183]. 
Enzymes  
(activity) 
Enzymes 
Abbreviation 
Gene symbols  
   
Chondroitin 4-O-sulfotransferase C4ST-1 C4ST1 (CHST11) 
 
C4ST-2 C4ST2 (CHST12) 
 
C4ST-3 C4ST3 (CHST13) 
Dermatan 4-O-sulfotransferase D4ST-1 D4ST1 (CHST14) 
Chondroitin 6-O-sulfotransferase C6ST-1 C6ST1 (CHST3) 
Uronyl 2-O-sulfotransferase UST UST 
GalNAc 4-sulfate 6-O -sulfotransferase GalNAc4S-6ST GALNAC4S-6ST (CHST15) 
Glucuronyl C-5 epimerase DS-epi1 DSE (SART2) 
 DS-epi2 DSEL 
    
 
Table 1.3 Enzymes involved in CS/DS synthesis in humans 
(tetrasaccharide modifying and catabolic enzymes). Adapted from [183]. 
Enzymes  
(activity) 
Enzymes 
Abbreviation 
Gene symbols 
   
I- Enzymes modifying the tetrasaccharide linkage region  
   
Xylose 2-O-kinase XylK FAM20B (gxk1) 
Galactose 6-O-sulfotransferase  C6ST1 (CHST3) 
Exostosin-like glycosyltransferase 2 (GlcNAcT-I) EXTL2 EXTL2 
Uronyl 3-O-sulfotransferase  HNK1ST (CHST10) 
   
II- Chondroitin sulfate hydrolases 
   
endo-β-N-acetylgalactosaminidase HYAL-1 HYAL1 
 HYAL-4 HYAL4 (CSHY) 
 SPAM1 SPAM1 
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There are three main groups of enzymes involved in GAG synthesis, modification 
and catabolism: The first group is glycosyltransferases which are involved in the synthesis 
of tetra-saccharide linkage regions and synthesis of the repeated disaccharides of CSPG 
[184]. The second group is sulfotransferases, which to date includes seven enzymes 
identified as being responsible for sulfation of CS/DS GAG. Sulfotransferase enzymes 
enzymes catalyse the transfer of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) sulfate 
group to GalNAc, GlcA, or IdoA sulfation sites on CS/DS GAG [171]. The third group is 
tetra-saccharides modifying enzymes (the catabolic enzymes in humans), which catabolize 
CS (Table 1.3) and is out of the scope of this study [183, 185-188]. 
1.11.5 Biosynthesis of CS/DS GAG chain 
The biosynthetic assembly of CS/DS GAG containing PGs occurs through 
sequential processes [189]. The first process is synthesis of the core protein, the second step 
is xylosylation of the core protein while the third process involves the addition of two Gal 
residues to the Xyl. The fourth process involves the completion of the common tetra-
saccharide linkage region which occurs through the addition of a glucuronic acid (GlcUA) 
residue. The fifth step involves the addition of a GalNAc residue to initiate the CS/DS 
biosynthesis. In the sixth step, two things occur; there is repeated addition of GlcUA residues 
alternating with GalNAc residues to elongate GAG chains. There is also the sulfate addition 
step where modification of these elongated GAG chains by variable O-sulfation and by 
variable epimerization of GlcUA to IdoUA occurs [190]. 
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1.12 Cell-surface PGs releasing mechanisms 
1.12.1 Enzyme catalysed cleavage 
Thrombin is a proteolytic enzyme (serine protease) that plays an important role in 
the blood coagulation process by cleaving fibrinogen to fibrin [191-195]. Thrombin is the 
product of the cleavage of prothrombin in the coagulation cascade. Prothrombin is 
synthesized in the liver in the presence of vitamin K. During the formation of thrombin, 
many peptides are released into the plasma and other proteins are split in two portions [196-
199]. The process of conversion of prothrombin to thrombin only occurs when tissues are 
injured and fibrin forms as a response to bleeding. Thrombin cleaves four arginine-glycine 
peptide bonds along the central globular region of fibrinogen. It activates several enzymes 
leading to the production of more thrombin by a positive feedback mechanism [200, 201]. 
Thrombin belongs to the trypsin family of S1 peptidases. Its catalytic activity is mediated by 
the thrombin receptor and involves the cleavage of arginine-lysine bonds and the cleavage 
of prothrombin at the N-terminal fragments [202-204]. 
Thrombin is synthesized in the liver and secreted into the general circulation as a 
complex multidomain glycoprotein [205]. The structure of thrombin consists of a surface 
loop which contains an active site that is in contact with the substrate. It also contains an 
anion binding exosite [205-207]. Thrombin forces the blood out of vessels at sites of BRB 
and it is associated with many retinal diseases [208-214]. The proteolytic activity of 
thrombin is illustrated in Figure 1.13. Direct thrombin inhibitors (DTIs) are a class of 
anticoagulants that block thrombin interactions by binding to thrombin to make it 
unavailable to the substrate [215, 216]. DTIs target three sites on thrombin namely the active 
or the catalytic site, exosite-1, and exosite-2 [216, 217]. DTIs have different modes of 
inhibition of thrombin; some can inhibit fluid-phase thrombin while others inhibit tissue-
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bound thrombin and some other DTIs can inhibit both fluid-phase and tissue-bound thrombin 
[218, 219]. Examples of DTIs are hirudin and lepirudin which irreversibly block both the 
active catalytic site and the exosite at the substrate binding site [215, 217]. 
 
 
 
 
 
 
 
Figure 1-13 Proteolytic activity of thrombin 
 
Thrombin (due to its multifunctional serine protease property) cleaves PGs between residues 
15 and 16 on the core protein from the cell surface [220]. 
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1.12.2 Receptor mediated shedding  
Shed PGs are heavy molecules. Their accumulation as a result of shedding can 
constitute problems in the transportation of these molecules through BM [221-223]. This 
may lead to the accumulation of shed PGs with the possibility that their subsequent 
interactions with lipids can lead to larger deposits in BM [221-223]. Consequently, their 
accumulation could lead to the development of drusen and block BM resulting in the loss of 
the selective permeability of BM [221-223]. PG shedding could also be due to thrombin 
protease-activated receptor (PAR-1) activation or thrombin proteolytic activity. The 
mechanism of PAR-1 shedding is shown in Figure 1.14 [194, 221-223]. 
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Figure 1-14 Mechanism of thrombin receptor PAR-1 mediated 
 shedding of PGs 
 
Thrombin is a multifunctional serine protease generated at sites of tissue injury and 
inflammation. Thrombin cleaves the peptide bond between receptor residues Arg 41 and Ser 
42 at thrombin receptor PAR-1 N-terminus. This activates the receptor and leads to 
downstream activation of intracellular kinases MEK-1, ERK and PTK and matrix 
metalloproteinase (MMP) which releases shed PG at 15 amino acids from the cell surface 
[221-223]. 
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1.13 Extracellular matrix composition 
Understanding the molecular basis of AMD disease is critical to transforming that 
knowledge to clinical use [39]. Based on the current understanding of AMD pathogenesis, 
there are many pathological processes that contribute to AMD. These processes at the 
molecular and biochemical level are: oxidative processes (can cause oxidative damage in the 
cells), metabolism of lipids in an abnormal way and apoptosis. They also include 
photoreceptor outer segments structure arrangement modification, ion channels dysfunction 
in the RPE, CNV, immune system variations and ECM composition changes [11, 117, 224]. 
The ECM composition is varied in the retina. The intra-cellular matrix on the other 
hand can experience alterations for example becoming depleted with the synthesis of new 
molecules or decaying of molecules leading to or indicating the occurrence of AMD. Any 
lysis of the intra cellular material could be converted to waste in the ECM, which itself has 
not been examined in detail as a possible approach to investigating AMD pathogenesis [36, 
52, 128, 147]. The retina contains a high concentration of lutein and zeaxanthin. Both of 
these compounds are macular pigments functioning as antioxidant and blue light filters 
protecting the retina from photo oxidative damage thereby halting AMD progression [109, 
123]. 
PGs play a role in lipid retention and the signalling pathways that regulate PG 
synthesis in atherosclerosis is regulated by the growth factors. This knowledge can be 
utilised to study AMD [97, 98, 225]. 
1.14 PG and lipid interactions 
The ECM composition is very important in controlling many biological processes 
that lead to the progression of AMD. For example, the length of secreted GAG chains is such 
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that increases in length mediated by stimulation of cells by growth factors produce a large 
increase in the interaction between PGs and lipids. GAGs structure plays a role in the 
lipoprotein retention while the core protein governs the cellular location and act as scaffold 
for the GAG chain. For example in atherosclerosis, the decorin GAG chain is increased in 
size after exposure to fatty acids [56]. Lipids and proteins are the main building blocks of 
most biological membranes and they form a membrane structure that allows the permeability 
of ions and large molecules. Lipid droplets consist of triglycerides and cholesterol esters. 
One of the most important lipids in AMD disease is cholesterol, as there are high levels of 
cholesterol in the lipids rich drusen lesions that are associated with AMD [62]. 
1.15 Growth factor signalling and PGs 
Sulfated GAGS have the ability to act as modulators to growth factors which is due 
to their negative charge [226]. Growth factors can also bind and interact with the cell surface 
matrix sulfated GAG [227]. This study focuses on the five growth factors, TGFβ, thrombin, 
PDGF, IGF and VEGF. This is because these growth factors cover the three major receptor 
agonists (serine/threonine receptor agonists, G-protein-coupled receptor (GPCR) agonists 
and tyrosine kinase receptor agonists) and have been reported to be related to the GAG 
hyperelongation of PG which are in turn involved in AMD. These growth factors have been 
shown to be present in the retina tissue [2, 13, 48, 170]. AMD disease impacts both the retinal 
endothelial cells and the RPE. The retinal endothelial cells form part of the vasculature 
choriocapillaris that adjacent to BM and modification of endothelial cells, is known to occur 
at the early stages of AMD disease [228]. Growth factors play vital roles in the various 
functions of endothelial cells including PG synthesis and GAG elongation which directly 
involves lipid binding and the thickening of BM in early AMD [2, 13]. The RPE on the other 
hand is polarized epithelial cells attached to the basement membrane which is the layer 
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adjacent to the inside of BM [10, 31]. The RPE is known to secrete many growth factors that 
play important roles in the retinal function of vision provision [31]. The cell surface PG in 
the RPE cells may impact the formation of drusen in the macula and the process of BM 
thickening [229]. For these reasons, the impacts of growth factors on endothelial and 
epithelial cells in AMD were investigated. 
1.15.1 Growth factors and endothelial cells 
Vasoactive growth factors are known to regulate PG synthesis and structure, hence 
their respective signalling pathways are potential therapeutic targets for lipid deposition 
diseases such as atherosclerosis and glomerulosclerosis [230]. Our laboratory has published 
findings that have demonstrated that in vascular smooth muscle, a number of growth factors 
increase the synthesis of CSPGs and GAG [3, 98, 225, 231-236]. The major growth factors 
involved in regulating the synthesis of PG in retinal endothelial cells are: transforming 
growth factor beta (TGFβ), thrombin; insulin-like growth factor (IGF); platelet-derived 
growth factor (PDGF) and vascular endothelial growth factor (VEGF) [2, 13]. 
There are two main pathways through which TGF-β transmits its signal; these are 
the canonical Smad-dependent pathway and the non-canonical Smad pathway [235, 237]. 
The canonical TGF-β/Smad signalling is transmitted via TGF-β binding to type I and type II 
receptor to form complex heteromeric complex that result in autophosphorylation of type I 
which then phosphorylate Smad2 and Smad3 [235, 238].  Phosphorylated Smad 2/3 binds 
with Smad4, moves to the nucleus and mediates gene transcription. Non-canonical Smad 
signalling includes extracellular signal-regulated kinase (ERK) signalling, p38 mitogen-
activated protein kinases (MAPKs), and phosphoinositide 3-kinase (PI3K)/AKT pathways. 
The noncanonical pathway can synergise with the canonical Smad pathway to regulate each 
other [239].  Recent studies have shed light on the importance of TGFβ signalling pathway 
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and the recovery of retinal degeneration [240]. TGFβ may act as a crucial controller of 
growth factor transportation to target cells [233, 241-247]. 
Thrombin on the other hand is known to stimulate the synthesis of biglycan in 
human VSMC [97, 248]. Thrombin is known to regulate inflammation in the endothelial 
cells through up regulation of various mediators and protein via thrombin GPCR mechanism 
[98, 249]. 
IGF, PDGF and VEGF are agonists of receptor tyrosine kinase (RTK) cell surface 
proteins whose pathways are known to participate in the development of many diseases [250, 
251]. Protein kinases are a group of enzymes that catalyse the transfer of a phosphate group 
from adenosine triphosphate (ATP) to a hydroxyl group of a serine or a threonine. RTKs 
function through the protein kinase domain located in the intracellular region of each RTK 
monomer. When the ligand binds to the extracellular region, this leads to elevated activity 
of tyrosine kinase receptors and consequent autophosphorylation of tyrosine residues in 
selective manners. The functions of these sites include maintenance of the conformation and 
activity of the kinase receptor, as docking sites for various growth factors, hormones, 
proteins and enzymes [252, 253]. VEGF-A plays a central role by affecting the CNV in 
AMD [39, 63, 254].  
CSPGs via their GAG chains bind lipid and cause lipid deposition in artery walls 
and promote atherosclerosis as explained in Figure 1.15. It is interesting that HSPGs, the 
CSPGs and sulfation are reduced with age [255]. This suggests a reduction in lipid binding 
and less lipid deposition in BM with age. However, it is possible that in contrast to HSPGs, 
the CSPG and their GAG chains could be longer and or more sulfated in AMD since the 
enzymes that regulate the HSPGs and CSPGs chain synthesis differ. Therefore, the effects 
of different growth factors may also be different, although the presence of longer chains 
would still mean more sulfation and lipid binding [8, 13, 48].   
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Figure 1-15 Growth factor mediated GAG hyperelongation and lipid 
retention 
 
Role of growth factor mediated GAG hyperelongation in the trapping of lipids in tissues. 
PGs have a basal or natural GAG chain length. However, under the influence of growth 
factors, the GAG synthesizing mechanism is activated leading to increased gene mRNA 
expression of GAG elongation and the secretion of PGs with elongated GAG chains. These 
chains have increased binding enzymes to LDL. Lipids trapped in tissues undergo chemical 
modifications which produce immunogens that initiate an inflammatory cascade and a 
chronic inflammatory disease process. 
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1.15.2 Growth factors and RPE cells 
The RPE is a tissue layer initiated and formed from the optic cup outer layer. The 
RPE has a critical role in the maintenance of the photoreceptors layer. The RPE serves the 
function of strengthening attachment to BM which enhances the re-vitalization of cells 
possibly by interactions between these cells in retina tissues. The RPE is adjacent to BM, 
which itself is not a proper membrane but rather a lamina composed of the RPE basement 
membrane, a heavy density collagen layer, elastic fibres and the choroid basement 
membrane [256-259]. RPE secretes many growth factors that are necessary for the 
maintenance of the retina tissues. Through secreting growth factors, RPE can regulate its 
own growth and influence the growth of adjacent cells. These growth factors include: TGFβ, 
thrombin, PDGF, IGF and VEGF [2, 260-263]. 
The ability of RPE to perform its physiological functions requires (i) reliable 
mechanisms of communication with the surrounding environment and (ii) an ability to 
receive and process many extracellular messengers via binding of growth factors that act as 
their specific receptors. Growth factors can be produced by different types of cells and can 
perform their actions on the same set of cells, adjacent cells and on cells with similar 
properties. Growth factors possess the distinctive property of high reactivity and 
consequently they are involved in many cellular biological processes such as ocular 
development and wound healing [252, 264]. Sulfated GAGs play an important role in 
regulating and enhancing the biological function of growth factors. For example FGF and 
their receptors are dependent on binding to sulfated GAG [265]. 
TGFβ is a serine/threonine kinase receptor agonist of the TGF-β superfamily 
expressed by retinal choroidal endothelial cells as well as RPE cells. TGF-β is involved in 
many biological processes including cell growth [236, 266]. 
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Thrombin is a GPCR agonist which is the largest class of signalling receptors found 
in the human genome [267]. Thrombin controls many physiological responses, including up 
regulating the expression of VEGF in endothelial cells [267]. Thrombin is the agonist of 
PAR-1, PAR-3 and PAR-4. PAR-1 is known to mediate thrombin activation in RPE cells. 
Thrombin is generated from prothrombin in the BRB breakdown in AMD disease leading to 
fibrin formation from fibrinogen. Thrombin is reportedly involved in the synthesis of PGs 
[2, 13, 98, 268]. It can also be involved in the production of PGs by shedding or so-called 
cleavage processes [2, 13, 159, 267-276]. 
Retinal PGs are composed of core protein with covalently attached GAG chains 
[56, 368]. PGs can interact with other molecules either via their core protein or their GAG 
chains to form bigger molecules [56]. PGs can be classified into three major groups 
according to their GAG composition and the location of their core proteins. These are cell-
surface shed PGs, modular PGs and small leucin rich PGs [2, 99, 446-448].  The cell-surface 
shed PGs are the focus of this study and the PGs in this group can be further divided into 
four major types based on the sulfation of their GAG chains. These are CSPGs, HSPGs, 
KSPGs and DSPGs [449]. The ECM PGs include syndecans, phosphacan, versican, 
glypicans, betaglycans, hyalectans, perlecan and lecticans [154, 450]. 
The RPE is largely responsible for the transportation of molecules of different sizes 
and charges from the sub-retinal space to the underlying choroidal circulation [451, 452]. 
The RPE cells need the GAGs for their various biological functions such as the 
transportation of molecules across the cell (with the RPE cells modifying elongated GAGs) 
[425, 426, 453]. Tissue injury can result in changes to the matrix PG composition. One way 
of changing the concentration of PGs in the ECM is by cell-associated PG shedding. Shed 
PGs are heavy molecules and their accumulation can cause problems in their transportation 
through the BM. The accumulated PGs can interact with lipids, producing heavier molecules. 
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This process leads to the development of drusen, blockage of BM and the loss of selective 
permeability of BM [154, 454]. 
RTK agonists include IGF, PDGF and VEGF. IGF is a polypeptide produced in the 
retina and RPE [277]. IGF is composed of 70 amino acids and acts on cells surfaces through 
IGF-1 receptor (IGF-1R), and multiple binding proteins to exert many effects including its 
regulation of VEGF [278]. Regulation of VEGF is mediated by IGF–mediated activation of 
mitogen-activated protein kinase. In addition, IGF plays a vital growth role in the production 
of photoreceptors. IGF shares nearly 50% similarity to insulin. IGF is reported to enhance 
the survival of senescing RPE cells [2, 245, 277, 279-284]. 
The PDGF family, is composed of four ligands; A, B, C and D. PDGF can function 
as an agonist either as a homodimer or a heterodimer ligand PDGF AB [285]. These ligands 
bind to PDGF cell surface tyrosine kinase receptors, signalling cascades RAS and 
phosphatidylinositol-II [285]. PDGF was found to be involved in many biological processes 
including the development of the retina. Moreover, overexpression of PDGF is associated 
with retina disorders [286, 287]. PDGF levels play important role in VEGF function and 
levels and impacting on the progression of AMD and other retinal diseases. VEGF also bind 
to HS impacting on the progression of AMD. [2, 96, 245, 288-294]. 
The VEGF family is composed of 4 different isoforms of VEGF; these are A, B, C 
and D [295]. VEGF-A triggers various steps of angiogenesis in AMD [296]. VEGF is 
produced in the RPE and released via the basal side membrane. VEGF is known to promote 
the formation of blood vessels in a process known as angiogenesis which negatively impacts 
endothelial cells [297, 298]. VEGF signalling is juxtacrine, acting on adjacent cells in direct 
contact with it [263, 264, 299]. VEGF production is induced by hyperosmotic stress in the 
RPE. However, it has not been confirmed that RPE can osmotically regulate other growth 
factors involved in CNV development, which are initiated from choriorcapillaris and break 
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through BM to the sub-RPE. Consequently, BM is percolated and RPE integrity is disrupted. 
The breakage of the BRB is the diagnostic sign of progression of Dry AMD to Wet AMD 
evidently by CNV [300-304]. AMD treatment using Pegaptanib, an anti-VEGF agent 
prevents binding to VEGF receptor [2, 294, 305-308]. 
1.16 Complement system and AMD 
Sulfated GAG chains are variable in length and sulfation. It has been shown that 
the quantity and sulfation of GAG within BM decreases with age [255]. This impacts the 
progression of AMD because there are likely to be fewer binding sites for complement factor 
H, a known risk factor for AMD especially when individuals have the Y402H polymorphism 
[309-311]. Factor H negatively regulates and prevents activation of the complement system 
[311, 312]. In addition to elements of the complement system being found in drusen, both 
genetic and animal studies have also strongly supported a pivotal role of the complement 
system in the pathogenesis of AMD. While complement is active at a low basal level in the 
normal retina as a protective mechanism, alterations in the regulation of the complement 
system can trigger significant pathology. Strong associations with AMD have been identified 
in association with particular mutations in the complement factor H (CFH) protein (Y402H), 
a key regulatory component of the alternative pathway in distinguishing self from non-self 
[10–13]. Thus, a growing body of histopathological, preclinical, and epigenetic data now 
supports a key role of inflammation in the pathogenesis of AMD, a disease which was not 
classically described as inflammatory in origin [163]. HS as an example is known to react 
with a variety of protein containing molecules such as lipoprotein lipase [313]. 
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1.17 Rationale for the study 
It is clear that more research into the early phase of AMD is needed to target early 
changes in the macula as most studies have focused on the later stages of the disease. Whilst 
approximately 15% of cases are wet AMD, 85% of cases are the dry form of AMD which 
has no available treatments. Treatments for wet AMD do not improve dry AMD [18, 39, 
111]. This suggests that research on early AMD might yield new treatment targets [2, 13]. 
Growth factors play important roles in PG synthesis and GAG elongation in endothelial 
cells. These growth factors may have an impact in changing the ECM composition and affect 
BM and the surrounding cell layers in early stages of AMD [13, 93]. On the basis that there 
is evidence for the accumulation of plasma derived lipids in early AMD, it is reasonable to 
propose that the trapping of lipids by modified PGs might underlay the disease process in 
the early stages of AMD; thus detailed studies of the synthesis and release of PGs by retinal 
cells are warranted in the search for a new therapeutic target [10, 11, 48, 50, 117]. It is 
important to determine the cause of AMD and in turn possible therapy, with focus on GAG 
synthesizing enzymes and their role in elongation of GAG chain on PG as well as the 
interrelation of the synthesis of PGs and shedding [170, 221-223]. 
1.17.1 Hypothesises of this study 
The hypothesises tested in this study were focused on early AMD and alterations to ECM 
composition. Therefore, the main hypothesises were:  
 Various genes involved in the mRNA expression of glycosaminoglycan (GAG) 
enzymes in relation to AMD growth factors impact PG synthesis and GAG 
elongation in retinal endothelial and epithelial cells. 
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 Major alterations in the composition of BM take place in the early stages of AMD. 
These alterations to BM and RPE cells are consequences of other alterations such as 
altered PG synthesis, structure, and sulfation and increased lipoprotein to PG binding 
ratio. 
 Growth factors potentially associated with AMD and could cause changes in the 
synthesis of PGs and GAG elongation.  
 Retinal endothelial cells activated PG synthesis as a response to some growth factors 
and that the cells synthesized and secreted PGs with elongated GAG chains. 
 VEGF does not contribute to GAG elongation on PGs and that anti-VEGF therapies 
do not have any actions on PG synthesis in retinal cells. There is no impact of VEGF 
or anti-VEGF therapies on PG synthesis and structure in the macula.  
 Growth factors have a great impact on the synthesis of PGs and GAGs elongation. 
PGs and elongated GAGs play important roles in early AMD alongside the 
imbalance of different growth factors. 
 If the PG band was generated via a PAR-1 mediated process, then BAPTA-AM 
would affect the PAR-1 pathway by mobilizing the intracellular calcium. Therefore, 
this should affect PG sulfation and block the cell surface shedding of PG through 
MMPs. On the other hand, if the PG band was due to thrombin activity, then BAPTA-
AM would not have any effect as the thrombin enzymatic activity was the mechanism 
in operation on the cell surface.  
 Growth factors impact PG synthesis and GAG elongation in RF/6A retinal 
endothelial cells and RPE-19 epithelial cells that surround BM and undergo 
thickening during early AMD. 
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 TGFβ, thrombin, PDGF, IGF but not VEGF dose dependently stimulated PG 
synthesis and GAG elongation. VEGF had no effect on the synthesis of PGs or GAG 
elongation. 
 Growth factors play an important role in early AMD might be supported, as PGs are 
part of the drusen components and part of the cellular materials that cause BM 
thickening. The interrelation of PGs, GAG elongation and growth factors observed 
in this study might be an important link leading to early changes in AMD.  
 
1.18 Project aims 
Aim 1- Investigation of the effects of multiple AMD related growth factors from three 
different receptor agonist familes TGFβ (a serine/threonine kinase receptor agonist), 
Thrombin (a GPCR agonist) and PDGF, IGF and VEGF (tyrosine kinase receptor 
agonists) on PG synthesis and GAG elongation in retinal choroidal endothelial cells 
(RF/6A). 
 
Aim 2- To study the effects of multiple growth factors on gene mRNA expression 
corresponding to the enzymes XT-1, ChPF, ChSy-1, ChGn-2, C4ST-1 and C4ST-2 involved 
in PG synthesis and GAG elongation in retinal choroidal endothelial cells (RF/6A). 
 
Aim 3- Investigation of the effects of multiple AMD related growth factors from three 
different receptor agonist familes TGFβ (a serine/threonine kinase receptor agonist), 
Thrombin (a GPCR agonist) and PDGF, IGF and VEGF (tyrosine kinase receptor 
agonists) on PG released in retinal pigmented epithelial cells (RPE-19). 
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Aim 4- To study the mechanism by which thrombin causes PG shedding and explore the 
mechanism of shedding in retinal pigmented epithelial cells (RPE-19). 
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2. Chapter 2: Materials and methods 
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2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM) (0 and 25 mM glucose), trypsin-
versene, antibiotics (10,000 U/ml penicillin and 10,000 μg/ml streptomycin) solution were 
purchased from Gibco BRL (NE, USA). Fetal Bovine Serum (FBS) was obtained from 
Invitro Technologies, Pty. Ltd (VIC, Australia). Reagents such as PDGF, thrombin, VEGF, 
SB431542, GM6001, chondroitin sulfate, 10X Dulbecco’s Phosphate Buffered Saline 
(PBS), sodium dodecyl sulfate (SDS), 2 β-mercaptoethanol, dimethyl sulfoxide (DMSO), 2-
propanol, FURA-2/AM, protease inhibitor and nuclear stain Hoechst 408 were purchased 
from Sigma-Aldrich, (MO, USA). Ethanol (absolute) was purchased from LabServ (VIC, 
Australia). Imatinib was obtained from Alfred Hospital Pharmacy (Australia). The PAR-1 
inhibitor SCH79797 was purchased from Invitro Technologies (VIC, Australia). Human 
recombinant IGF-1 was given as a gift by Prof. Wenhua Zheng (Faculty of Health Sciences, 
University of Macau, Taipa, Macau and Key Laboratory of Ophthalmology, Zhongshan 
Ophthalmic Center, Sun Yat-sen University, Guangzhou 510006, China). Scintillation fluid 
Instagel was obtained from Packard (Groningen, The Netherlands). 
Anti-phospho-p44/p42 ERK1/2, anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), anti-rabbit IgG monoclonal antibody and human TGF-β were purchased from 
Cell Signalling Technology (MA, USA). An enhanced chemiluminescence (ECL) detection 
reagent was from GE Healthcare (NSW, Australia). Bovine Serum Albumin (BSA) was 
purchased from Bovogen Biologicals Pty. Ltd. (VIC, Australia). Chromogenic (Bench mark) 
and chemiluminescent (Magic Mark XP) molecular weight markers were purchased from 
Invitrogen (AK, New Zealand). SN30978 was provided by Dr Graeme Lancaster (Baker IDI 
Heart and Diabetes Institute, Melbourne, VIC, Australia). Anti-Smooth muscle actin 
antibodies, smooth muscle actin (SMA), endothelial nitric oxide synthase (eNOS) antibody, 
von Willebrand factor (vWF) were obtained from Dako Corporation (California, USA). 
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Anti-CRALBP [B2] cellular retinal-binding protein was from Abcam (MA, USA). Horse 
serum, Alexa Fluor 488 donkey anti-mouse or anti-rabbit IgG, Alexa Fluor 594 donkey anti-
mouse or anti-rabbit IgG, bicinchoninic acid (BCA) protein assay kit were from Thermo 
scientific (IL, USA). 
Quantitative-Real-time Polymerase Chain Reaction (Q-RT-PCR) primers for the 
enzymes chondroitin 4-O-sulfotransferase-1 (C4ST-1), chondroitin 4-O-sulfotransferase-2 
(C4ST-2) and chondroitin sulfate synthase-1 (ChSy-1) gene were based on their respective 
GenBank sequences. These primers were synthesized by GeneWorks Pty Ltd (SA, 
Australia). Xylosyltransferase-1 (XT-1), chondroitin polymerizing factor (ChPF), biglycan 
N-acetylgalactosaminyltransferase-2 (ChGn-2) and housekeeping 18S primers were 
purchased from Qiagen (VIC, Australia). RNeasy Mini Kit (contains sterile, RW1 buffer, 
RPE buffer, RPE buffer and RNase-free water), QuantiTect Reverse Transcription Kit 
(contains gDNA Wipeout Buffer, Quantiscript Reverse Transcriptase, Quantiscript RT 
Buffer, RT Primer Mix and RNase-free water), two-step Q-RT-PCR kit (contains 2×Rotor-
Gene SYBR Green PCR Master Mix and RNase-free water) were also purchased from 
Qiagen (VIC, Australia). 
 Methyl β-D-xylopyranoside (Xyloside), Sepharose CL-6B, sodium borohydride, 
diethylaminoethyl-sephacel (DEAE-sephacel), Whatman 3MM chromatography paper were 
supplied by Biolab (Mulgrave, Australia). Carrier-free 35S-sulfate was obtained from MP 
Biomedicals (LA, USA). Cetyl pyridinium chloride (CPC) was purchased from Unilab 
Chemicals and Pharmaceuticals (Mumbai, India). Rainbow™[14C] methylated protein 
molecular weight markers were from GE Healthcare Bio-Sciences Corp. (Piscataway, NJ). 
Tris Base and glycine were obtained from Amresco (OH, USA). Tween 20, Poly-Prep 
columns, 30% acrylamide/Bis Solution, ammonium persulfate (APS), Trans-blot® Turbo™ 
RTA mini polyvinylidene fluoride (PVDF) transfer kit (containing 40 mini-sized PVDF 
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membranes, 80 transfer stacks, 5×transfer buffer), polyvinylidene fluoride (PVDF), 
tetramethylethylenediamine (TEMED) and Quantity One imaging software were from 
BioRad Laboratories (CA, USA). Target genes and primers sequences of the GAG 
synthesizing enzymes were purchased from GeneWorks Pty Ltd (SA, Australia) and dapted 
from [314-318]. 
 
 
Table 2.1 Antibodies, type and dilution used in this study  
N. Antibody Type  Dilution  
1 Anti-phospho-p44/p42 ERK1/2 Primary 1:1000 
 Anti-phosphoAKT Primary 1:1000 
2 Anti- GAPDH Primary 1:5000 
3 HRP-anti-rabbit IgG Secondary 1:1000 
4 SMA Primary 1:1000 
5 eNOS Primary 1:1000 
6 vWF Primary 1:1000 
7 Anti-CRALBP [B2] cellular retinal-
binding protein 
Primary 1:1000 
8 Alexa Fluor 488 donkey anti-mouseor or 
anti-rabbit IgG 
Secondary 1:400 
9 Alexa Fluor 594 donkey anti-mouse or 
anti-rabbit IgG 
Secondary 1:400 
10 Hoechst 408  Secondary 1:500 
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2.2 Methods 
2.2.1 Cell culture 
Monkey retinal choroidal endothelium cells (RF/6A) (ATCC® CRL­1780™) and 
human retinal pigmented epithelial cells (RPE-19) (ATCC® CRL-2302™) were purchased 
from American type culture collection (ATCC®). Cells were thawed by gently shaking them 
in a water bath at 37ºC, washed with 10 ml DMEM (20% FBS in 5 mM glucose and 1% 
antibiotics) and centrifuged at 900 rpm for 3 minutes. Cells were then grown and passaged 
from frozen stock culture for experiments using between 3-20 passages. Prior to starting the 
experiments, confluent cultures were quiescent in DMEM (0.1% heat inactivated FBS) for 
48 hours. Aseptic conditions were maintained during all culturing and subculturing 
procedures. 
Confluent cells were trypsinised and centrifuged at 900 rpm for 3 minutes after 
which the total number of cells was determined for calculating the number of cells needed 
(5x 106 to 2 x107 cells/ml) for other planned experiments. The cells were resuspended in the 
freezing medium (1: 10 ratios of DMSO to DMEM (5 mM glucose, 20% FBS)) with 1 ml 
of freeze suspension per cryogenic vial. Each vial was screwed tightly and placed in holders 
and stored at -80ºC overnight. Vials were later transferred to liquid nitrogen for long term 
storage. Cells were also maintained in DMEM 5mM glucose, 10% FBS heat inactivated at 
56ºC for 30 minutes (according to Invitro Technologies recommendations), and 1% 
antibiotics at 37ºC in 5% CO2. 
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2.2.2 Cell characterization using fluorescent imaging 
2.2.2.1 Retinal choroidal endothelium cells (RF/6A) 
RF/6A cells were characterized using endothelial specific immunocytochemistry 
markers and immunofluorescence microscopy. Cells were grown on glass coverslips grade 
number 1.5 (22x22 mm) and then rendered quiescent via serum deprivation. The resultant 
quiescent cells were fixed in 2% paraformaldehyde in 1 N phosphate buffer solution for 10 
minutes and then permeabilized and blocked for 30 minutes in 0.1% Triton X-100, 1% 
normal horse serum. Cells were then incubated for 90 minutes at room temperature in a 
humidified chamber, with smooth antibodies to either muscle alpha-actin, endothelial nitric 
oxide synthase or von-Willebrand factor overnight followed by Alexa 488 or 594 and 
Hoechst staining for 30 minutes. Coverslips were used to cover the slides, dried at 4ºC for 
24 hours, and cells were imaged using a Nikon C1 confocal microscope, with excitation 
wavelengths of 519 nm and 617nm. 
2.2.2.2 Retinal pigmented epithelial cells (RPE-19) 
Retinal pigmented epithelial cells (RPE-19) were characterized using anti-
CRALBP [B2] retinal epithelial cell-specific marker. 
2.2.3 Freezing RF/6A or RPE-19 cells 
The old media was removed from the confluent cells in 75 cm2 flasks and 3 ml of 
trypsin added to the cells for 2-5 minutes at 37°C until the cells became detached from the 
flask. Trypsinized cells were transferred into a 50 ml falcon tube and 30 ml of DMEM added 
before the mixture was centrifuged at 900 rpm for 3 minutes. The supernatant was decanted 
and 10 ml (10% DMSO in 20% FBS heat inactivated DMEM) was added to the cells. One 
ml of the culture media was transferred to each of 1.5 ml vials at (5×106 to 2×107 cells/ml) 
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after which each vial was screwed tightly and placed in holders to store at −20°C. Vials were 
then transferred to -80oC overnight or returned to liquid nitrogen for long term storage. 
2.2.4 Thawing RF/6A or RPE-19 cells 
Cells were removed from liquid nitrogen and warmed in a 37oC incubator in a 
controlled 5% CO2 atmosphere. Fresh medium (6 ml) was added just before the thawed 
samples were suspended in centrifuge tubes containing 6 ml warmed 20% FBS heat 
inactivated DMEM (5 mM DMEM containing 20% (v/v) FBS and 1% antibiotics and 
subsequently centrifuged at 900 rpm for 3 minutes. The mixture was re-centrifuged with 
samples being re-suspended in fresh medium before being added to 25 cm2 small tissue 
culture flask. Approximately 20% heat inactivated FBS was used only when thawing cells 
or growing new cells until cells reached their normal growth rate. All other treatments 
required the use of 10% heat inactivated FBS. Cells media was replaced with fresh media 
every 24 to 48 hours. 
2.2.5 Subculturing RF/6A or RPE-19 cells 
Confluent flasks were trypsinised and transferred into a 50-ml falcon tube 
containing DMEM (5mM glucose, 10% heat inactivated FBS at 56ºC for 30 minutes and 1% 
antibiotics). The falcon tubes were centrifuged at 900 rpm for 3 minutes. The supernatant 
was discarded and the precipitated pellets re-suspended in fresh DMEM. The RF/6A or RPE-
19 cells were counted prior to plating and sub-culturing cells. 
2.2.6 Cell counting 
For cell count assays, the ZTM Particle Counter (Beckman Coulter, NSW, Australia) 
was used. One counter was primed with 7 ml of cell suspension then mixed with 19 ml PBS 
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to achieve a diameter in the range of 8-24 µm and a count volume of 0.5 ml. The average of 
three counts was used for any desired calculation. 
2.2.7 Radiolabel incorporation and quantitation of 35S-sulfate into PG 
RF/6A or RPE-19 cells were grown to confluence in 24-well plates at a density of 
20,000-60,000 cells per well and serum deprived for 48 hours. Cells treated in 0.5 ml (5 mM 
glucose DMEM, 0.1% heat inactivated FBS) containing 35S-sulfate (50 or 25 μCi/ml) 
quiescent cells were changed to fresh media in the presence and absence of antagonist for 
24 hours. The antagonists were pre-incubated for 30 minutes prior to treatment with 
antagonists. Secreted or cell-associated PGs were collected with protease inhibitors (5 mM 
benzamidine in 0.1 M 6-aminocaproic acid) to prevent degradation. The amount of 
radiolabel incorporated into PGs was then measured. 
2.2.8 Quantitation of PGs using CPC precipitation assay 
35S-sulfate incorporated into PGs was quantitated according to the CPC 
precipitation assay. At the end of sulfate incorporation experiments, 50 μL of the medium 
was spotted on Whatman 3MM chromatography paper and left to dry at room temperature 
for 24 hours, washed five times for 30 minutes using 1% CPC and 0.05 M NaCl. The 
residuals remaining on the filter paper surface were placed in a 20 ml scintillation vial to 
which 8 ml scintillation cocktail was added. The 35S-sulfate was then counted by a beta 
counter instrument (Perkin Elmer Liquid Scintillation Analyzer Trib-Carb 2810 TR) using 
QuantaSmart TM software. The sulfate incorporated into PGs was quantified. 
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2.2.9 Harvesting and isolation of PGs by ion exchange chromatography 
The harvested PGs were purified by ion-exchange chromatography on DEAE-
Sephacel anionic exchange mini columns. Samples were washed five times with low salt 
EDTA-triton buffer (8M urea, 2 mM disodium EDTA, 0.5% Triton X-100, 0.25 M NaCl, 50 
mM Tris/HCl, pH 7.5) to remove free 35S-sulfate. PGs were eluted using high salt buffer (8 
M urea/3 M NaCl). Ethanol/potassium acetate precipitation technique was used to 
concentrate the harvested PGs. 
2.2.10 Separation of PGs by SDS-PAGE  
Ethanol solution (1.3% potassium acetate in 95% ethanol) with 5 μL of chondroitin 
sulfate 10mg/ml (as cold carrier) was used to precipitate equal counts of isolated PGs (10,000 
- 50,000 cpm) or an equal aliquot precipitate overnight (see sections 2.2.10.1 and 2.2.10.2). 
Separation of PGs was performed on gradient separating (SDS-PAGE) (4-13% PGs size or 
4-20% for xyloside experiments GAG elongation) and stacking gels with 3% acrylamide. 
Precipitated pellets were resuspended in 20 µl of buffer (containing 480 g Urea and 745 
Disodium EDTA mg dissolved in 1 litre at pH 7.5). Sample buffer 20 µl (containing 3 ml 
dH2O, 1 ml 0.5M Tris-HCl, pH 6.8, 1.6 ml 10% SDS, 1.6 ml 50% glycerol, 400 µl 2 β-
mercaptoethanol and 400 µl 0.05% bromophenol blue) was mixed with 20 µl of resuspended 
sample. The mixture was heated at 95ºC for 5 minutes to denature the proteins. Gels were 
run overnight at 60 V at room temperature, fixed (5% methanol, 7% acetic acid) for 1 hour 
and soaked in 20 gl-1 polyethylene glycol, 12.5% methanol for 4 hours. The sizing marker 
used was (Rainbow™ [14C]). Imaging was performed on dried gels imaging cassette using 
(Fujifilm BAS-MS 2040 imaging plate) for 4-10 days. The Cyclone plus phosphor imager 
(Perkin Elmer) image plate scanner was used to obtain digital images. Figure 1.2 shows this 
technique .  
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2.2.10.1 Equal counts 
The equal count method was applied to each lane on the gel that had equal density; 
this method was used when the interest was to detect the changes in the size of PGs and not 
their amount. 
2.2.10.2 Equal aliquot 
This method was used when the gel reflected the number of counts in the sample 
(similar to the CPC) and through this it was possible to determine any difference in the total 
amount of one or more PGs. The purpose of loading by equal counts or the equal aliquot 
method was to evaluate whether the size of the PGs had changed under experimental 
conditions. 
2.2.11 Synthesis of xyloside-initiated GAG chains 
Quiescent cells were treated with β-D-xyloside (0.5 mM) in DMEM (0.1% FBS, 
0.1% DMSO) and incubated for 24 hours. Prior to treatment with radiolabelled 35S-sulfate 
(50 or 25 mCi/ml), the cells were treated with the respective agonist or antagonist. The PGs 
were harvested after 24 hours according to the protocols earlier described earlier in sections 
2.2.7 to 2.2.10. See Figure 2.2. 
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Cells were cultured, serum deprived for 48 hours, treated with growth factors and inhibitors. This was based on the experimental design used as 
well as the cell type. The cells were radiolabelled with 35S-sulfate. Isolated PGs (isolated via size exclusion chromatography) and PGs/ GAG 
sizing using SDS-PAGE results are presented as gel pictures. The other half refers to spot on Whatman 3MM paper, CPC washed and analysed 
on scintillation counter. 
Figure 2.1 Flow chart of the methodology used to study PGs 
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(A) In the synthesis of PGs, GAG chains are disaccharides linked via sulfate bonds. These 
chains are linked by xylose to a core protein on a serine amino acid in the linker region to 
form the PGs. 
(B) The mechanisms involved into GAG chains building on artificial xyloside for the 
exclusion of the core protein which constitute one third of the molecular size of the PGs. 
Hence any increase in the size of the smear on the SDS will show as an increase in the GAG 
chain length. 
Figure 2.2 Use of xyloside to measure cellular GAG synthesizing capacity and 
mechanism involved into GAG chains building on artificial xyloside 
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2.2.12 Western blotting 
2.2.12.1 Preparation of cell lysates for Western blotting 
To harvest protein from the treated cells, the cells were gently washed with 1x PBS 
and harvested by adding 55 µl of lysis buffer (containing 9.7 ml of RIPA buffer (0.01% 
TritonX100, 150mM NaCl, 50mM Tris pH 7.5, 1mM EDTA, 1μM EGTA pH 9.0, 0.05% 
NP-40, 80μM PMSF) with 200 μl of 50x inhibitor [6-amino caproic acid (100mM) + 
benzamidine (5mM)] and 100 μl of 100mM orthovanadate.). The cells were collected and 
homogenised by passing samples through 19-gauge syringe, 5-10 times to homogenise the 
cells into the buffer. Samples were centrifuged at 1000 rpm for 10 minutes at 4oC and the 
supernatant collected for protein content determination and use in other required 
investigations. 
2.2.12.2 Types of samples transfer on gel 
Protein content was measured using bicinchoninic acid (BCA) assay by resolving 
30-40μg of protein on 10% SDS-PAGE with a 4% stacking gel. Sample transfer was 
achieved with either wet or semi dry procedures. Wet transfer was conducted with PVDF 
membrane soaked in 100% ethanol for activation for 1 minute, rinsed with water and re-
soaked in transfer buffer (3.7% SDS, 20% methanol, 48 mM Tris base, 39 mM glycine) at 
4°C. The gel was removed with care from the glass plates and the cassette was prepared as 
follows: clear plastic, sponge, filter paper, membrane, gel, filter paper, sponge and the black 
plastic. The transfer was set to 100V for 1 hour at 4°C. 
For semi dry transfer, PVDF membrane activation was performed by immersion in 
100% ethanol until it became translucent after which it was immediately transferred to 1X 
transfer buffer (BIO-RAD) which was also used to equilibrate the stacks. One of the wetted 
stacks was positioned on the cassette and this acted as the bottom ion reservoir stack, and 
then the wetted membrane was put on top of the stack on the cassette. For the last step, the 
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gel was put on the PVDF. The exclusion of bubbles from the gel was performed by passing 
a roller over the gel to expel any gas trapped. After this, the second wetted stack was 
transferred with it acting as top ion reservoir stack. The trans-Blot Turbo transfer system was 
used for the transfer (set for mixed molecular weight), the cassette was locked and inserted 
into the transfer system. 
2.2.12.3 Blocking and probing of the membrane 
Membranes were blocked in 5% BSA for 1 hour at room temperature with gentle 
shaking, with the aim of this step being to limit non-specific binding of antibodies. The 
membranes were washed thrice for 5 minutes using 1 x Tris-Buffered Saline and Tween-20 
(TBST) buffer (10mM Tris base, 0.15M NaCl, 1% Tween-20, pH7.6). They were incubated 
with primary rabbit monoclonal antibodies (anti-phosphoErk1/2 and anti-phosphoAKT 
(1:1000) (diluted using 5% BSA) for 30 minutes at 37oC and anti-GAPDH (1:5000) over 
night in a cold room (4oC). The membranes were washed thrice for 5 minutes using 1 x Tris-
Buffered Saline and Tween-20 (TBST) buffer. Secondary HRP-anti-rabbit IgG (1:1000) was 
applied for 1 hour at room temperature with the membranes shaken. They were then washed 
3 consecutive times with TBST buffer for 5 minutes. 
2.2.12.4 Image densitometry 
Blots were visualized using chemiluminescence (ECL™ Western Blotting analysis 
system, Amersham™) using the BIO-RAD gel documentation system and then processed 
utilizing XRS® imaging software. The XRS software was used to view western blot images 
and the images were rotated to align the band for the protein of interest horizontally in the 
window view. The rectangle tool function in the software was used to accurately cover the 
band of interest and the respective background that was later subtracted from the band 
density. The density of the loading GAPDH was assessed using the same procedure 
described above. 
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2.2.13 Intracellular calcium assay  
To measure intracellular calcium released, cells were initially plated onto 96-well 
plates (10000 cells/well) after which they were cultured to 80% confluency and then serum 
deprived (DMEM 5mM glucose 1% FBS) was added for 48 hours. Fura-2-acetoxymethyl 
ester, which is a calcium release indicator known as (Fura-2AM), Formula: C44H47N3O24, 
(2µM, 30 minutes, 37ᵒC) was added to the cells with 2µM probenecid and 0.01% pluronic 
F-127 added to enhance the quantification of intracellular calcium as these bind to the 
calcium in the cell. Experiments were conducted in HANKS buffer (10mM HEPES, 5mM 
KCL, 140mM NaCl, 1mM MgCl2, 2mM CaCl2, 11mM Glucose). Cells were briefly 
incubated with antagonists for 15 minutes before stimulation with agonists. Fluorescence 
was quantified at 4 second intervals at 340nm and 380nm excitation and 510nm emission 
wavelengths using Flexstation 3 plate reader (Molecular Devices, Sunnyvale, CA). The 
calcium bound to FURA-2/AM in the cell was determined by subtracting basal fluorescence 
from peak fluorescence resulting from agonist addition. See Figure 2.3 below. 
 
  
74 
 
 
 
 
 
Fluorescent FURA-2/AM was firstly added to the cells because binding to the intracellular 
calcium enhanced its measurements. Secondly, agonist activated receptor led to the 
activation of an intermediate downstream step pathway in the cells, which in turn caused the 
release of the intracellular calcium that was bound to the FURA-2/AM. Finally, fluorescence 
strength was directly proportional to the amount of released intracellular and extracellular 
calcium. 
 
  
Figure 2.3 Diagram of the processes involved in the intracellular calcium assay 
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2.2.14 Quantification of GAG biosynthetic enzyme gene expression 
2.2.14.1 RNA extraction and analysis 
Cells were grown to a density of 50,000 cells on 60 mm dishes in DMEM (5mM 
glucose, 10% FBS and 1% antibiotics). Medium was replaced after 24 hours and cells were 
cultured until they reached confluence. They were allowed to quiesce in DMEM for 48 
hours. After 48 hours, the cells were exposed to short incubation with the antagonists (30 
minutes) before their subsequent exposure to agonists for time course studies.  
Total RNA was isolated by using the RNeasy mini kit (Qiagen) following the 
manufacturer’s protocol. The medium was initially aspirated and the cells lysed immediately 
with lysis buffer (350 µL/well) and 2 β-mercaptoethanol. The cells were then scraped and 
collected in 1.5 ml Eppendorf tubes. Homogenisation was performed several times through 
a 20-gauge needle. The tubes with the homogenate were stored at room temperature for a 
few minutes. Approximately 140µL of chloroform was added to each tube and shaken for 
15 seconds before being incubated for 3 minutes at room temperature. This was followed by 
a centrifugation step for 15 minutes at 10,000 rpm at 4ᵒC. In a new Eppendorf, the top 
colourless aqueous phase was decanted and mixed with 100% ethanol (350 µl). RNeasy mini 
spin column was loaded with 700 µl of the sample and centrifuged at 10,000 rpm at room 
temperature for 15 seconds. The flow-through was discarded and the process repeated with 
remaining sample. DNA digestion was performed on the column using RNase-Free DNase 
Set (Qiagen). Ethanol (350 µl of 70%) was added prior to centrifugation. A specified volume 
of RLT buffer (350ul) was transferred to the RNeasy spin column and centrifuged at 10,000 
rpm for 15 seconds; the flow-through was collected and directly transferred onto the RNeasy 
spin column membrane and allowed to stand for 15 minutes. This was followed by the 
addition of (350 µL) of RLT Buffer to the RNeasy spin column, after which the samples 
were centrifuged at 10,000 rpm at room temperature for 15 seconds. RPE buffer (500 µl) 
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was added to the RNAse spin column, following the removal of the flow through, and then 
re-centrifuged at room temperature for 15 seconds at 10,000 rpm. Samples were again 
centrifuged at 10,000 rpm for 2 minutes at room temperature.  
The spin column was placed in a new 2 ml collection tube and centrifuged at full 
speed for 1 minute. The content of the spin column was transferred into another 1.5 ml 
Eppendorf collection tube and 35µL of RNase-free water added to the spin column 
membrane. The content was centrifuged at 10,000 rpm at room temperature for 1 minute. 
Extracted RNA was immediately cooled on ice prior to the quantification of RNA by a 
Nanodrop2000 spectrophotometer (Thermos fisher Scientific). The ratio 260/280nm 
wavelength was used to determine the purity of RNA which was in the range of 1.8-2.1. 
2.2.14.2 Synthesis of cDNA 
First strand cDNA was synthesized from 500 ng RNA as per Quantitect reverse 
trancriptase kit (Qiagen) protocol. There were 2 steps in the process, the first step was the 
elimination of genomic DNA (gDNA) and the second step was the reverse transcription. In 
the first step, purified RNA was incubated for 2 minutes at 42ᵒC with 2μL of gDNA wipeout 
buffer before being stored on ice. In the second step, the reverse transcription master mix 
was prepared as followed: 1μL QuantiTec reverse trancriptase was added to 4μL 
Quantiscript RT buffer and 1μL RT primer mix. The contents from the 2 steps were mixed 
and incubated for 15 minutes at 42°C for cDNA synthesis before reverse transcriptase was 
inactivated by incubating the content at 95°C for 3 minutes. 
2.2.14.3 Quantitative Q-RT-PCR 
Quantification of mRNA expression of GAG enzyme genes was achieved with Q-
RT-PCR utilizing a Rotor-Gene Q (Qiagen) and Quanti Fast SYBR Green PCR Master Mix 
kit (Qiagen). Each reaction tube contained 5μL of SYBR Green, 1μL of 10μM mix of 
forward and reverse primers, 1μL of 500ng cDNA and 2 μL of RNA free water. The 
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reactions were run in a Rotor-Gene Q. The Q-RT-PCR reaction was placed in a thermal 
cycler with the conditions of the following two steps. First step cycling conditions were: 
Hold for 5 mins at 95ºC (initial activation step). Step two cycling was comprised of 40 cycles 
(95ºC 7 sec, 60ºC 15 sec; combining annealing/extension). The data was normalised to 18S 
rRNA house keeping gene. The mRNA levels were quantified using comparative Delta-
Delta (ΔΔ) Ct method. 
 
Table 2.1 Target genes and primers sequences of the GAG synthesizing 
enzymes. Adapted from [314-318]. 
Gene Target gene Q-RT-PCR primer sequence (5'- 3') 
XT-1 
Forward 
Reverse 
GTGGATCCCGTCAATGTCATC 
GTGTGTGAATTCGGCAGTGG 
 
ChGn-2 
 
Forward 
Reverse 
GGGCTAATGGCATAGGCTATCA 
CTTTGTCAATTTGGGAATGAAGAA 
ChPF 
 
Forward 
Reverse 
AGATCCAGGAGTTACAGTGGGAGAT 
CCGGGCGGGATGGT 
ChSy-1 
 
Forward 
Reverse 
CCCGCCCCAGAAGAAGTC 
TCTCATAAACCATTCATACTTGTCCAA 
C4ST-1 
 
Forward 
Reverse 
GGCCCTGCGCAAAG 
GGGTGTGTGGGTCGATGAG 
C4ST-2 
 
Forward 
Reverse 
AACGAGGAGTTCTACCGCAAGT 
GCTTGTGTGGTTGGCGTACA 
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2.2.14.4 Quantitation using comparative Cycle-threshold (Ct)  
Cycle threshold (Ct) values for each individual GAG enzyme gene expression 
sample were recorded and compared with non-treated control. Both values were normalised 
against the endogenous ribosomal 18S rRNA housekeeping gene. The quantification of 
results was calculated using the formula below. 
ΔCt= Ct (gene interest) – Ct (18S gene) 
ΔΔCt= ΔCt (Sample) – ΔCt (Reference) 
Fold regulation = 2-ΔΔCt 
 
2.2.15 Statistical analysis 
Statistical data analysis was performed. Data were first normalised and expressed 
as the mean ± standard error of the mean (SEM) of at least three independent replicates 
unless stated otherwise. A one-way ANOVA was used to calculate statistical significance of 
normalised data, followed by least significant difference post-hoc analysis. Results were 
considered significant when the probability was less than 0.05 (*p<0.05) and 0.01 
(**p<0.01). 
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3. Chapter 3: Effect of growth factors on PGs produced by 
retinal endothelial cells 
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3.1 Abstract 
A major feature of early AMD is the thickening of BM in the retina and an alteration 
of its composition with increased lipid content. In some pathological conditions, such as 
atherosclerosis PGs are responsible for lipid retention in various tissues including VSMC 
with some growth factors known to increase the length of GAG chains. This increase in 
chain length can lead to an increase in interactions with lipids. Using RF/6A choroidal 
endothelial cells, this project investigated the effects of selected AMD relevant growth 
factors such as TGFβ, thrombin, PDGF, IGF and VEGF on PG synthesis and GAG chain 
elongation. Cells were confirmed as endothelial in origin using the specific cell markers 
endothelial nitric oxide synthesis and von Willebrand factor and imaged using confocal 
microscopy. Cell cultures were treated with growth factor and were radiolabelled with 35S-
sulfate. PGs were isolated by ion exchange chromatography and sized using SDS-PAGE. 
Radiosulfate incorporation was determined by CPC precipitation technique. Xyloside was 
added and cellular GAG synthesizing capacity was measured. RF/6A cell signalling was 
studied by phospho-Erk and phospho-Akt western blotting. VEGF treatment did not 
stimulate any change in PG synthesis or pAKT levels but caused a large increase in pERK 
levels. The agonists TGFβ, thrombin, PDGF, and IGF dose dependently stimulated 
radiosulfate incorporation and GAG elongation by 50%, 40%, 30% and 30% respectively, 
as well as stimulating xyloside initiated GAG elongation. Surprisingly, VEGF had no effect 
on radiosulfate incorporation or xyloside GAG formation. These findings demonstrate that 
AMD relevant agonists caused GAG hyperelongation of PGs synthesized and secreted by 
retinal choroidal endothelial cells. In addition, the findings also suggest PGs as a novel 
potential target in AMD and that one effect of growth factors on endothelial cell PG 
production might be to contribute to the thickening of BM, a feature of early AMD. Future 
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studies should examine the relevance of these changes on enhanced lipid binding and the 
development of AMD. 
3.2 Introduction 
There is an increasing recognition that some major diseases are associated with the 
deposition of lipids in tissues [50, 173, 174, 319]. For example, apolipoproteins on LDL 
particles can become trapped and deposited in tissues where subsequently biochemical 
modifications generate immunogenic particles initiating an inflammatory reaction [173, 
174]. This inflammatory response often becomes chronic or unresolved and is the underlying 
pathology of diseases including atherosclerosis [320]. The biochemical events underlying 
the trapping of lipids in tissues involve a role for PGs [321, 322]. PGs are protein 
carbohydrate adducts which are ubiquitously expressed. PGs play a role in normal 
physiology such as in the function of joints but modified PGs are associated with disease 
processes [231, 323-326]. Some small leucine-rich PGs such as biglycan have CS and DS 
GAG chains which are sulfated, highly negatively charged and avidly bind to positively 
charged amino acid residues of apolipoproteins on LDL particles [97, 248, 326-329]. A wide 
range of growth factors and hormones stimulate the gene mRNA expression of GAG 
synthesising enzymes leading to hyperelongation of GAG chains [97, 248, 330-335]. The 
relationship between the size (length) of a GAG chain and propensity to bind lipid particles 
is related to the basal or natural size of GAG chains with increase in the GAG size leading 
to a marked increase in the binding to lipids [62, 97, 98, 268, 289, 336, 337]. Therefore, 
initial tissue insults lead to increased expression and availability of growth factors, hormones 
and cytokines. These compounds can cause an increase in GAG length with increased lipid 
binding and the initiation of a pathological cascade. This cascade, ultimately sets off the 
inflammatory response which can lead to a more serious and acute manifestation of the 
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disease. There is strong clinical evidence for the role of GAG elongation in early human 
atherosclerosis [3, 48, 50, 325, 338]. 
There are presently no clinical therapies which target this early stage of GAG 
modification. However, there have been studies which have shown an association of GAG 
elongation with the development of atherosclerosis [168, 339]. Successful proof of concept 
studies in animal models showing that blocking GAG elongation can prevent lipid deposition 
and atherosclerosis have been reported [289]. 
This project investigated the actions of multiple growth factors and hormones on a 
retinal endothelial cell model to address the question; does the phenomenon of GAG 
elongation occur in these cells as an underlying cause of the unknown thickening of BM in 
early AMD? Apart from this, this study also investigated the actions of protein tyrosine 
kinase and protein serine/threonine kinase growth factor receptor agonists as well as GPCR 
agonists; all are known to stimulate hyperelongation of GAG chains on biglycan produced 
by VSMC [98, 231, 268, 332, 335, 340]. The process of GAG hyperelongation can be 
investigated in-depth by supplying cells with exogenous xyloside. The xyloside serves as a 
false acceptor for the initiation of the synthesis of small free GAG chains known as “xyloside 
GAGs”. Consequently, in this study, several agonists were evaluated to assess their existence 
and role in this process in retinal cells [3, 233, 341]. 
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3.3 Materials and methods 
3.3.1 Materials 
DMEM (0 and 25 mM glucose), trypsin-versene, antibiotics (10,000 U/ml 
penicillin, 10,000 μg/ml streptomycin) were purchased from Gibco BRL (NE, USA). FBS 
was from Invitro Technologies, Pty. Ltd. (VIC, Australia). PDGF-BB, thrombin, SB431542, 
PBS (10X), SDS, DMSO and chondroitin sulfate were purchased from Sigma-Aldrich, (MO, 
USA). UO126 was purchased from Promega (Madison, WI, USA). Human TGFβ, anti-
pErk1/2 (Thr202/Tyr204), anti-GAPDH and VEGF were obtained from Cell Signalling 
Technology (MA, USA). Imatinib was obtained from Alfred Hospital Pharmacy (Australia). 
IGF-1 was obtained as a gift from Prof. Wenhua Zheng (Faculty of Health Sciences, 
University of Macau, Taipa, Macau and Key Laboratory of Ophthalmology, Zhongshan 
Ophthalmic Center, Sun Yat-sen University, Guangzhou 510006, China). Carrier-free 35S-
sulfate was purchased from MP Biomedicals (LA, USA). CPC was obtained from Unilab 
Chemicals and Pharmaceuticals (Mumbai, India). Whatman 3MM chromatography paper 
was purchased from Biolab (Mulgrave, Australia); Insta-Gel Plus Scintillation fluid Instagel 
was obtained from Packard (Groningen, The Netherlands). SN30978 was provided by 
Dr Graeme Lancaster (Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia). 
3.3.2 Methods 
3.3.2.1 Cell culture 
Human vascular smooth muscle cells (VSMCs) were obtained from discarded 
sections of saphenous veines from patients undergoing coronary artery bypass grafting at the 
Alfred Hospital; the acquisition of the vessels was approved by the Alfred Hospital Ethics 
Committee. RF/6A (ATCC® CRL­1780™) cells were purchased from the American Type 
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Culture Collection (ATCC®). Cells were thawed at 37°C, then allowed to routinely grown 
in DMEM (5mM glucose, 10% heat inactivated serum and 1% antibiotics (1×104 U/ml 
penicillin and 1×104 μg/ml streptomycin) at 37°C in 5% CO2). RF/6A cells were seeded on 
60 mm dishes and 24 well-plates. Cells were grown to confluence before being rendered 
quiescent by serum deprivation for 48 hours. 
3.3.2.2 Cell characterization 
RF/6A cells were grown on 1.5 glass coverslips and then rendered quiescent via 
serum deprivation. After treatment, cells were fixed in 2% paraformaldehyde in 1 N 
phosphate buffer solution for 10 minutes and then permeabilized and blocked in 0.1% Triton 
X-100, 1% horse serum for 30 minutes. Cells were incubated for 90 minutes with anti- 
smooth muscle α-actin, endothelial nitric oxide synthase or von-Willebrand factor antibodies 
overnight followed by Alexa-Flour 488 or 594 and Hoechst stain for 30 mins. Coverslips 
were then mounted on slides, and cells were imaged using a Nikon D-eclipse C1 confocal 
microscope. 
3.3.2.3 Quantitation of radiolabel incorporation into PGs 
Quantitation of radiolabel incorporated into PGs 35S-sulfate was performed on 
RF/6A in 24-well plates (at a density of 20000-60000 cells per well), quiescent cells were 
changed to fresh medium containing 50 μCi/ml 35S-sulfate in the presence and absence of 
thrombin, TGF-β, VEGF, IGF, or PDGF for 24 hours. Secreted PGs were harvested and 
protease inhibitors (5mM benzamidine in 0.1 M 60 aminocaproic acid) were added to 
prevent degradation. Incorporation of the radiolabel into PGs was measured quantitatively 
according to the CPC precipitation assay, as described previously [342]. Aliquots of the 
medium on Whatman 3MM filter paper were rinsed several times in 1% CPC with 0.05 M 
NaCl. The filter paper was dried and its radioactivity measured by liquid scintillation 
counting. 
85 
 
3.3.2.4 Synthesis of xyloside GAG chains 
Cellular GAG synthesizing capacity was measured using xyloside techniques. 
Quiescent cells were treated in 0.5 ml DMEM / 0.1% FBS supplemented with xyloside (0.5 
mM) under basal conditions and in the presence of agonists before the addition of 35S-sulfate 
(50 μCi/ml) for a further 24 hours. Amino-disaccharides bind with artificial xyloside to 
initiate GAG chain. Secreted xyloside GAG chains were harvested, isolated, concentrated, 
and SDS-PAGE was used for the quantification. 
3.3.2.5 SDS-PAGE analysis of PG size 
PGs and xyloside GAGs labelled with  35S-sulfate were sized by SDS-PAGE after 
isolation through DEAE-Sephacel anionic exchange mini columns [343]. Radiolabelled PGs 
were added to pre-equilibrated columns and then washed extensively with low salt buffer 
(8M urea, 0.25M NaCl, 2mM disodium EDTA, 0.5% TritonX-100). PGs were eluted with 
high salt buffer (8M urea, 3M NaCl, 2mM disodium EDTA 0.5% Triton X-100) and 
fractions containing the highest levels of 35S-sulfate (cpm) were used. Equal amounts of PGs 
were precipitated by ethanol solution (1.3% potassium acetate in 95% ethanol) [97, 332]. 
Chondroitin which serves as a cold carrier was added. Equal amounts of samples (20 µl) 
were dissolved in (20 µl) NONO buffer (8 M urea, 2 mM disodium EDTA, at pH 7.5). 
Radiolabelled samples were separated on 4-13% PGs or 4-20% (xyloside-GAGs) acrylamide 
gels and 3% acrylamide stacking gel at 60 V overnight. Gels were fixed, dried and exposed 
to an imaging plate (Fujifilm BAS-MS 2040 imaging plate) for approximately 4-5 days. 
Images were developed on a Cyclone Plus Phosphor Imager (Perkin Elmer). 
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3.3.2.6 Western blotting  
To harvest the protein from the treated cells, the cells were gently washed with 
1xPBS and harvested by adding 55 µl of lysis buffer (containing 9.7 ml of RIPA buffer 
(0.01% TritonX100, 150mM NaCl, 50mM Tris pH 7.5, 1mM EDTA, 1μM EGTA pH 9.0, 
0.05% NP-40, 80μM PMSF) with 200 μl of 50x inhibitor [6-amino caproic acid (100mM) + 
benzamidine (5mM)] and 100 μl of 100mM orthovanadate). The cells were collected and 
homogenised by passing samples through a 19-gauge syringe, 5-10 times to homogenise the 
cells into the buffer. Samples were centrifuged at 1000 rpm for 10 minutes at 4oC and the 
supernatant was collected (protein content) for further investigations. Total cell lysates were 
resolved by SDS-PAGE on 10% gels and transferred onto PVDF membranes. Membranes 
were blocked with 5% bovine serum albumin and incubated with anti-phospho-Akt (Ser473) 
and anti-phospho-Erk1/2 (Thr202/Tyr204) rabbit monoclonal antibody followed by HRP 
anti-rabbit IgG and ECL detection. Blots were imaged using the Bio-Rad gel documentation 
system and densitometry analysis was performed with Lab imaging software. 
3.3.2.7 Statistical analysis 
Data was normalised and expressed as the mean ± standard error of the mean (SEM) 
of three independent experiments unless stated otherwise. Data were analyzed using a one-
way ANOVA. Statistical significance of the normalised data was calculated and analyzed 
using the least significant difference post-hoc analysis. Results were considered significant 
when the probability was less than 0.05 (*p<0.05) and 0.01 (**p<0.01). 
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3.4 Results 
3.4.1 Characteristics of RF/6A cells 
RF/6A morphology characteristics were assessed and compared to a reference culture to 
show only morphological characteristics of the cells (Figure 3.1).    
 
 
 
 
 
 
 
 
 
Phase contrast image of RF/6A cells passage 12, x200 magnified. The morphology of the 
cells was typical of that available in published literature (which were hexagonal shape, 
structure and orientation of the cells). Endothelial cells in intact vascular tissue are not 
hexagonal in shape, but rather are thin and elongate. Endothelial cells that are stressed, as is 
standard for isolation and culture, generally have a cobblestone/polygonal morphology, and 
unless flow is applied, are distinct in gross appearance to those of intact vessels. A Nikon 
camera microscope was used to capture the image. 
Figure 3-1 Phase contrast image of RF/6A cells 
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3.4.2 Characterization of RF/6A cells 
RF/6A cells were characterized using immunofluorescence and confocal 
microscopy techniques. Human VSMCs were used as a negative control and both cell types 
were stained with two endothelial specific markers and a marker for VSMCs. The markers 
used were endothelial eNOS and vWF as markers for endothelial cells and SMA as a marker 
for smooth muscle cells. 
The results demonstrated that RF/6A cells were positive for eNOS (Figure 3.2A) 
and vWF (Figure 3.2B) while being negative for SMA (Figure 3.2C). VSMCs cells were 
negative for eNOS (Figure 3.2D) and vWF (Figure 3.2E) while being positive for SMA only 
(Figure 3.2F). RF/6A cells showed the typical hexagonal shape and the results confirmed 
the endothelial cell lineage of the cells used in this project. 
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The photomicrographs top row (A-C) show RF/6A cells and the bottom row (D-F) show 
human VSMCs. Confocal images of cells stained for expression of specific endothelial 
markers, cellular localization cytoplasm (refers to the specific binding of endothelial markers 
with cellular cytoplasm) (A and D) eNOS (B and E) vWF and (C and F) vascular smooth 
muscle cell marker SMA cellular localization cytoplasm and cytoskeleton. presumably, 
'localization cytoplasm and cytoskeleton' refers to SMA expression/distribution Primary 
antibodies 1:1000, secondary antibodies 1:400, green Alexa Fluor 488 donkey anti- rabbit 
IgG, red Alexa Fluor 594 donkey anti-mouse IgG, nuclear stain blue Hoechst 408 1:500 and 
blocking serum (Normal Horse Serum) (1:100). Magnifications for all images were x400 
except (E) x200. 
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Figure 3-2 Characterisation of RF/6A cells 
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3.4.3 The effect of AMD relevant growth factors on PG synthesis in 
RF/6A cells 
This project conducted a systematic study of the effect of growth factors and 
hormones on the synthesis and size of PGs secreted by RF/6A cells. The heavily sulfated 
nature of the PGs enabled their synthesis to be monitored through the metabolic 
incorporation of radiosulfate. Choroidal endothelial cells were grown until confluency, 
serum deprived for 24 hours and radiosulfate and growth factors were added for 24 hours.  
A small aliquot of harvested media was spotted on Whatman chromatography paper for 
quantification and the remainder processed through ion exchange columns and further 
concentrated for PG size determination analysis using SDS-PAGE [344]. 
3.4.3.1 Effect of serine/threonine receptor agonist TGFβ on PG synthesis and 
GAG elongation in RF/6A cells 
Published work in our laboratory has used 24 hour-time course experiments to 
incubate cells with agonists and/or antagonists for the study of the synthesis of PGs and 
GAGs elongation which is a process that would take more than 20 hours [96, 97, 233, 235, 
289]. Cells were treated with TGFβ over a dose range of 0 to10 ng/ml for 24 hours which 
resulted in a significant (P<0.05) increase in radiosulfate incorporation at all concentrations 
tested. TGFβ gradually increased 35S-sulfate incorporation into synthesized PGs and GAGs 
elongation. This increase was across the range of concentrations 0.1, 0.2, 0.5, 1, 2, 5, 10 
ng/ml, peaking at 2 ng/ml to reach approximately 50% sulfate incorporation compared to the 
basal level. This increase was similar to the response observed in VSMCs with TGFβ [97, 
233, 235, 236]. Sulfate incorporation decreased dose-dependently above 2 ng/ml TGFβ to 
resemble a curve shape (Figure 3.3A). SDS-PAGE gel showed the associated increase in the 
size of PGs. The electrophoretic mobility using the same amount of radioactivity of intact 
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35S-sulfate labelled PG was resolved on SDS-PAGE. The SDS-PAGE gel of the PGs that 
were isolated from the RF/6A cells treated with various concentrations of TGFβ for 24 hours, 
a band of approximately 95 -120 kDa which corresponded in size to the CS/DS PG compared 
with 95 kDa at basal (Figure 3.3B). 
TGFβ dose dependently stimulated sulfate incorporation into PGs and a noted 
reduced electrophoretic mobility which meant an increase in the PGs overall molecular size 
was observed. These results correlate with 35S-sulfate incorporation shown in Figure 3.3A. 
These novel findings indicated that there was potentially lipid-binding PG expressed by 
retinal endothelial cells. RF/6A cell synthesis and expression of this PG responded to TGFβ 
by increasing the size of the GAG chains as core protein is of a fixed size. 
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(A) Histogram shows the radiosulfate incorporation for cells across a range of TGFβ 
concentrations. (B) SDS-PAGE of the isolated PGs shows a smear 95-120 kDa compared 
with 95 kDa at basal (4-13% acrylamide gradient gel). RF/6A cells were treated with TGFβ 
(0.1, 0.2, 0.5, 1, 2, 5, and 10 ng/ml or without (-) basal (control) and 35S-sulfate radiolabel 
(50mCi/well) was added for 24 hours. The experiment was performed three times, **p<0.01 
(agonist vs. basal) using a 1-way ANOVA. 
  
A B 
Figure 3-3 Effect of serine/threonine receptor agonist TGFβ on PG 
synthesis and GAG elongation in RF/6A cells 
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3.4.3.2 Effect of thrombin on PG synthesis and GAG elongation in RF/6A cells 
Cells were treated with GPCR agonist thrombin and assessed for PG synthesis. 
Figure 3.4A shows the 35S-sulfate incorporation for cells across a range of thrombin 
concentrations. Thrombin significantly and gradually increased 35S-sulfate incorporation 
into synthesized PGs across the range of concentration 0.1, 0.3, 1, 3, 10, 30 U/ml for 24 
hours. 35S-sulfate incorporation peaked at 10 U/ml to reach a 40% increase in 35S-sulfate 
incorporation into synthesized PGs and GAG elongation, in comparison with the basal level 
which decreased after 10 U/ml thrombin. Treatment with the TGFβ 2 ng/ml had similar 
results to the previous data seen in the experiment shown in Figure 3.3A. The SDS-PAGE 
gel showed an associated increase in the size of PGs after TGFβ 2 ng/ml treatment. The 
SDS-PAGE gel of the PGs isolated from the choroidal endothelial cells treated with various 
concentrations of thrombin for 24 hours showed slight increases in the size of PGs which 
was 100-120 kDa at 10 U/ml compared with 95 kDa at basal. TGFβ 2 ng/ml showed 
increases in the size of PGs which was 100-120 kDa compared with 95 kDa at basal (Figure 
3.4B). 
These results indicated that thrombin dose dependently stimulated PG sulfate 
incorporation. Thrombin at 10 U/ml gave the highest sulfate incorporation and PG size 
increase.  
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(A) Histogram shows the radiosulfate incorporation for cells across a range of thrombin 
concentrations and (B) SDS-PAGE gel of the PGs. RF/6A cells were treated with thrombin 
(0.1, 0.3, 1, 3, 10, and 30 U/ml) or without (-) basal (control), cells were treated with TGFβ 
(2ng/ml) as a positive control and 35S-sulfate radiolabel (50mCi/well) was added for 24 
hours. The experiments were repeated at least 3 times with similar results. **p<0.01 and 
*p<0.05 (agonist vs. basal) using a 1-way ANOVA. 
  
A B 
Figure 3-4 Effect of GPCR agonist thrombin on PG synthesis and GAG 
elongation in RF/6A cells 
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3.4.3.3 Effect of tyrosine kinase receptor agonist VEGF on PG synthesis and 
GAG elongation in RF/6A cells 
The effect of VEGF on PG synthesis and GAG elongation in RF/6A cells was 
measured. The histogram in Figure 3.5 showed the 35S-sulfate incorporation for cells across 
a range of VEGF concentrations. VEGF did not lead to an increase in 35S-sulfate 
incorporation into synthesized PGs across the range of concentration 2, 5, 10, 20, 50, 100 
ng/ml. Treatment with the TGFβ 2 ng/ml as a positive control was consistent with previous 
TGFβ results. SDS-PAGE gel showed that VEGF did not cause any significant change in 
the size of PGs at any concentration of VEGF tested (Figure 3.5B). 
Interestingly there was no response of the cells to VEGF in either radiosulfate 
incorporation or electrophoretic mobility. In the same experiment, the cells responded to 
TGFβ presence indicating that the cells were viable and responsive. The SDS-PAGE gel also 
showed that VEGF did not stimulate PGs GAG elongation. Although it should be noted that 
the effect of VEGF on PG synthesis appears not to have been reported for any cell type. 
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A) Histogram shows the radiosulfate incorporation for cells across a range of VEGF 
concentrations and (B) SDS-PAGE gel of the PGs. RF/6A cells were stimulated with agonist 
VEGF (2, 5, 10, 20, 50 and 100 ng/ml) or without (-) basal (control), Cells were treated with 
TGFβ (2ng/ml) as a positive control and 35S-sulfate radiolabel (50mCi/well) was added for 
24 hours. (The experiments were repeated at least 3 times with similar results. **p<0.01 
(agonist vs. basal) using a 1-way ANOVA. 
  
A B 
Figure 3-5 Effect of tyrosine kinase receptor agonist VEGF on PG 
synthesis and GAG elongation in RF/6A cells 
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3.4.3.4 Effect of tyrosine kinase receptor agonist PDGF on PG synthesis and 
GAG elongation in RF/6A cells 
Another tyrosine kinase receptor agonist PDGF was also tested for its effects on PG 
synthesis in RF/6A cells. The histogram in Figure 3.6 shows the 35S-sulfate incorporation of 
cells across a range of PDGF concentrations. PDGF significantly and gradually increased 
35S-sulfate incorporation into synthesized PGs. This increase was across the range of 
concentration 2, 5, 10, 20, 50, 100 ng/ml, peaked at 20 - 50 ng/ml to reach a 30% increase 
in 35S-sulfate incorporation into synthesized PGs and GAGs elongation in comparison with 
the basal. 35S-Sulfation decreased at PDGF 100 ng/ml (Figure 3.6A). SDS-PAGE gel 
analysis showed an associated increase in the size of PGs. The SDS-PAGE gel of the PGs 
that were isolated from the retinal choroidal endothelial cells and treated with various 
concentrations of PDGF for 24 hours showed slight increases in the size of PGs which was 
100 - 120 kDa at concentration of 50 ng/ml PDGF compared with 95 kDa at basal (Figure 
3.6 B). 
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(A) Histogram shows the radiosulfate incorporation for cells across a range of PDGF 
concentrations (B) SDS-PAGE gel of the PGs. RF/6A cells were stimulated with agonist 
PDGF (1, 2, 5, 10, 20, 50 and100 ng/ml) or without (-) basal (control), cells were treated 
with TGFβ (2ng/ml) as a positive control and 35S-sulfate radiolabel (50mCi/well) was added 
for 24 hours. The experiments were repeated at least 3 times with similar results. **p<0.01 
and *p<0.05 (agonist vs. basal) using a 1-way ANOVA. 
 
  
Figure 3-6 Effect of tyrosine kinase receptor agonist PDGF on PG 
synthesis and GAG elongation in RF/6A cells 
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3.4.3.5 Effect of tyrosine kinase receptor agonist IGF on PG synthesis and GAG 
elongation in RF/6A cells 
The cells responses to IGF, another tyrosine kinase receptor agonist was assessed. 
The histogram in Figure  3.7shows the 35S-sulfate incorporation for cells across a range of 
IGF concentrations. IGF significantly and gradually increased 35S-sulfate incorporation into 
synthesized PGs across the range of concentration 2, 5, 10, 20, 50, 100 ng/ml. This peaked 
at 50 ng/ml for a 30% increase in 35S-sulfation in comparison with the basal.35S-sulfation 
decreased after IGF (50 ng/ml). The treatment with the TGFβ 2 ng/ml as a positive control 
had a stimulatory impact on PGs sulfate incorporation as had been observed in earlier results 
(Figure 3.7A). The SDS-PAGE gel showed the associated increase in the size of PGs. The 
SDS-PAGE gel of the PGs that were isolated from retinal choroidal endothelial cells and 
treated with various concentrations of IGF for 24 hours resulted in slight increases in the size 
of PGs which was 100 - 120 kDa at 50 ng/ml compared with 95 kDa at basal. TGFβ use at 
2 ng/ml showed increases in the size of PGs which was 100 - 120 kDa compared with 95 
kDa at basal (Figure 3.7B). 
The cells treated with IGF 10, 20, 50, 100 ng/ml significantly increased 35S-sulfate 
incorporation into synthesized PGs and GAGs elongation indicated that IGF dose 
dependently stimulated PGs sulfate incorporation and at 50 ng/ml gave the highest 
stimulation. IGF dose dependently stimulated PG sulfate incorporation & GAG elongation. 
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(A) Histogram shows the radiosulfate incorporation for cells across a range of IGF 
concentrations (B) SDS-PAGE gel of the PGs. RF/6A cells were stimulated with agonist 
IGF (2, 5, 10, 20, 50 and 100 ng/ml) or without (-) basal (control), Cells were treated with 
TGFβ (2ng/ml) as a positive control and 35S-sulfate radiolabel (50mCi/well) was added for 
24 hours and analysed as described in the text. The experiments were repeated 3 times with 
similar results. **p<0.01 and (agonist vs. basal) using a 1-way ANOVA. 
  
A B 
Figure 3-7 Effect tyrosine kinase receptor agonist IGF on PG synthesis 
and GAG elongation in retinal RF/6A cells 
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3.4.4 Effect of TGFβ, PDGF and thrombin on xyloside initiated GAG 
synthesis in RF/6A cells 
The effect of growth factors on the GAG synthesizing potential of cells was 
assessed with three growth factors that stimulated the cells to synthesize PG. These growth 
factors were from three different receptor families (TGFβ serine/threonine receptor agonist, 
PDGF tyrosine kinase receptor agonist and thrombin GPCR agonist). Xylose is the first 
sugar added to the serine residue on a core protein of a PG, the addition of artificial xyloside 
(exogenous) to the cell cultures stimulated the cells to respond to xyloside [341]. 
Consequently, cells synthesized what was termed xyloside-GAGs which were short GAG 
chains [231, 341]. Our lab has used this technique to assess the effects of different agonists 
and antagonists on VSMCs [96, 234, 343]. 
Cells were treated as described in the previous set of experiments and in the 
additional presence of β-D-xyloside (0.5 mM). Cells were treated with TGFβ (2 ng/ml), 
PDGF (50 ng/ml) and thrombin (10 U/ml) in the presence or absence of respective 
antagonists, SB431542, imatinib and SCH79797. Quantitative analyses were performed on 
xyloside-GAGs production. The histogram in Figure 3.8A showed the xyloside-initiated 
GAG 35S-sulfate incorporation. TGFβ, PDGF and thrombin each stimulated B-D-xyloside 
initiated GAG radiosulfate incorporation by 150%, 30% and 100% respectively, and the 
responses were inhibited by the addition of their respective antagonists (Figure 3.8A). 
SDS-PAGE in Figure 3.8 showed the change in size of xyloside-GAGs. All three 
agonists increased the size of xyloside-GAGs and the responses were completely inhibited 
by the respective antagonists. The increase in radiosulfate incorporation correlated with the 
increase in the size of xyloside GAGs. The xyloside-GAGs showed an increase in the 
molecular weight as the basal was approximately 15 - 20 kDa and in the presence of TGFβ 
(2 ng/ml) the molecular weight increased to 30 - 45 kDa. With the addition of TGFβ 
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antagonist SB431542 (10μM), the response was inhibited and remained at the basal level. 
PDGF (50 ng/ml) increased the xyloside-GAGs molecular weight by around 20 -30 kDa, 
larger than the basal while the addition of the antagonist imatinib (10μM) completely 
blocked the response. Thrombin (10 U/ml) increased the molecular weight of xyloside-
GAGs by around 20- 40 kDa compared to basal (Figure 3.8B). 
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(A) Histogram shows that the radiosulfate incorporation for cells xyloside-GAGs resulted 
from addition of agonists and/or antagonist. (B) SDS-PAGE gel of initiated xyloside -GAG 
(4-20% acrylamide gradient gel). Cells were treated with TGFβ (2 ng/ml) with or without 
SB 431542 (10μM) or without (-) basal (control), PDGF (50 ng/ml) with or without imatinib 
(10μM) and thrombin (10 U/ml) with or without SCH 79797 (10μM). Cells were pre-treated 
with antagonists for 30 minutes. The cell culture media was supplemented with  B-D-
xyloside (0.5mM) to enable the production of xyloside-GAGs as explained in the text, then 
35S-sulfate (50mCi/well) was added for a further 24 hours. The experiment was performed 
three times, **p<0.01 for agonists or ##p<0.01 for antagonists (agonist vs. basal and 
antagonist vs. agonist) using a 1-way ANOVA. 
A B 
Xyloside 
GAG 
Figure 3-8 Effect of TGFβ, PDGF and thrombin on xyloside initiated 
GAG synthesis in RF/6A cells 
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3.4.5 Effect of VEGF and IGF on xyloside initiated GAG synthesis in 
RF/6A cells 
Further investigations were conducted on the effects of VEGF and IGF on xyloside 
initiated GAG synthesis. The histogram in Figure 3.9 showed that IGF (50 ng/ml) stimulated 
xyloside initiated GAG sulfate incorporation by 30% while VEGF did not show any 
xyloside-GAG synthesis. The positive control TGFβ (2 ng/ml) effect was similar to 
observations from previous experiments and inhibitor of TGFβ showed the expected 
responses (Figure 3.9A). SDS-PAGE showed that the change in size of xyloside-GAGs 
slightly induced by IGF (50 ng/ml) but significantly increased while VEGF showed no 
change in the size of xyloside-GAGs. As expected the TGFβ (2 ng/ml) which was a positive 
control, increased xyloside-GAGs and its inhibitor blocked the agonist, similarly to the basal 
level. Xyloside-GAGs treatment with TGFβ (2 ng/ml) showed molecular weights in the 
range of 20 - 40 kDa compared with 15 - 20 kDa at basal (Figure 3.9B). The relevant AMD 
growth factors TGFβ, PDGF, IGF and thrombin stimulated GAG elongation in RF/6A cells 
however surprisingly VEGF did not show any effect on these cells and corresponded to the 
VEGF result observed in Figure 3.5. 
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(A) Histogram shows the radiosulfate incorporation for cells xyloside-GAGs resulting from 
the addition of agonists and/or antagonist. (B) SDS-PAGE gel of initiated xyloside-GAG (4-
20% acrylamide gradient gel). Cells were treated with VEGF (10 and 50 ng/ml), IGF (10 
and 50 ng/ml) or without (-) basal (control), TGFβ (2 ng/ml) in the absence or in the presence 
of SB 431542 (10μM). Cells were also pre-treated and incubated with antagonists for 30 
minutes. The cell culture media was supplemented with xyloside (0.5mM) to enable the 
production of xyloside GAGs as explained in the text, then 35S-sulfate (50mCi/well) was 
added for a further 24 hours. The experiment was carried out thrice, **p<0.01 and *p<0.05 
for agonists or ##p<0.01 for antagonists and (agonist vs. basal and antagonist vs. agonist) 
using a 1-way ANOVA. 
  
A B 
Xyloside 
GAG 
Figure 3-9 Effect of VEGF and IGF on xyloside initiated GAG synthesis 
in RF/6A cells 
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3.4.6 Effect of VEGF on pAkt and MAP kinase signalling  pathway in 
RF/6A cells 
Western blots of lysates from these treatments were probed for pAkt (Ser473).  
GAPDH was used as the loading control (Figure 3.10 A and B). The results obtained from 
the radiosulfate incorporation experiments for the effect of VEGF highlighted the need to 
further explore the absence of a response of the retinal endothelial cells to VEGF. Hence, 
we investigated the two main signalling pathways that are well known to be activated by 
VEGF in VSMCs [97, 235]. The first is the Phosphorylation of the polyfunctional ERK and 
the second is the ubiquitous serine/threonine protein kinase Akt. These are involved in many 
diseases for example AMD, atherosclerosis and schizophrenia [235, 253, 345, 346]. Cells 
were treated for time intervals in the range of 0-60 minutes with VEGF and for 30 minutes 
with the positive control PDGF. In this study, pAKT (Ser473) was measured and it was 
found that VEGF (50 ng/ml) did not stimulate pAKT (Ser473) in RF/6A cells (Figure 3.10). 
The positive control PDGF (50 ng/ml) substantially activated pAKT (Ser473) by 
approximately 12-fold and the presence of the pharmacological Akt1/2 phosphorylation 
inhibitor SN30978 partially blocked the phosphorylation [235, 253].  
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(A) Western blot of lysates from these treatments were probed for pAkt (Ser473). GAPDH 
was used as the loading control. (B) Histograms depict the fold-change of phosphorylated 
proteins. Cells were untreated (-) basal (control) or pre-treated for 30 minutes with the 
Akt1/2 inhibitor SN30978 (2 µM) and then stimulated with VEGF (50ng/ml) for 15, 30 and 
60 minutes, or treated with PDGF (50ng/ml) for 30 minutes as a positive control. 
Experiments were repeated three times, **p<0.01 for agonists and ##p<0.01 for antagonists 
(agonist vs. basal and antagonist vs. agonist). 
  
A 
B 
Figure 3-10 Effect of VEGF on pAkt Ser 473 phosphorylation in 
RF/6A cells 
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A second signalling pathway activated by VEGF was the phosphorylation of the 
mitogen activated protein MAP kinase pathway involving extracellular signal-regulated 
kinases ERK [347, 348]. In response to VEGF (50ng/ml) in the RF/6A cells for 15 and 60 
minutes, there was a substantial and statistically significant increase in pERK 
(Thr202/Tyr204) (Figure 3.11). The positive control PDGF significantly activated pERK 
(Thr202/Tyr204). The selective inhibitor of ERK1/2 kinase UO126 blocked the cells 
response to PDGF, VEGF (50ng/ml) for 15 and 60 minutes. However, it stimulated pERK 
(Thr202/Tyr204) in retinal choroidal endothelial cells by around 2-fold and almost 50% of 
the positive control agonist PDGF (50 ng/ml) 30-minute response in the presence of UO126 
inhibitor totally blocked the phosphorylation. VEGF over the time course (0 - 60 min), 
significantly increased the phosphorylation of ERK reaching the peak at 15 min while in the 
presence of UO126 inhibitor, phosphorylation decreased markedly (Figure 3.11 A and B). 
The results indicated that from the PDGF stimulation of these cells, there was an active 
VEGF receptor mediated signalling pathway. 
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(A) Western blot of lysates from these treatments were probed for phospho-Erk1/2 
(Thr202/Tyr204). GAPDH was used as the loading control. (B) Histograms depict the fold-
change of phosphorylated proteins. Cells were untreated (-) basal (control) or pre-treated for 
30 min with the ERK1/2 kinase inhibitor UO126 (10 µM) and then stimulated with VEGF 
(50ng/ml) for 15, 30 and 60 minutes, or treated with PDGF (50ng/ml) for 30 minutes as a 
positive control. Experiments were repeated three times. **p<0.01 or *p<0.05 for agonists 
and ##p<0.01 for antagonists (agonist vs. basal and antagonist vs. agonist). 
  
A 
B 
Figure 3-11 Effect of VEGF on phospho-Erk1/2 signalling pathway in 
RF/6A cells 
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3.5 Summary of results  
In this chapter, monkey choroidal endothelial cells RF/6A were studied with the 
following findings: 
 The RF/6A cells morphological and endothelial protein expression characteristics were 
confirmed as endothelial in origin because RF/6A cells were negative for SMA but positive 
for eNOS and vWF.  
 TGFβ dose-dependently stimulated PG 35S-sulfate incorporation and GAG elongation in 
RF/6A cells. 
 Thrombin dose-dependently stimulated PG 35S-sulfate incorporation and GAG elongation. 
 PDGF dose-dependently stimulated PG 35S-sulfate incorporation and GAG elongation.  
 IGF dose-dependently stimulated PG 35S-sulfate incorporation and GAG elongation.  
 VEGF did not stimulate PG 35S-sulfate incorporation and GAG elongation.  
 TGFβ, PDGF, thrombin and IGF stimulated xyloside initiated GAG 35S-sulfate 
incorporation and elongation, while VEGF did not. 
 VEGF did not stimulate pAKT (Ser473) in choroidal endothelial cells. 
 VEGF stimulated pERK (Thr202/Tyr204) in choroidal endothelial cells. 
In summary RF/6A cells were negative for SMA but positive for eNOS and vWF. 
Confirmation that monkey retinal cells were of endothelial origin was achieved. TGFβ, a 
serine/threonine kinase receptor agonist; Thrombin, a GPCR, the tyrosine kinase receptor 
agonists PDGF and IGF dose-dependently stimulated PG sulfate incorporation and GAG 
elongation as well as xyloside-GAG initiation. However, VEGF, a tyrosine kinase receptor 
agonist did not produce any measurable changes in PG synthesis or size. There were 
significant differences in these stimulation results especially with TGFβ and thrombin. 
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3.6 Discussion 
This chapter presented experiments that tested the specific hypothesis that growth 
factors potentially associated with AMD cause changes in the synthesis of PGs and GAG 
elongation. This study found that retinal endothelial cells secreted a PG of the size 100 – 120 
kDa which was reported to be associated with lipid binding in other tissues [13]. The agonists 
of the three major classes of cell surface receptors (activation of the receptors or receptor 
signalling pathways), namely protein tyrosine kinase, protein serine/threonine kinase and a 
GPCR all caused significant increases in the synthesis of PGs and in the size of the PGs 
which was an indication of GAG hyperelongation [340, 349]. These growth factors were 
chosen because they were likely to be found in the retinal tissues [2, 350, 351]. Xyloside-
GAG size increased significantly as a result of the stimulation action of several agonists 
(TGFβ, thrombin, PDGF and IGF) which has been used as a measure of cellular GAG 
synthesizing capacity. However and notably, the protein tyrosine kinase receptor agonist, 
VEGF, which is associated with retinal pathologies, did not stimulate PG synthesis or size 
or the synthesis or size of xyloside GAGs, but weakly increased pAKT (Ser473) and 
relatively strongly increased pERK (Thr202/Tyr204) levels in the cells. This indicated that 
the signalling pathway for VEGF was present and active in these cells. These results strongly 
support the hypothesis that retinal endothelial cells activated PG synthesis as a response to 
some growth factors and that the cells synthesized and secreted PGs with elongated GAG 
chains. These elongated GAG chains have the capacity to increase binding of plasma-derived 
lipids and could initiate a pathological process in the macula.  
The findings in this study are in agreement with published results from our 
laboratory as observed from studies with these growth factors in VSMCs. The results in this 
chapter demonstrate that the process of growth factor initiated GAG hyperelongation occurs 
in retinal endothelial cells. It has been shown that the interaction of lipids with the GAG 
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chains on PGs or even free GAG chains released from PGs occurred over a wide range of 
GAG sizes but significantly increases above the basal size, which has been termed 
hyperelongation [48]. This consequently leads to increases in binding to cationic residues of 
apolipoproteins on lipoproteins [352]. Further investigation is needed to characterize the 
exact molecule that is generated by the growth factor signalling and determine if it is a lipid-
binding PG. However, this study verified that GAG hyperelongation occurred in response to 
the action of growth factors that were relevant to retinal disease [96, 289]. 
The absence of a response to VEGF is interesting from the perspective of both cell 
biology and therapeutics. From a cell biology perspective, this is the first agent that we have 
identified that did not stimulate GAG hyperelongation. This study has demonstrated that 
VEGF significantly stimulated the pERK (Thr202/Tyr204) pathway in these cells. Our 
previous laboratory research had shown that there were several pathways involving ERK to 
GAG hyperelongation [353]. In particular response to TGFβ, pERK (Thr202/Tyr204) was 
upstream of the phosphorylation of the transcription factor Smad2 and phosphorylation of 
Smad2 in the linker region correlates with hyperelongation of GAG chains on biglycan in 
VSMCs [97, 238, 353]. Both PDGF and thrombin stimulated an increase in cellular pERK 
(Thr202/Tyr204) with thrombin acting via transactivation of the EGF receptor and PDGF 
directly via the kinase mediated signalling pathway. Both agonists stimulate GAG 
hyperelongation. It is not yet clear why VEGF stimulates ERK phosphorylation but does not 
stimulate GAG hyperelongation. The signalling for PG core protein is distinct from the 
pathways leading to GAG hyperelongation and have more similarities with the pathways 
controlling the cell cycle including stimulation of the pAKT (Ser473) pathway. Both TGFβ 
and PDGF stimulate pAKT (Ser473) as the pathway to stimulate biglycan in VSMCs [235, 
253]. VEGF did not stimulate pAKT (Ser473) levels in the retinal endothelial cells so it is 
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not surprising that it did not increase the PG core proteins sufficiently enough to be observed 
as an increase radiosulfate incorporation as shown in Figure 3.11 A and B. 
The therapeutic implications of VEGF not stimulating GAG elongation are 
intriguing. The current hypothesis would be that VEGF does not contribute to GAG 
elongation on PGs and that anti-VEGF therapies do not have any actions on PG synthesis in 
retinal cells. Thus, there is no impact of VEGF or anti-VEGF therapies on PG synthesis and 
structure in the macula. However, there is nothing from our results that VEGF impacts on 
GAG elongation. It remains valid to explore the role of GAG hyperelongation as a potential 
therapeutic target for the treatment of early AMD. 
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3.7 Conclusions 
This study observed that representative agonists of protein tyrosine kinase, 
serine/threonine kinase and GPCRs all stimulated GAG hyperelongation and secreted PG 
from retinal endothelial cells. A notable exception is VEGF which had no effect, 
notwithstanding the fact that the cells responded to VEGF with a modest increase in pErk. 
These results raise the possibility that growth factor mediated hyperelongation of GAG chain 
and PGs may be playing a role in early AMD and may therefore represent a potential target 
for the development of new therapeutic agents. It is intriguing that the VEGF did not 
stimulate PG synthesis, creating an opportunity for a therapeutic area completely distinct 
from that which is the most prominent for the present therapy of AMD. 
This project found that retinal endothelial cells expressed a PG with a molecular 
weight similar to that of lipid-binding PGs secreted by other cells. In addition, representative 
agonists at protein tyrosine kinase, serine/threonine kinase and GPCRs stimulated GAG 
hyperelongation on a secreted PG from endothelial cells. The exception was VEGF which 
had no effect on GAG hyperelongation and the size of xyloside GAGs. The findings from 
this project surprisingly showed that VEGF stimulated MAP kinase activity in these cells as 
assessed by an increased level of pERK [96, 174, 238, 273, 354, 355]. The occurrence of 
GAG hyperelongation in retinal endothelial cells was demonstrated and this lays the 
foundation for a later complete analysis of the properties of the PG and its lipid binding 
capacity. 
The findings from these studies support the hypothesis that AMD relevant agonists 
impact the elongation of GAG chains of PGs synthesized by retinal choroidal endothelial 
cells. Future studies should examine the relevance of these changes to the development of 
AMD. 
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The novelty of this research provided insight into dry AMD stage therapy and 
disease understanding. Future research should investigate other agonists and hormones in 
the retinal endothelial cells as well for epithelial cells that surround BM. Another area of 
future research should focus on full characterization of PGs secreted by retinal endothelial 
cells and the signalling pathways of growth factors especially TGFβ and Thrombin.  
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4. Chapter 4: GAG synthesizing mRNA expression 
involved in PG synthesis stimulated by growth factors or 
hormones in retinal endothelial cells 
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4.1 Abstract 
This study investigated selected genes which are rate limiting in the process of GAG 
hyperelongation. Increased gene mRNA expression of XT-1, ChGn-2, ChPF, ChSy-1, 
C4ST-1 and C4ST-2, correlated with GAG hyperelongation. Investigation of the effects of 
agonists TGFβ, thrombin, PDGF and VEGF on the mRNA expression indicated that TGFβ, 
thrombin and PDGF stimulated the synthesis of PGs and GAG elongation in retinal 
endothelial cells. Notably, VEGF application had no effect on the gene mRNA expression 
of GAG hyperelongation or the synthesis of PGs. The altered gene mRNA expression and 
its role in the synthesis of PGs and GAG elongation, could open a new possibility for AMD 
therapy with TGFβ, thrombin and PDGF mediated pathways as therapeutics targets for early 
AMD. 
4.2 Introduction 
Growth factors are proteins that stimulate the growth of specific tissue cells [2, 13]. 
Growth factors can be bound to GAG moieties in the highly sulfated PG with high negative 
charges that in turn enhance growth factors and GAG binding reactions [2, 96]. An example 
of a sulfated PG is HS which has been reported to react with many molecules including many 
growth factors [313]. GAG play crucial roles supporting, triggering and protecting the 
activities and function of growth factors [164-169]. 
In recent years there have been significant advances in the understanding of the 
signalling pathways that control PG hyperelongation [48, 49, 170]. Recent advances in 
genetics have improved scientific knowledge of AMD development [115, 356] and have led 
to the identification of several genes which are related to GAGs elongation [315, 357]. Table 
4.1 lists a subset of the three groups of glycosyltransferase and sulfotransferase enzymes and 
118 
 
their genes that are involved that were investigated in this study. Therefore, this study 
explored the GAG synthesizing gene mRNA expression of enzymes that mediate GAG 
elongation. The impact of selected growth factors, namely TGFβ, thrombin, PDGF and 
VEGF on GAG elongation was also assessed. For more details, please refer to our published 
work (published in 2016) [13].  
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Table 4.1 Glycosyltransferase and sulfotransferase enzymes (used in this 
study) involved in CS/DS synthesis in humans. Adapted from [170, 183]. 
 
Enzymes activity Enzyme abbreviation Gene symbols 
   
I- Glycosyltransferases involved in synthesis of the tetrasaccharide linkage region 
   
Xylosyltransferase XT-1 XYLT1 
   
II- Glycosyltransferases involved in synthesis of the repeating disaccharide region of CS chains 
   
Chondroitin synthase (GalNAcT-II, GlcAT-II) ChSy-1 CHSY1 
Chondroitin polymerizing factor (GalNAcT II, GlcAT II) ChPF CHPF (CSS2) 
Chondroitin GalNAc transferase (GalNAcT-I, GalNAcT-II) ChGn-2 CSGALNACT2 
 
  
III- Sulfotransferases involved in CS/DS synthesis  
Chondroitin 4-O-sulfotransferase C4ST-1 C4ST1 (CHST11) 
 C4ST-2 C4ST2 (CHST12) 
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Sulfated GAGs are important in that they determine the level of GAG interactions 
with other molecules including LDL [5, 268, 358, 359]. Sulfated GAGs are linear polymers 
consisting of repeating disaccharide units of glucuronic acid (GlcUA) and N-
acetylgalactosamine (GalNAc) (Table 4.1). XT-1 on the other hand are enzymes that 
catalyse the transfer of D-xylose from uridine diphosphate xylose (UDP-xylose) to specific 
serine residues in the PG core protein, which is the first step in the biosynthesis of GAG. 
The specific catalytic activity of XT-1 involves the transfer of a beta-D-xylosyl residue from 
UDP-D-xylose to the serine hydroxy group on the core protein [183, 316, 360].  
The bio synthesis of CS/DS is illustrated in Figure 4.1. GAG chain synthesis and 
polymerisation requires the presence of three enzymes. These enzymes are chondroitin 
GalNAc transferase (GalNAcT-I), chondroitin GalNAc transferase (GalNAcT-II) and 
GlcAT-II with only ChGn-2 (involved in GAG chain elongation) investigated in this study 
[170, 183, 314, 361]. ChPF and human chondroitin synthase (ChSy-1) augment 
glycosyltransferase activities and expressions of ChSy-1 activity [170, 183, 362-364]. 
Chondroitin 4-O sulfotransferase-1 (C4ST-1) mediates CS 4-O-sulfation and determine the 
length of CS chains, while Chondroitin 4-Osulfotransferase-2 (C4ST-2) catalyses the 4-O-
sulfation of the non-reducing terminal GalNAc residues [183, 232, 365, 366]. 
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Figure 4-1 Bio synthesis of CS/DS chain 
Gene mRNA expression for GAGs synthesis enzymes involves entry into ER for core protein synthesis. Once outside the ER, xylose becomes 
attached to the core protein and this step initiates the build-up of the other linkages which occur inside cis-Golgi. The synthesis of the repeated 
disaccharides takes place in the trans-Golgi. Yellow marked enzymes are glycosyltransferases while purple marked enzymes are sulfotransferases. 
Both groups of genes function in harmonization and synchronisation to synthesize the PGs and in GAGs build up and elongation [183, 190]. 
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4.3 Materials and methods 
4.3.1 Materials 
DMEM (0 and 25 mM glucose), trypsin-versene, antibiotics (10,000 U/ml 
penicillin, 10,000μg/ml streptomycin) were purchased from GIBCO, (Grand Island, USA). 
FBS was obtained from Invitro Technologies, Pty. Ltd. (VIC, Australia). PDGF-BB, 
thrombin, VEGF and PBS (10X) were purchased from Sigma-Aldrich, (MO, USA). TGF-β 
and VEGF were from Cell Signalling Technology (MA, USA). 
Quantitative Real-time Polymerase Chain Reaction’s primers for enzymes C4ST-
1, C4ST-2 and ChSy-1 gene were based on their respective GenBank sequences (Table 2.1) 
and purchased from GeneWorks Pty Ltd (SA, Australia). XT-1, ChPF, ChGn-2 and 
Housekeeping 18S ribosomal gene, biglycan gene primers, RNeasy Mini Kit (containing 
sterile, RW1 buffer, RPE buffer and RNase-free water) were obtained from Qiagen (VIC, 
Australia). QuantiTect Reverse Transcription Kit (containing gDNA Wipeout Buffer, 
Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix and RNase-free 
water), the RNase-Free DNase set (containing 1500kunits RNase-free DNase I, RNase free 
buffer RDD and RNase-free water), two-step Q-RT-PCR kit (containing 2×Rotor-Gene 
SYBR Green PCR Master Mix and RNase-free water) were also purchased from Qiagen 
(VIC, Australia). 
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4.3.2 Methods 
4.3.2.1 Cell Culture 
RF/6A (ATCC® CRL­1780™) cells were grown in DMEM 5mM glucose, 10% 
FBS and 1% antibiotics at 37ºC in 5% CO2. Confluent cultures were quiesced in DMEM 
0.1% FBS for 48 hours before experimentation. 
4.3.2.2 Subculturing and treatment of RF/6A cells 
Cells were initially rinsed with 1 ml of trypsin and the trypsin aspirated from cells 
after which another 3ml of trypsin was added and the cells were incubated at 37ºC for 2-5 
minutes. Ten millilitres (10 ml) of medium was added to the cells before they were 
transferred into Falcon tubes and centrifuged at 900 rpm for 3 minutes. The appropriate 
volumes (5×106 to 2×107 cells/ml) of suspended cells were made up to 10 ml using a new 
medium with the medium changed every 2-5 days. Calculated number of cells were grown 
in 6-well plates until they reached confluence. Quiescent cells were replaced in fresh 
medium, treated with either TGFβ (2 ng/ml) or thrombin (10 U/ml), PDGF (50 ng/ml), and 
VEGF (50 ng/ml) for 24 hours at 37ºC in 5% CO2. Samples were collected for RNA 
extraction using the RNeasy mini kit (Qiagen). 
4.3.2.3 Measurement of mRNA expression for GAG synthesizing enzyme gene 
The mRNA expression levels of the GAG enzyme genes XT-1, ChGn-2, ChPF, 
ChSy-1, C4ST-1 and C4ST-2 were determined by Q-RT-PCR. Total RNA was extracted 
from treated or untreated RF/6A cells using RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. RNA concentration and purity were checked by a 
Nanodrop2000 spectrophotometer (Thermo Fisher Scientific). First strand cDNA was 
synthesized for 1μg RNA using Quantitect reverse transcriptase kit (Qiagen) protocol. 
Purified RNA was incubated for 2 minutes at 42ᵒC with 2μL of gDNA wipeout buffer before 
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being stored on ice. Then 1μL of QuantiTec reverse trancriptase was added to 4μL 
Quantiscript RT buffer and 1μL RT primer mix. The mixture was incubated for 15 minutes 
at 42ᵒC. Quantitative RT-PCR was performed using Qiagen Rotor Gene Q and QuantiFast 
SYBR Green PCR Master mix kit (Qiagen). The data was normalised to the 18S rRNA gene 
house keeping gene. Relative expressions of the GAG synthesizing gene mRNA expression 
levels were quantified using comparative delta Ct method. 
4.3.2.4 Statistical Analysis 
Data was normalised and expressed as the mean± standard error of the mean (SEM) 
of at least three independent experiments unless stated otherwise. A one-way ANOVA was 
used to calculate statistical significance of normalised data, followed by least significant 
difference post-hoc analysis. Results were considered significant at p<0.01 or p<0.05 as 
indicated. 
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4.4 Results 
4.4.1 Time course of TGFβ and thrombin for glycosyltransferase genes 
mRNA expression in RF/6A 
Firstly, the effect of TGFβ and thrombin on gene mRNA expression of PG 
synthesizing and GAG elongation enzymes XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and 
C4ST-2 was assessed. These agonists, TGFβ and thrombin had been shown to have the 
highest PG synthesis and xyloside initiated GAG elongation in some earlier studies 
discussed in chapter one of this thesis. [2, 13]. Time course experiments of (0-6 hours) were 
used based on our laboratories findings [232, 236]. TGFβ (2 ng/ml) treatment resulted in an 
increase of almost 2-fold at 2 hours and reached the maximum of 3.7-fold, at 4 hours in XT-
1 gene mRNA expression of GAG synthesis. This gradually decreased to a 3-fold increase 
at 6 hours. Thrombin (10 U/ml) treatment increased XT-1 gene mRNA expression at 2 hours 
by 2-fold, and a peak of 3.5-fold at 4 hours before it decreased to 3-fold at 6 hours. Maximum 
XT-1 gene mRNA expressions using TGFβ and thrombin (individually) were at 4 hours as 
shown in Figure 4.2. 
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) or Thrombin (10 U/ml) for 0-6 
hours; (–) refers to basal (control). Total RNA was harvested and the GAG synthesizing gene 
mRNA expression of XT-1 analysed using Q-RT-PCR. The 18s rRNA gene was used as a 
housekeeping gene. The experiment was performed three times, **p<0.01 (agonist vs. basal) 
using a 1-way ANOVA. 
  
Figure 4-2 Time course 0 to 6 hours of TGFβ and thrombin on the gene 
mRNA expression of XT-1 in RF/6A cells 
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Cells were treated with TGFβ (2 ng/ml) and the time course of ChGn-2 gene mRNA 
expression was measured at 2, 4 and 6 hours. At 2 hours, ChGn-2 gene mRNA expression 
increased by 2.5-fold, a peak of 3.4-fold was reached at 4 hours and decreased to 
approximately 3.2-fold at 6 hours. Thrombin (10 U/ml) treatment increased ChGn-2 gene 
mRNA expression to 2-fold at 2 hours and a peak of 3.5-fold which decreased to 3-fold at 6 
hours (Figure 4.3). Both TGFβ and thrombin showed similar trends in mediating gene 
mRNA expression of ChGn-2 and the peak expression of 3.5-fold was reached at 4 hours, 
as illustrated in Figure 4.3. 
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) and Thrombin (10 U/ml) for 0-
6 hours. Total RNA was harvested and the gene mRNA expression of ChGn-2 was analysed 
using qRT-PCR. 18s rRNA gene was used as a housekeeping gene. The experiment was 
performed three times, **p<0.01 (agonist vs. basal) using a 1-way ANOVA. 
  
Figure 4-3 Effect of TGFβ and thrombin on the gene mRNA expression of 
ChGn-2 mediating GAG chain elongation in RF/6A cells for 0-6 hours 
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As shown in Figure 4.4, RF/6A cells treated with TGFβ (2 ng/ml) showed a gradual 
increase in gene mRNA expression of ChPF for all the three time-intervals. At 2 hours, ChPF 
expression reached a 2-fold increase while at 4 hours, this had increased to 2.8-fold and 
reached the peak of 3.2-fold at 6 hours. Thrombin (10 U/ml) treatment followed a similar 
trend to TGFβ. It showed a 2-fold increase at 2 hours, 2.4-fold at 4 hours and peak ChPF 
gene mRNA expression of 2.8-fold at 6 hours. Both agonists resulted in peak gene mRNA 
expression at 6 hours.  
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) and Thrombin (10 U/ml) for 0-
6 hours. Total RNA was extracted and the gene mRNA expression of ChPF analysed using 
Q-RT-PCR. 18s rRNA gene was used as a housekeeping gene. The experiment was 
performed three times, **p<0.01 (agonist vs. basal) using a 1-way ANOVA. 
 
 
  
Figure 4-4 Effect of TGFβ and thrombin on the gene mRNA expression 
of ChPF mediating GAG chain elongation in RF/6A cells for 0-6 hours 
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TGFβ (2 ng/ml) treatment increased gene mRNA expression of ChSy-1; at 2 hours, 
the expression increased by 2.5-fold and reached the maximum of 4-fold increase at 4 and 6 
hours (Figure 4.5). Thrombin (10 U/ml) treatment increased gene mRNA expression of 
ChSy-1 at 2 hours by 2.5-fold and at 4 hours by 3.8-fold before it decreased to 3.6-fold at 6 
hours (Figure 4.5). TGFβ effect was slightly higher than thrombin but both agonists had peak 
gene mRNA expression of ChSy-1 at 4 hours. 
 
 
  
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RF/6A cells were prepared and treated with TGFβ (2 ng/ml) and Thrombin (10 U/ml) for 0-
6 hours. Total RNA was extracted and the gene mRNA expression of ChSy-1 analysed using 
Q-RT-PCR. 18s rRNA gene was used as a housekeeping gene. The experiment was 
performed three times, **p<0.01 (agonist vs. basal) using a 1-way ANOVA. 
Figure 4-5 Effect of TGFβ and thrombin on the gene mRNA expression of 
ChSy-1 mediating GAG chain elongation in RF/6A cells for 0-6 hours 
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4.4.2 TGFβ and thrombin time course for sulfotransferases C4ST-1 and 
C4ST-2 gene mRNA expression of GAG elongation enzymes in RF/6A 
cells 
C4ST-1 sulfates are found at position 4 of GalNAc residues in PG and regulate the 
chain length in PG [168, 365]. TGFβ (2 ng/ml) time course experiments (Figure 4.6) showed 
a gradual increase in mRNA expression of the C4ST-1 gene; 2.3-fold at 2 hours, 3.5-fold at 
4 hours and a peak of 4-fold at 6 hours. Treatment with thrombin (10 U/ml) resulted in an 
increase of 2.5-fold at 2 hours, 4-fold at 4 hours and a drop to 3.4-fold at 6 hours. The time 
course experimental results for TGFβ (2 ng/ml) and thrombin (10 U/ml) were different. 
TGFβ stimulation was higher than thrombin stimulation at 6 hours, while thrombin 
stimulation was higher than TGFβ at 4 hours.  
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) and Thrombin (10 U/ml) for 0-
6 hours. Total RNA was extracted and the mRNA expression of the C4ST-1 gene analysed 
using Q-RT-PCR. The 18s rRNA gene was used as a housekeeping gene. The experiment 
was performed three times, **p<0.01 (agonist vs. basal) using a 1-way ANOVA. 
  
Figure 4-6 Effect of TGFβ and thrombin on the gene mRNA expression of 
C4ST-1 mediating GAG chain elongation in RF/6A cells for 0-6 hours 
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In the biosynthesis of PGs, the newly synthesised CS chain is modified by the action 
of the sulfotransferase C4ST-2 which catalyses 4-O sulfation of GalNAc residues in CS 
chains. TGFβ (2 ng/ml) treatment increased the mRNA expression of the C4ST-2 gene to 
1.8-fold at 2 hours, a peak expression of 3.2-fold at 4 hours before it dropped to 2.8-fold at 
6 hours. Treatment with thrombin (10 U/ml) resulted in a sharp increase in mRNA 
expression of the C4ST-2 gene of 2.2-fold at 2 hours, reached the peak of expression of 3.8-
fold at 4 hours and decreased to 3-fold expression at 6 hours. The effect of thrombin was 
higher in comparison to TGFβ although both reach the peak expression of C4ST-2 at 4 hours 
as illustrated in Figure 4.7. 
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) and Thrombin (10 U/ml) for 0-
6 hours. Total RNA was extracted and the mRNA expression of the C4ST-2 gene was 
analysed using Q-RT-PCR. The 18s rRNA gene was used as a housekeeping gene. The 
experiment was performed three times, **p<0.01 (agonist vs. basal) using a 1-way ANOVA. 
  
Figure 4-7 Effect of TGFβ and thrombin on the gene mRNA expression of 
C4ST-2 mediating GAG chain elongation in RF/6A cells for 0-6 hours 
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Previous results (Figures 4.2-4.7) clearly showed that the mRNA expression of the 
XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 genes were at their peak at 4 hours as 
a response to TGFβ and thrombin treatments. The effects of several growth factors targeting 
different classes of receptors were studied. The conditions used were the same as those used 
in the above experiments on the expression of these genes. Some genes had peak expressions 
at 6 hours but this study used a 4-hour time course to explore the effect of agonists on mRNA 
expression of these genes. The reason for this is that in most experiments, the difference 
between 4 hours and 6-hour responses was not substantial. Another reason for using the 4 
hour time-frame was that in each set of experiments conducted, multiple agonists were used. 
Given that their (agonist) effect on the cells response in the gene mRNA expression was 
assessed and multiple agonists have different peak expression time courses, it was important 
to select an optimum time-period for the agonists [13, 232, 236]. 
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4.4.3 Exploring the role of agonists TGFβ, thrombin, PDGF or VEGF on 
the mRNA expression of XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and 
C4ST-2 genes in RF/6A cells 
It was observed that some genes showed highly variable responses (high or low 
expression) to each agonist treatment which was likely due to their function in GAG 
elongation (Figure 4.1-4.6) [236, 367].  
RF/6A cells were treated either with TGFβ, thrombin, PDGF or VEGF for 4 hours 
and the mRNA expression of the XT-1 gene was determined relative to untreated cells shown 
in Figure 4.8A. TGFβ, thrombin and PDGF stimulated the mRNA expression of the XT-1 
gene by 3.8, 3.0 and 2.8-fold respectively. However, VEGF did not stimulate the mRNA 
expression of the XT-1 gene at this time point. The mRNA expression of the ChGn-2 gene 
at 4h was also measured and expression determined relative to untreated cells. TGFβ, 
thrombin and PDGF stimulated the mRNA expression of the ChGn-2 gene by 3.2, 2.8 and 
1.8-fold respectively, while VEGF did not stimulate the mRNA expression of the ChGn-2 
gene (Figure 4.8B).  
The cell responses to treatment with either TGFβ, thrombin or PDGF for 4 hours 
resulted in stimulation of the mRNA expression of the ChPF gene by 2.7, 2.4 and 1.7-fold 
respectively. However, VEGF showed no effect on mRNA expression of the ChPF gene as 
illustrated in Figure 4.8C. The mRNA expression of the ChSy1 gene increased by 4.5-fold 
when cells were treated with TGFβ for 4 hours while thrombin treatment stimulated the gene 
mRNA expression by 4.2-fold and PDGF by 2.8-fold. VEGF had no effect on the mRNA 
expression of the ChSy1 gene (Figure 4.8D).  
Cells treated with TGFβ, thrombin, PDGF or VEGF for 4 hours resulted in 
increased mRNA expression of the C4ST-1 gene (Figure 4.8E). Thrombin addition resulted 
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in a 4.2-fold increase which was the highest response amongst all the agonists tested in this 
experiment. While TGFβ response was 3.8-fold, which is lower than the thrombin effect 
only in this experiment. While PDGF treatment increased the expression by 2-fold, VEGF 
treatment did not affect mRNA expression level of the C4ST1 gene. The mRNA expression 
of the C4ST-2 gene of GAG elongation showed similar trends to C4ST-1 gene mRNA 
expression when cells were treated with TGFβ, thrombin, PDGF and VEGF (Figure 4.8F). 
TGFβ treatment resulted in a 4.5-fold increase in the mRNA expression of the ChSy1 gene. 
Thrombin increased the mRNA expression of C4ST-1 and C4ST-2 genes by 4.3-fold and 
3.5-fold respectively. 
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RF/6A cells were prepared and treated either with TGFβ (2 ng/ml), Thrombin (10 U/ml), 
PDGF (50 ng/ml) and VEGF (50 ng/ml) for 4 hours. Total RNA was extracted and the 
mRNA expression of (A) XT-1, (B) ChPF, (C) ChGn-2, (D) ChSy-1, (E) C4ST-1 and (F) 
C4ST-2 genes analysed using Q-RT-PCR. The 18s rRNA gene was used as a house keeping 
gene. The experiment was performed three times, **p<0.01 (agonist vs. basal) using a 1-
way ANOVA. 
  
Figure 4-8 Effect of TGFβ, thrombin, PDGF, and VEGF on the gene mRNA 
expression of XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 in RF/6A cells 
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4.4.4 Effect of TGFβ on the mRNA expression of XT-1, ChGn-2, ChPF, 
ChSy-1, C4ST-1 and C4ST-2 genes mediating GAG chain elongation in 
RF/6A cells for 0-24 hours 
Based on previous experimental results on the sulfation of PGs (chapter 3 Figure 
3.8 and 3.9), the effects of TGFβ, PDGF, IGF, VEGF and thrombin on xyloside initiated 
GAG synthesis in RF/6A cells were evaluated. It was observed that TGFβ and thrombin 
applications resulted in the highest cell responses to PG sulfation among the tested 
compounds; TGFβ, thrombin, PDGF, IGF and VEGF. Moreover, the treatment of six 
different genes XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 with agonists indicated 
that TGFβ and thrombin treatment resulted in the highest effect [13]. TGFβ mediated a 
significant increase in mRNA expression of GAG synthesis enzyme genes in a 24 hour time 
course of TGF-β treatment of RF/6A cells. 
RF/6A cells were treated in the presence or absence of TGFβ for 2–24 hours (Figure 
4.9). TGF-β treatment resulted in significant increases in mRNA expression of the XT-1 
gene at all-time points or intervals in comparison to non-treated basal levels with a maximum 
expression of 3.5-fold achieved at 4 hours (Figure 4.9A). TGFβ increased the expression of 
ChGn-2 by 3-fold at 4 and 6 hours (Figure 4.9B), the histogram (over 24 hours) of ChGn-2 
gene. The effect of TGFβ on the expression of ChPF over 24 hours showed a significant 
increase at 6 hours with a 3-fold maximum increase. ChSy-1 gene mRNA expression was 
also affected by TGFβ treatment. Its expression increased by 4-fold at 6 hours, fluctuated 
and stabilised at 3.7-fold until the 20-hour time-point before increasing to 4.2-fold at 24 
hours interval, which meant the expression was biphasic. The sulfanotransferase C4ST-1 
gene mRNA expression was stimulated by TGFβ treatment by 4-folds at the 6-hour time 
point and then decreased, while the other sulfanotransferase C4ST-2 gene mRNA 
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expressions increased by 3-fold at 4 hours and then decreased afterwards. Figures 4.9 D and 
E show the 2-hour time difference between the two sulfotransferases optimum gene mRNA 
expression time course experimental result and confirmed the findings from previous results 
in this chapter (Figure 4.6 and Figure 4.7). 
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RF/6A cells were prepared and treated with TGFβ (2 ng/ml) for 0-24 hours. Total RNA was 
extracted and the mRNA expression of (A) XT-1, (B) ChPF, (C) ChGn-2, (D) ChSy-1, (E) 
C4ST-1 and (F) C4ST-2 genes analysed using Q-RT-PCR. The 18s rRNA gene was used as 
a house keeping gene. The experiment was performed three times, **p<0.01 (agonist vs. 
basal) using a 1-way ANOVA. 
  
Figure 4-9 Effect of TGFβ on the gene mRNA expression of XT-1, ChGn-2, 
ChPF, ChSy-1, C4ST-1 and C4ST-2 mediating GAG chain elongation in 
RF/6A cells for 0-24 hours 
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4.5 Summary of results  
 From 0 to 6 hours, TGFβ peaked at 4 hours with mRNA expression of XT-1, ChGn-
2, ChSy-1, and C4ST-2 genes increased by 3.2-fold. TGFβ peaked at 6 hours with 
mRNA expression of ChPF and C4ST-1 genes in RF/6A cells. 
 From 0 to 6 hours, thrombin peaked at 4 hours with mRNA expression of XT-1, 
ChGn-2, ChSy-1, C4ST-1 and C4ST-2 genes. It also peaked at 6 hours with mRNA 
expression of the ChPF gene in RF/6A cells. 
 From 0 to 6 hours, TGFβ and Thrombin treatment resulted in the highest stimulation 
effect; both significantly stimulated the gene mRNA expression with the optimum 
expressions reached at 4 hours in RF/6A cells. 
 TGFβ at 4 hours stimulated the mRNA expression of all the genes measured; XT-1, 
ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2. Its stimulatory effect was the highest 
among all the agonists used except with the sulfotransferases (C4ST-1 and C4ST-2) 
in RF/6A cells. 
 At 4 hours, thrombin stimulated the mRNA expression of all the measured genes XT-
1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2. Its stimulatory effect was the 
second highest among all the agonists used except with the sulfotransferase. It 
resulted in the highest stimulation of RF/6A cells. 
 PDGF at 4 hours stimulated the mRNA expression of four genes XT-1, ChPF, ChSy-
1 and C4ST-1 except ChGn-2 and C4ST-2 in RF/6A cells. 
 VEGF did not show any significant effect in increasing the gene mRNA expression 
of all the following genes XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 in 
RF/6A cells. 
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 TGFβ over the 0 to 24 hour period stimulated the gene mRNA expression of all the 
genes, XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 reached peak expression 
between 4-6 hours and decreased or remained unchanged afterwards in RF/6A cells.  
 Only the gene mRNA expression of ChSy-1 in the presence of TGFβ treatment 
showed a biphasic response as it increased to reach maximum expression levels at 6 
hours and decreased before it increased again at 24 hours in RF/6A cells. 
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4.6 Discussion  
This chapter investigated the roles of different genes in GAG elongation in RF/6A 
cells. The genes XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 and C4ST-2 which are rate limiting 
in the process of GAG hyperelongation were investigated [13, 368]. Increased expressions 
of several genes were correlated with GAG hyperelongation. In addition, the effect of 
various agonists on the expression of these genes as potential mediators of pathological 
change in early AMD disease was assessed [13, 168, 170, 289, 314, 358, 361, 363]. 
From previous experimental findings (in chapter three), it was established that the 
agonists, TGFβ, thrombin, PDGF, IGF and VEGF stimulated an increase in radiosulfate 
incorporation, GAG elongation and xyloside-GAG synthesis. However, VEGF treatment did 
not stimulate any changes in PG synthesis, while TGFβ and thrombin treatments resulted in 
the highest cells responses [2, 13]. In this study, TGFβ and thrombin were used in treatments 
with different gene mRNA expression and their levels were measured to determine the peak 
time for gene mRNA expression of GAG elongation enzymes over a 0-6-hour time course. 
The mRNA expression levels of some genes peaked as early as 4 hours while the mRNA 
expression level peak of other genes was delayed until as late as 6 hours. This indicated that 
the peak mRNA expressions of these genes were probably required after the peak 
expressions of other genes (at 4 hours) as all genes work in harmonisation in terms of time 
and level of expression [369-371].  
The mRNA expressions peaked following TGFβ treatment at 4 hours with XT-1 
(3.7-fold), ChGn-2 (3.5-fold), ChSy-1 (4-fol) and C4ST-2 (3.2-folds) genes. In addition, 
mRNA expressions peaked following TGFβ treatment at 6 hours with ChPF (3.2-fold) and 
C4ST-1 (4-fold) genes. The mRNA expressions also peaked following thrombin treatment 
at 4 hours with XT-1 (3.5-fold), ChGn-2 (3.5-fol), ChSy-1 (3.8-folds), C4ST-1 (3.8-fold) 
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and C4ST-2 (3.7-fold) genes. Finally, mRNA expressions peaked following thrombin 
treatment at 6 hours with the ChPF (2.8-fold) gene. 
The application of growth factors (TGFβ, thrombin and PDGF) significantly 
increased mRNA expression of the XT-1 gene by 3.6, 3.0 and 2.8-fold respectively. These 
findings suggested that it was important to control or inhibit the expression of XT-1 to 
prevent GAG elongation [236]. Reports have shown that transcription factors of the 
specificity protein1 (Sp1) group, in particular specificity protein 3 (Sp3), could be involved 
in the control of mRNA expression of the XT-I gene [183, 366, 372]. 
Another glycosyltransferase investigated in this study was ChGn-2 and the results 
obtained followed the same trends as observed in XT-1 in response to the three agonists 
used. The exception was PDGF which did not show any significant effect. The positive 
responses of ChGn-2 to the action of TGFβ thrombin meant that the linkage tetrasaccharide 
could have been formed through the biosynthesis of the entire GAG chain via the formation 
of N-acetyl-𝛽-D-galactosamine (D-GalNAc) linked by a 𝛽1-4glycosidic bond. There was a 
“no response effect” of PDGF on ChGn-2 (Figure 1.7B) [168, 170, 183, 366].  
ChPF responses to the TGFβ, thrombin and PDGF treatment are shown in Figure 
1.7C. All the three agonists increased the mRNA expression of the ChPF gene and hence 
stimulated two key functions. The first was in the synthesis of PGs through induction of 
glycosyltranseferase activity involving GalNAcT-II and GlcAT-II. The second function was 
on GAGs hyperelongation because it synergized with ChSy-1 in the GAGs polymerization 
process. In addition, co-expression of ChSy-3 with ChPF resulted in CS polymerization 
activity (as ChPF is a chain modification enzyme that works in the repeating disaccharide 
and linkage regions) (Figure 1.7C)  [48, 170, 314, 366, 373]. ChSy-1 gene mRNA expression 
of GAG elongation responded positively to TGFβ, thrombin and PDGF. This indicated that 
these agonists at varying levels stimulated GAG polymerization and elongation as the core 
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function of ChSy-1 in the presence of co-expression of ChPF to polymerise GAGs (Figure 
1.7D)  [13, 170, 183, 232, 374].  
Sulfotransferases are a group of enzymes that are involved in the synthesis of PGs 
and the sulfation of elongating GAG chains. Therefore, this study explored the effect of 
agonists TGFβ, thrombin, PDGF and VEGF on two sulfotranserase enzymes. C4ST-1 
showed significant increases in expression due to the effect of TGFβ, thrombin and PDGF. 
Interestingly, thrombin treatment resulted in the highest cell response to C4ST-1 gene 
mRNA expression while in all the previous experiments, TGFβ treatment had resulted in the 
highest response. C4ST-1 plays a vital and distinct regulatory role not only in CS 4-O-
sulfation, but also in the amount of CS synthesis. Interestingly it has been reported that, a 
lack of C4ST-1 resulted in a significant sharp decrease in cellular and whole-body level of 
CS which confirmed that it was the most important sulfotransferase out of other 
sulfotransferases, C4ST-2, C4ST-3, and D4ST-1 [13, 168, 183, 232, 365, 366]. C4ST-2 gene 
mRNA expression increased due to the effects of thrombin (highest) and TGFβ (less than 
thrombin) treatments while the PDGF effect was insignificant. This could have been due to 
the role of C4ST-2 in comparison to C4ST-1 as C4ST-2 mediated 4-O-sulfation of the non-
reducing terminal GalNAc residue resulted in the elongation of CS chains [183, 236, 366].  
The agonists (TGFβ, thrombin and PDGF) with the highest fold increase on mRNA 
gene expression could also possibly have had the greatest effect on the concentration of PGs 
or the length of GAGs, which can be correlated with our other findings in PGs sulfation and 
xyloside GAG initiated experiments [13, 170].  Both TGFβ and thrombin treatments resulted 
in significant increases in the mRNA expression of XT-1, ChGn-2, ChPF, ChSy-1, C4ST-1 
and C4ST-2 genes. Although the TGFβ effect was the highest on the mRNA expression of 
the glycosyltransferase gene in comparison to thrombin, it was slightly lower than the 
thrombin effect on the mRNA expression of the sulfotransferase gene. These findings 
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indicated that TGFβ was more effective than thrombin in the synthesis of PGs and GAG 
elongation. Therefore further research should be focused on TGFβ effects during early AMD 
disease and treatment regimens [2, 48, 62, 97, 170, 235, 253]. This did not necessarily mean 
that glycosyltransferases were more important than sulfotransferases because our 
observations could also have been due to a synergistic effect. The harmonization of a number 
of genes stimulated simultaneously could have resulted in high mRNA expression of the 
genes encoding the enzymes involved [13, 369, 371].  
PDGF stimulated mRNA expression of XT-1, ChPF, ChSy-1 and C4ST-1 genes 
but there was no significant response in mRNA expression of the ChGn-2 and C4ST-2 genes. 
A potential explanation for this observation is that the former four genes play more important 
roles than the latter two genes in the synthesis of PGs and GAG elongation in RF/6A cells. 
This explanation could be strengthened by inferences from their vital functions. For 
example, C4ST-1 actions cannot be compensated for by any other sulfotransferase and the 
co-expression of ChPF and ChSy-1 have polymerization activity. The XT-1 gene is involved 
in the early steps of GAG synthesis and elongation. The reason for ChGn-2 non-response to 
PDGF treatment is unknown but it is possible its action could be substituted or performed 
by the action of another gene. It could also be that there is a link between ChGn-2 and C4ST-
2 actions with both being needed in any activity (sulfation at C-6 position of GalNAc 
residues in CS is mediated by C6ST-1, so it might involve a sort of synergy). Moreover, the 
results obtained in this study are in agreement with other published research in the field for 
the same genes but different agonists [170, 232, 236, 359]. The findings in this section 
provide possible reasons for the low stimulation effect of xyloside GAGs elongation and the 
sulfation of PGs in comparison to TGFβ and thrombin [13, 183, 236, 366, 375]. 
VEGF application showed no increase in measured expressions in any of the 
mRNA expressions of genes involved in GAG elongation and this correlated with the 
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previous results of PGs sulfation and xyloside GAGs elongation (Chapter 3, Figures 8 and 
9) [13].  The results confirmed that VEGF was not involved in PG synthesis [2, 13, 94, 307, 
376-378]. Another possibility could be that because of the vital role of PGs in the blockage 
of blood vessels in atherosclerosis, VEGF stimulation of PGs would have led to blockages 
in cells. This would have defeated the purpose of having VEGF participating in the growth 
of these vessels. The unique eye tissues which are sensitive and the special morphology of 
the capillaries of the retina could also have played some role in the lack of response observed 
[2, 13].  
It was quite interesting that VEGF had no effect on the mRNA expression of the 
GAG enzyme, PG sulfation and GAG elongation genes in RF/6A cells. There are various 
possible factors that could cause an imbalance of the growth factors at the age over 55 years 
and these include ageing, smoking and genetics [124]. An abnormal balance could result in 
more PGs or initiate GAG elongation in BM, that bind to LDL (in case of high serum lipid 
levels) as well as other molecules. This would lead to the thickening of BM and the loss of 
its unique permeability. The exchange of waste becomes difficult and the build-up of debris 
and waste in ECM leads to the formation of drusen in BM and the RPE layer. At this stage, 
the levels of HS increase in retinal ECM and drusen [379]. This increase could result in 
stimulating the RPE to over produce VEGF. This represents the second process of growth 
factor imbalance and over time, leads to the wet stage of AMD associated with the growth 
of blood vessels and their penetration of BM and RPE layers [380]. Literature was carefully 
searched and there is no any reported data regarding the levels of growth factors related to 
AMD. 
This proposal is based on our findings that:  
Our previous finding in PGs sulfation and xyloside GAG initiation experiments 
showed that thrombin and TGFβ resulted in the highest stimulation [13]. The same 
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“stimulation trends” were previously observed when studying the effect of both growth 
factors on gene mRNA expression of GAG elongation but the TGFβ effect was higher than 
the thrombin effect. Thrombin stimulates VEGF in various cell kinds including choroidal 
endothelial cells and it is known that VEGF produces angiogenesis [381-383]. Although 
thrombin was more likely to be involved in retinal disease however, no study has shown that 
thrombin stimulated RPE cells to secrete VEGF. Thrombin is likely to be involved in retinal 
disease although, no study has shown that thrombin stimulated RPE cell to secret VEGF 
[383]. TGFβ on the other hand has been reported to contribute to AMD through up regulation 
of VEGF produced by RPE which is controlled by MAP kinase pathways. Therefore, MAP 
kinase inhibitors could possibly be explored as therapeutic agents for AMD [24, 97, 384, 
385]. TGFβ is implicated in the synthesis of PG as it activates the phosphorylation of ERK 
and p38 [97, 236, 386-388]. 
The TGFβ treatment was performed for 24 hours (time required by cell to synthesise 
complete PGs) on the mRNA expression of the following genes XT-1, ChGn-2, ChPF, 
ChSy-1, C4ST-1 and C4ST-2 to evaluate TGFβ effects over time [5, 233, 236]. All the genes 
had similar results with peak gene mRNA expression between 4-6 hours and decreasing or 
remaining unchanged afterwards. The only exception was ChSy-1 whose expression 
increased to the maximum at 6 hours and decreased before it increased again at 24 hours. 
This biphasic expression could have been because of its function in the earlier stages of the 
synthesis of PGs and the fact that it also worked with ChPF in GAGs polymerization. These 
findings are in agreement with other published data obtained from in vivo and in vitro studies 
[168, 236]. The process of GAG elongation involves the transmission of signals from growth 
factors and hormones to the receptors [170, 190, 365, 389].  
The findings in this study demonstrated that AMD relevant agonists (except VEGF) 
had varying impacts on the genes that caused the elongation of GAG chains of PGs 
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synthesised by retinal choroidal endothelial cells. This confirmed the previous findings in 
Chapter 3. The results shed light on the importance of the imbalance of these growth factors 
and their important roles in the development of AMD or halting its progression [2, 52, 117, 
390]. Future studies should examine the relevance of mRNA expression changes of genes 
relevant to the development and treatments of AMD and possibly other PG associated genes. 
Further research is needed on the interrelation of TGFβ, thrombin and PDGF with VEGF as 
potential therapeutic targets for early AMD. 
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4.7 Conclusions 
In conclusion, the exploration of the effect of agonists on the mRNA expression of 
relevant genes and their role in the synthesis of PGs and GAG elongation can help future 
research in AMD. The findings in this study, support our proposed hypothesis that growth 
factors impact on the synthesis of PGs and GAGs elongation. PGs and elongated GAGs play 
important roles in early AMD alongside the imbalance of growth factors. Future research 
should focus on the interrelation of TGFβ, thrombin and PDGF with VEGF. We also propose 
that future laboratory experiments should continue to use human retinal cells and when 
animal trials are needed, monkey cells or zebra fish should be used to generate accurate 
findings. Important future experiments should also study enzyme protein levels, activity or 
knockout experiments, and hopefully these future findings can be correlated with the 
findings of this study. 
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5. Chapter 5: Effects of growth factors on PGs in RPE 
cells involved in AMD 
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5.1 Abstract 
Retinal epithelial cells secrete many growth factors that are necessary in 
maintaining the various functions of retina cells. These growth factors can in turn regulate 
cell growth. This study examined the effects of selected AMD relevant growth factors TGFβ, 
thrombin, PDGF, IGF and VEGF on PGs in retinal epithelial cells. Cells were characterized 
to be of epithelial origin using the specific cell marker CRALBP and confocal microscopy. 
Cell cultures were treated with growth factors in the presence or absence of the appropriate 
inhibitors and radiolabelled with 35S-sulfate. PGs were isolated by ion exchange 
chromatography and sized using SDS PAGE. Radio sulfate incorporation was determined 
by the CPC precipitation technique. To measure cellular GAG synthesizing capacity, 
xyloside was added and cellular GAG synthesizing capacity measured. AMD relevant 
growth factors TGFβ, thrombin, PDGF, IGF and VEGF had no effect on RPE cell synthesis 
of PGs. Only thrombin produced PGs from the cell surface through mechanisms other than 
intracellular synthesis. 
5.2 Introduction 
5.2.1 RPE and its functions. 
The RPE is located in the area between the photoreceptors and the choriocapillaris 
of the choroid as shown in Figure 1.2 [391]. The RPE regulates the flow of molecules from 
the choroidal circulation to the retina, a function controlled by their junctional structure 
[392]. The RPE also plays vital roles in preserving the photoreceptors and their structure 
[393]. Protein expression by the RPE is a highly organized and complicated process and any 
alteration to this process could lead to abnormalities in the expression of growth factors and 
in the secretion of structural proteins [157]. 
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5.2.2 Role of RPE in the interphotoreceptor matrix (IPM) PGs 
Retinal adhesion to RPE is controlled by the interphotoreceptor matrix (IPM), 
which is the sub-retinal space between the photoreceptors and the RPE. The components of 
the IPM are either synthesized by the photoreceptors or the RPE. The RPE synthesizes most 
IPM components such as GAGs, PGs, CSPG and hyaluronic acid [394-396]. CSPGs 
participate in many vital cellular biological functions such as cell adhesion, cell growth and 
receptor binding [397]. Although the exact site for IPM PG synthesis has not been 
established, similar sulfated PGS observed in the IPM were also found in the RPE [398]. 
5.2.3 Cell surface PGs in the RPE 
PGs core proteins are synthesised in the retinal endoplasmic reticulum (RER). 
Some PGs such as decorin and biglycan are released into the lumen while others remain 
embedded in the cell membrane (cell surface PGs) such as syndecan. Cell surface PGs also 
include HSPGs which have one or more covalently attached HS chains [391, 399, 400]. The 
exchange and transportation of macromolecules between the cells includes HSPGs which 
act as cell surface receptors for many macromolecules. These macromolecules include 
growth factors whose entry into the cells is mediated by HSPGs mediated endocytosis [401-
403]. 
5.2.4 Role of growth factors in PG synthesis 
Please see all the important background information on the relation among PG and 
AMD that was decribed earlier in Chapter One (page 58) [247, 261, 376, 404-408]. 
RPE secretes molecules and growth factors which serve various functions such as 
maintaining the choriocapillaris endothelium and photoreceptors structure integrity. This is 
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achieved via interactions with other molecules. RPE regulates these molecules through 
paracrine and autocrine factors. For example, PG interaction with growth factors and their 
receptors is thought to be one of its most important biological functions. However, there is 
a need to understand the RPE regulation role, in order to develop therapies for the early stage 
of AMD [157, 245, 258, 261, 308]. 
The photoreceptor and the RPE cells development are interdependent. The RPE 
plays an important role in the photoreceptors ECM composition which is critical to 
retinopathy in general and specifically to AMD. Analysis of the soluble component of the 
ECM composition revealed 98% protein and only 2% PGs. Aberrant PG expression is 
reported to be correlated with retinal degeneration, changes in the retina and RPE which are 
signs in the development of AMD  [245, 259, 307, 377, 409, 410]. 
Numerous studies have been reported on the role of lipid deposition in AMD as a 
symptom of disease progression. There are several age-related mechanisms and processes 
that can lead to deposition of ECM lipids and drusen beneath the retina [411]. The RPE loses 
its ability to maintain cholesterol homeostasis and transportation with ageing [412]. In 
addition, RPE dysfunction can lead to the accumulation of membrane attack complex around 
these cells and lipid deposition [2, 62, 159, 259, 413]. 
LDL and high density lipids (HDL) are important components of the lipid deposits 
which can interact with other molecules. They also play a role in transporting the carotenoids 
lutein and zeaxanthin into the plasma [414]. HDLs are considered to be the main transporter 
of these molecules into retina with these carotenoids playing crucial roles in protecting and 
maintaining healthy ocular tissues [415]. Another lipid interaction occurs with PGs with 
elongated GAG chains which show higher binding affinity to LDL [96, 268, 289, 416, 417]. 
Although healthy tissues can process lipid deposits, tissues can lose the ability to efflux 
cholesterol[8]. This is critical to lipid deposition influencing macular degeneration and 
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progression of AMD. On the other hand, omega-3 fatty acids are reported to play positive 
roles in the prevention of AMD [62, 159, 418-420]. 
Our lab has carried out numerous studies on the effects of growth factors on PG 
synthesis and GAG elongation in endothelial cells. Therefore in this chapter, the role of 
growth factors in PG synthesis and structure in RPE cells will be investigated to determine 
whether they might play a role in early AMD [2, 13]. The previous experiments on the 
endothelial cells in chapter three showed the effect of growth factors on GAG elongation, 
this study is set to run similar experiments on the RPE. 
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5.3 Materials and methods 
5.3.1 Materials 
DMEM (0 and 25 mM glucose), trypsin versene and antibiotics (10,000 U/ml 
penicillin, 10,000μg/ml streptomycin) were purchased from Gibco BRL (NE, USA). FBS 
was obtained from Invitro Technologies, Pty. Ltd (VIC, Australia). Anti-CRALBP [B2] was 
purchased from Abcam (MA, USA). Blocking serum and Alexa Fluor 488 donkey anti-
mouse or anti-rabbit IgG were purchased from Thermo scientific (IL, USA). PDGF, 
thrombin, VEGF, SB431542, GM6001, chondroitin sulfate, PBS 10X which also contains 
magnesium and calcium supplement, SDS, DMSO, 2-propanol and Fura-2AM and Nuclear 
stain Hoechst 408 were purchased from Sigma-Aldrich, (MO, USA). Human TGF-β was 
purchase from Cell Signalling Technology (MA, USA).  Imatinib was obtained from Alfred 
Hospital Pharmacy (Victoria, Australia). The PAR-1 inhibitor SCH79797 was purchased 
from Invitro Technologies (VIC, Australia). Human IGF-1 was obtained as a gift from Prof. 
Wenhua Zheng (Faculty of Health Sciences, University of Macau, Taipa, Macau and Key 
Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 
Guangzhou 510006, China). UO126 was obtained from Promega (Madison, WI, USA). 
Scintillation fluid Instagel was purchased from Packard (Groningen, The Netherlands). 
Methyl b-D-xylopyranoside (xyloside), Sepharose CL-6B, sodium borohydride, DEAE-
sephacel, Whatman 3MM chromatography paper from Biolab (Mulgrave, Australia). 
Carrier-free 35S-sulfate was purchased from MP Biomedicals (LA, USA). CPC was obtained 
from Unilab Chemicals and Pharmaceuticals (Mumbai, India). Rainbow™[14C] methylated 
protein molecular weight markers were purchased from GE Healthcare Bio-Sciences Corp. 
(Piscataway, NJ). TEMED, Tris Base and Glycine were obtained from Amresco (OH, USA). 
Tween 20, Poly-Prep columns and APS were purchased from BioRad Laboratories (CA, 
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USA). Protease inhibitor and all other chemicals and reagents were of the highest 
commercially available standard grade, and were purchased from Sigma-Aldrich (NSW, 
Australia). 
5.3.2 Methods 
5.3.2.1 Cell culture 
Human RPE-19 (ATCC® CRL-2302™) cells were purchased from the American 
Type Culture Collection. Cells were maintained in DMEM 5mM glucose, 10% heat 
inactivated serum and 1% antibiotics at 37°C in 5% CO2. Experiments were performed on 
cells between 3-20 passages. RPE-19 cells were seeded on 60 mm dishes and 24 well-plates 
at cell densities of 5×106 to 2×107 cells/ml. Once cells reached confluence, they were 
rendered quiescent by serum deprivation (0.1% heat inactivated FBS) for 48 hours. 
5.3.2.2 Immunohistochemistry cell characterization 
RPE-19 cells were stained for immunohistochemistry characterization using anti-
CRALBP antibody which is retinal epithelial cell specific markers [247, 421]. Cells were 
grown to confluence on 1.5 glass coverslips (22x22 mm) at a cell density of (5×106 to 2×107 
cells/ml) and then serum deprived. Cells were then fixed in 2% paraformaldehyde in 1 N 
phosphate buffer for 10 minutes at room temperature, then allowed to permeabilize and 
blocked for 30 minutes at room temperature in 0.1% Triton X-100, 1% normal horse serum. 
Cells were incubated for 90 minutes at room temperature in a humidified chamber, incubated 
overnight with primary antibody anti-CRALBP, washed first followed by Alexa-Flour 488 
or 594 and Hoechst stain for 30 mins. Coverslips were mounted on slides and cells imaged 
using a Nikon D-eclipse C1con focal microscope. 
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5.3.2.3 Quantitation of radiolabel incorporation into proteoglycans  
Cells were radiolabelled with 35S-sulfate (25mCi/ml) for 24 hours at 37ºC in 5% 
CO2 in 24-well plates. Cells were then washed thoroughly and media were added with or 
without agonist and antagonist for 1-4 hours. Cell-associated and secreted PGs were isolated 
using Ion column chromatography and collected with protease inhibitors. Quantitative 
measurement of radiolabel incorporated on PGs was performed by applying CPC 
precipitation assay. 
5.3.2.4 Synthesis of xyloside GAG chains 
β-D-xyloside (0.5 mM) was used to measure cellular GAG synthesizing capacity. 
Five hundred microliters of DMEM (0.1% FBS) supplemented with xyloside (0.5 mM) was 
added to the quiescent cells under basal conditions and in the presence of agonists. After 
this, 35S-sulfate (50 μCi/ml) was added and cells were incubated for a further 24 hours. 
Secreted PGs and xyloside GAG were harvested, isolated, concentrated, and SDS-PAGE 
was used for the quantification of PGs. 
5.3.2.5 SDS-PAGE analysis of PG size 
PGs labelled with 35S-sulfate were eluted through DEAE-Sephacel anionic 
exchange mini columns. These were added to pre-equilibrated columns and then washed 
extensively with low salt buffer. PGs were eluted with high salt buffer and fractions that 
contained the highest levels of 35S-sulfate (cpm) were used. Equal amounts of PGs were 
precipitated by ethanol solution and chondroitin added. Samples were re-constituted in 
sample buffer (0.5 M Tris–HCl pH 6.8, 10% SDS, 50% glycerol, 2-mercaptoethanol and 
equal amounts of buffer (8 M urea, 2 mM disodium EDTA, at pH 7.5) was added. Radio 
labelled samples were separated on 4-13% PGs or 4-20% (xyloside-GAGs) acrylamide gels 
and 3% acrylamide stacking gel at 60 V overnight. Gels were fixed on plastic template, dried 
in a fume hood overnight and exposed to an imaging plate (Fujifilm BAS-MS 2040 imaging 
162 
 
plate) for approximately 4-5 days. Images were developed on a Cyclone Plus Phosphor 
Imager (Perkin Elmer). 
5.3.2.6 Statistical analysis 
Statistical analysis was performed on the normalized data using a one-way 
ANOVA. Data were expressed as the mean± standard error of the mean (SEM) of at least 
three independent experiments unless stated otherwise. Statistical significance of the data 
was calculated and analysed using least significant difference (LSD) post-hoc analysis. 
Results were considered significant when the probability was less than 0.05 (*p<0.05) and 
0.01 (**p<0.01). 
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5.4 Results 
5.4.1 Characterisation of human human RPE-19 
Human RPE cells were characterized by phenotype and immune histochemical 
markers. RPE-19 cells were grown to confluence with microscopic images and morphology 
characteristics the cells were of epithelial origin. The most important morphological features 
of the RPE-19 (Figure 5.1) were the hexagonal shape which contained several multinuclear 
cells [259, 422-424]. The cells were confirmed to be of epithelial origin (Figure 5.1).    
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Figure 5-1 Phase contrast image of human RPE-19 
 
RPE-19 cells passage 18 and magnification x400. The morphology of the cells was typical 
of those reported in the literature [259, 423], which were hexagonal in shape with limited 
pigmentation and multinuclear cells.  
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5.4.2 Immunohistochemical characterization of human RPE-19 
Immunohistochemistry was used with anti-CRALBP (cellular retinal-binding 
protein) a specific antibody marker against RPE-19 cells. The marker binds to its cellular 
localization at the cytoplasm of the cells. Confocal microscopy was utilized to obtain 
magnified images (Figure 5.2). Hoechst nuclear stain blue while retinal epithelial cell marker 
stained all cells (especially cytoplasm) green, the colour of the secondary antibody. Results 
confirmed that the cells used were of retinal epithelial origin [247, 421]. 
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Confocal microscope images of RPE-19 Magnification x200, (A) nuclear stain Hoechst 408 
which stains the nuclei blue, (B) retinal epithelial marker which stains the cytoplasm of the 
cells with the green colour Alexa Fluor 488, (C) both images were merged together in one 
image. Cells were fixed, then characterized using retinal epithelial cells specific markers 
primary Anti-CRALBP [B2] (1:1000), secondary antibody Alexa Fluor 488 donkey anti-
mouse or anti-rabbit IgG (1:400), nuclear stain Hoechst 408 (1:500), blocking serum 
(Normal Horse Serum) (1:100) and using Immunohistochemistry assay. Results confirmed 
that the cells used were of retinal epithelial origin [247, 421].  
 
A C B 
 
Figure 5-2 Immunohistochemical characterization of human RPE-19 cells 
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5.4.3 Effect of TGFβ on the 35S-sulfate associated PGs in RPE-19 cells 
The effect of serine/threonine kinase receptor agonist TGFβ on PGs of RPE cells 
was determined in this section. As in the previous experiments with retinal choroidal 
endothelial cells, its addition resulted in the highest stimulation of sulfate incorporation into 
PGs, hence it was considered as a positive control in these experiments [13]. Figure 5.3 
shows the dose response experiments performed on RPE cells with TGFβ concentrations of 
0, 0.2, 0.5, 1, 2, 5, and 10 ng/ml in the presence of 35S-sulfate radiolabel for 24 hours. The 
35S-sulfate associated PGs were isolated using Ion column chromatography and measured 
using quantitative radiolabel incorporated CPC precipitation assay. In contrast to what was 
observed in endothelial cells, TGFβ at all concentrations tested did not stimulate the 35S-
sulfate associated PGs. Treatment with the TGFβ inhibitor SB 431542 (SB, 10 μM) used as 
a control did not induce any inhibitory effect as there was no stimulation of the 35S-sulfate 
associated PGs. The results indicated that SB 431542 did not have any effect on basal 
condition (Figure 5.3A). The 35S-sulfate associated PGs were run on the SDS-PAGE gel and 
the result showed there was no band of 35S-sulfate PGs that was of interest at 100-200  kDa 
(Figure 5.3B).  
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(A) The histogram shows the 35S-sulfate associated PGs for cells across a range of TGFβ 
concentrations. (B) SDS-PAGE gel shows the 35S-sulfate associated PGs. RPE-19 Cells 
were treated with TGFβ (0.0, 0.2, 0.5, 1, 2, 5, and 10 ng/ml) for 24 hours.  Cells were also 
pre-treated for 30 min with the SB 431542 (SB, 10 μM) and in the presence of 35S-sulfate 
radiolabel (25mCi/well). The experiments were done three times with similar results. 
 
Figure 5-3 Effect of TGFβ on the 35S-sulfate associated PGs in RPE-19 
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5.4.4 Effect of VEGF on the 35S-sulfate associated PGs in RPE-19 
The surprising negative results of TGFβ on the production of PGs in RPE-19, 
generated a research question. “Would a tyrosine kinase receptor agonist VEGF have an 
impact on the 35S-sulfate associated PGs in RPE-19?” The results of experiments carried out 
to answer this question are shown in Figure 5.4. Figure 5.4 shows the dose-response 
experiments which were designed to expose the cells to the following doses of VEGF; 0, 2, 
5, 10, 20, 50 and 100 ng/ml in the presence of 35S-sulfate radiolabel for 24 hours. The 35S-
sulfate associated PGs were measured under basal conditions and in the presence of VEGF 
(0.0, 2, 5, 10, 20, 50 and 100 ng/ml). Results from the assay with all these concentrations 
indicated that VEGF did not stimulate the 35S-sulfate associated PGs. Treatment with the 
TGFβ (2 ng/ml) as a positive control in the retinal choroidal endothelial cells did not also 
cause any stimulation of the 35S-sulfate associated PGs in the RPE (Figure 5.4A). The SDS-
PAGE gel result showed no bands of 35S-sulfate PGs appeared (Figure 5.4B). 
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(A) The histogram shows the 35S-sulfate associated PGs for cells across a range of VEGF 
and TGFβ concentrations. (B) The SDS-PAGE gel shows the 35S-sulfate associated PGs. 
RPE-19 Cells were treated with VEGF and TGFβ with the following doses 0, 2, 5, 10, 20, 
50 and 100 ng/ml and (2 ng/ml) for 24 hours in the presence of 35S-sulfate radiolabel 
(25mCi/well). The experiments were done three times with similar results. 
 
A 
B 
Figure 5-4 Effect of VEGF on 35S-sulfate associated PGs in RPE-19 cells 
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5.4.5 Effect of PDGF, IGF, VEGF and thrombin on 35S-sulfate associated 
PGs in RPE-19 
Previous assessment of the impact of various concentrations of TGFβ 
(serine/threonine kinase receptor agonist) and VEGF (tyrosine kinase receptor agonist) on 
PGs in RPE-19 cells had shown no effects on 35S-sulfate associated PGs, secreted or cell 
surface. Two other agonists relevant to retinal disease were subsequently investigated; the 
effect of agonists on tyrosine kinase and GPCR receptor agonists PDGF, IGF, VEGF and 
thrombin on RPE-19 PG. Quiescent cells were treated with thrombin with cells being under 
basal conditions for all treatments. Cells treated were with thrombin (10ng/ml) in the 
presence or absence of the PAR-1 inhibitor SCH 79797 (10μM). Results in Figure 5.5 
indicated that with the addition of thrombin in the absence of the inhibitor, there was a 50% 
increase in 35S-sulfate associated PGs and the detection of two PGs bands. However, the 
presence of the PAR-1 inhibitor SCH 79797 had no effect on 35S-sulfate associated PGs. The 
treatment of 50 ng/ml PDGF with or without the addition of PDGF inhibitor, imatinib 
(10μM) also showed no effect on the 35S-sulfate associated PGs. The addition of the inhibitor 
showed no inhibition effect on 35S-sulfate associated PGs when both were compared to the 
basal. The addition of two doses (low and high, 20 and 50 ng/ml of VEGF), also had no 
effect on the appearance of PGs nor 35S-sulfate associated PGs. Similar results were obtained 
when the cells were treated with 50 ng/ml of IGF. These results showed that only GPCR 
agonist thrombin stimulated 35S-sulfate associated PGs in RPE cells (Figure 5.5A). SDS-
PAGE gel analysis showed two bands of unknown PGs approximately 260-340 kDa in size. 
The PGs band in the presence of the inhibitor was smaller and less intense compared to the 
other band in the presence of thrombin (Figure 5.5B). In conclusion, only thrombin produced 
an 35S-sulfate associated PGs band approximately 260-340 kDa in size. 
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Figure 5-5 Effect of PDGF, IGF, VEGF and thrombin on 35S-sulfate 
associated PGs in RPE-19 
 
(A) The histogram shows the 35S-sulfate associated PGs. (B) SDS-PAGE gel shows the 35S-
sulfate associated PGs. RPE-19 Cells were untreated (basal), treated with PDGF (50 ng/ml) 
in the absence and presence of imatinib (10μM), thrombin (10 U/ml) in the absence and 
presence of SCH 79797 (10μM), VEGF (20 and 50 ng/ml) and IGF (50 ng/ml) for 24 hours, 
in the presence of 35S-sulfate radiolabel (25mCi/well). Cells were also pre-treated and 
incubated with antagonists for 30 minutes. The experiments were performed three times with 
similar results.  
A B 
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5.4.6 Effect of PDGF, TGFβ and thrombin on stimulation of xyloside 
initiated GAG 35S-sulfate association and GAG elongation in RPE-19 
In the previous set of experiments to investigate the effect of growth factors on the 
GAG synthesizing potential of the retinal endothelial cells, visualization difficulties were 
encountered due to weak bands on SDS-PAGE. This research focused on three growth 
factors PDGF, TGFβ and thrombin, for studying xyloside-GAG synthesis in RPE cells. 
These were from three different growth factor receptor families, TGFβ serine/threonine 
receptor agonist, PDGF tyrosine kinase receptor agonist and thrombin GPCR agonist. 
Xylose is the first sugar added to the serine residue on a core protein of a PG. The addition 
of artificial xyloside (exogenous) to the cell cultures stimulated the cells to respond to 
xyloside as a false acceptor [341] and consequently synthesize xyloside GAGs which are 
short GAG chains [231, 341]. This technique has been used to assess the effects of different 
agonists and antagonists in VSMCs [96, 234, 343].  
Cell preparations and incubations were as described in the previous set of 
experiments and in the additional presence of β-D-xyloside (0.5 mM). Cells were treated 
with TGFβ (2 ng/ml), PDGF (50 ng/ml) and thrombin (10 U/ml) or with their antagonists, 
SB431542, imatinib and SCH79797 in the presence of artificial xyloside. CPC quantitation 
of radiolabel associated into PGs analyses was performed on the cell cultures. Xyloside 
GAGs production and size were determined using SDS-PAGE. These experiments showed 
the effect of TGFβ (2 ng/ml), PDGF (50 ng/ml) and thrombin (10 U/ml) on stimulation of 
xyloside-initiated GAG 35S-sulfate incorporation and elongation. The histogram showed the 
xyloside-initiated GAG 35S-sulfate incorporation of TGFβ, PDGF and thrombin stimulated 
xyloside initiated GAG into CPC precipitable material and elongation by 10%, 10% and 
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110% respectively. These responses were inhibited by the addition of the relevant 
antagonists SB431542 and imatinib but not SCH79797 (Figure 5.6A).  
SDS-PAGE of the isolated xyloside-GAGs showed the change in size of xyloside-
GAGs as all three agonists increased the size of xyloside-GAGs and this response was 
completely inhibited by the respective antagonists. It is important to note that the increases 
in radio sulfate incorporation were correlated with the increases in the size of xyloside 
GAGs. In the presence of TGFβ (2 ng/ml), the molecular weight increased to 15 kDa when 
compared to the basal. The addition of TGFβ antagonist SB431542 (SB 10μM) resulted in 
xyloside-GAG band equal the same size as the basal level (15 kDa). PDGF (50 ng/ml) 
increased the xyloside GAGs molecular weight by around 10 kDa more than the basal while 
the addition of the antagonist imatinib (Imat 10μM) completely blocked the response. 
Thrombin (10 U/ml) addition increased the molecular weight of xyloside by around 15 kDa 
more than the basal. In addition to xyloside initiated GAGs band, thrombin also showed a 
distinctive band at more than 200 kDa in the presence and absence of inhibitor SCH79797. 
These bands were also observed in previous experiments of PGs (Figure 5.6B). 
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(A) The histogram shows the 35S-sulfate associated in stimulated xyloside initiated GAG and 
GAG elongation. (B) SDS-PAGE gel of 35S-sulfate associated in stimulated xyloside 
initiated GAG and GAG elongation (4-20% acrylamide gradient gel) shows the associated 
xyloside GAGs. Cells were untreated (basal) or treated with TGFβ (2 ng/ml) in the absence 
or presence of SB 431542 (10μM), PDGF (50 ng/ml) in the absence or presence of imatinib 
(10μM) and thrombin (10 U/ml) in the absence or presence of SCH 79797 (10μM). Cells 
were pre-treated and incubated with antagonists for 30 minutes. The cell culture media was 
supplemented with xyloside (0.5mM) to enable the production of xyloside GAGs as 
explained in the text. Then, 35S-sulfate (25mCi/well) was added for a further 24 hours. The 
experiment was carried out thrice. **p<0.01 for agonists or ##p<0.01 for antagonists and 
*p<0.05 using a 1-way ANOVA. 
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Figure 5-6 Effect of PDGF, TGFβ and thrombin on stimulating xyloside 
initiated GAG 35S-sulfate associated and GAG elongation in RPE-19 
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5.4.7 Effect of other GPCRs angiotensin II and endothelin-1 35S-sulfate 
associated PGs in RPE-19 
Based on previous experimental results, a new question arose “are there any other 
GPCR agonists which can give similar effects to thrombin?”. To answer this question, cells 
exposed to 35S-sulfate for 24 hours were treated with angiotensin II (1 uM) in the absence or 
presence of its inhibitor candesartan (10 μM), endothelin-1 (100 nM) in the absence or 
presence of its inhibitor bosentan (10 μM) and thrombin (10 U/ml) in the absence or presence 
of PAR-1 inhibitors SCH 79797 (10 μM) and E5555 (10 μM) for 24 hours. Figure 5.7A 
shows that thrombin addition increased the 35S-sulfate associated PGs by almost 50% when 
compared to the basal while the presence of SCH 79797 and E5555 did not show any clear 
inhibitory effect on 35S-sulfate associated PGs. On the other hand, with respect to GPCR 
agonists, neither angiotensin II nor endothelin-1 had any stimulatory effect on 35S-sulfate 
associated PGs. The SDS-PAGE gel showed that with thrombin (10 U/ml) at 24 hours there 
was a more intense band with a molecular weight of around 260-340 kDa corresponding to 
associated PGs. The presence of PAR-1 inhibitors SCH 79797 and E5555 resulted in 
inhibitory effects on the PGs band. Only thrombin resulted in the appearance of PGs while 
the other GPCR agonists (Angiotensin II & Endothelin-1) did not (Figure 5.7).  
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(A) The histogram shows 35S-sulfate associated PGs. (B) SDS-PAGE gel shows the 35S-
sulfate associated PGs. RPE-19 cells were untreated (basal), treated with angiotensin II (1 
uM) in the absence or presence of candesartan (10 μM), endothelin-1 (100 nM) in the 
absence or presence of bosentan (10 μM) and thrombin (10 U/ml) in the absence or presence 
of SCH 79797 (10 μM) and E5555 (10 μM) for 24 hours. Cells were also pre-treated and 
incubated with antagonists for 30 minutes. The experiments were performed thrice with 
similar results obtained. 
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Figure 5-7 Effect of other GPCRs angiotensin II and endothelin-1 
35S-sulfate associated PGs in RPE-19 
178 
 
5.4.8 Effect of thrombin on the release of 35S-sulfate associated PGs in 
RPE-19 
To determine thrombin dose response course effect on PGs, RPE-19 cells were 
exposed to the radiolabel 35S-sulfate and thrombin concentrations at 0.0, 0.1, 0.3, 1, 3, 10 
and 30 U/ml incubated for 24 hours. In another experiment, thrombin (10 U/ml) in the 
presence of SCH 79797 (10 μM) was pre-treated and incubated for 30 minutes. Figure 5.8A 
shows 35S-sulfate associated PGs measured at each concentration. The peak effect of 
thrombin addition was at 10 U/ml which resulted in 70% increase in 35S-sulfate associated 
PGs. In the presence of PAR-1 inhibitor SCH 79797 (10 μM), there was no inhibition of 35S-
sulfate associated PGs. The SDS-PAGE gel showed that 35S-sulfate associated PGs 
increased with thrombin concentrations. There were bands generated at the range of 
approximately 260-340 kDa in response to the various doses of thrombin applied. The 
intensity of the bands was observed to increase with increasing concentrations of thrombin. 
The use of SCH 79797 resulted in no inhibition of the PGs band (Figure 5.8B). 
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(A) The histogram shows the 35S-sulfate associated PGs. (B) is a representative gel of 
thrombin experiments. The SDS-PAGE gel shows 35S-sulfate associated PGs. RPE-19 cells 
were treated with 35S-sulfate radiolabel (25mCi/well) for 24 hours, washed carefully and 
new medium added with thrombin at different concentrations (0.0, 0.1, 0.3, 1, 3, 10 and 30 
U/ml). Cells were pre-treated with thrombin (10 U/ml) in the presence of SCH 79797 (10 
μM) and incubated for 30 minutes as negative control. Experiments were carried out three 
times and similar results were obtained. 
 
A B 
Figure 5-8 Dose-response of thrombin treatment on 35S-sulfate associated 
PGs in RPE-19 
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5.4.9 Time course of thrombin for 35S-sulfate associated PGs in RPE-19 
The experimental results demonstrated that only thrombin addition caused the 
appearance of a PGs band and it was the only agonist that caused an increase in the 35S-
sulfate labelled PGs from the cell surface. These findings generated two new questions. The 
first was what was the time course of thrombin action on RPE-19 cells that resulted in an 
increase 35S-sulfate release and an appearance of PGs bands on the gel. The second question 
was whether the appearance of PGs was due to synthesis (it would take more than 20 hours) 
or some other processes?  
To answer these questions, cells were treated with 35S-sulfate radiolabel 
(25mCi/well) for 24 hours, washed carefully and new medium added without the addition of 
agonist (control) for 0, 0.25, 0.5, 1, 2 and 4 hours. Additional wells with cells were treated 
with thrombin for 0, 0.25, 0.5, 1, 2 and 4 hours. Figure 5.9A showed that thrombin addition 
resulted in a gradual increase in 35S-sulfate release into the media until it reached a 60% 
increase at 4 hours. The control showed no significant increase at all points. The SDS-PAGE 
gel showed the 35S-sulfate release and the appearance of a PGs band at a thrombin dose of 
(10 U/ml) at one hour with a molecular weight of around 260-340 kDa (Figure 5.9B).  
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(A) The histogram shows the sulfate incorporation in PGs. (B) The SDS-PAGE gel shows 
the 35S-sulfate associated PGs. RPE-19 cells were treated with 35S-sulfate radiolabel 
(25mCi/well) for 24 hours, washed carefully and new medium added in the absence and 
presence of thrombin (10 U/ml) for 0-4 hours. The experiments were performed in triplicates 
with similar results obtained. 
 
  
A B 
Figure 5-9 Time course experiment for the release of 35S-sulfate 
labelled PGs from the cell surface by thrombin 
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5.5 Summary of results  
 The RPE-19 cells were confirmed to be of retinal epithelial origin using 
immunohistochemical markers characteristic of retinal epithelial cells. 
 TGFβ application did not stimulate 35S-sulfate PGs associated released into the 
media from the cells. Treatment with the inhibitor SB 431542 (SB, 10 μM) as a 
negative control did not induce any inhibitory or stimulatory effect. However, the 
obtained results suggested that this inhibitor did not have any effect under basal 
conditions. The SDS-PAGE gel result showed no appearance of PGs of interest (100-
200 kDa). 
 VEGF did not stimulate PGs associated 35S-sulfate released into the media. 
Treatment with TGFβ (2 ng/ml) as a positive control in the retinal choroidal 
endothelial cells did not induce any stimulation of PGs associated 35S-sulfate released 
into the media. The SDS-PAGE gel result showed no appearance of bands of interest 
(PGs) (100-200 kDa). 
 Only GPCR agonist thrombin stimulated the release of 35S-sulfate labelled PGs from 
the cell surfaces and showed two bands of unknown PGs, approximately 260-340 
kDa on SDS-PAGE gel. 
 The xyloside-initiated GAG 35S-sulfate associated experiments of TGFβ, PDGF and 
thrombin and their antagonists showed that all agonists evaluated stimulated xyloside 
initiated GAG radio sulfate associated into CPC precipitable material and elongation. 
The responses were blocked by the addition of the relevant antagonists except with 
thrombin. 
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 The xyloside GAGs experiments showed that all agonists caused an increase in the 
molecular weight of the xyloside initiated GAGs with thrombin causing the highest 
increase. The addition of the antagonists inhibited stimulation.  
 Thrombin treatment also revealed distinctive bands in the xyloside-initiated GAG 
35S-sulfate associated experiments of more than 200 kDa in the presence and absence 
of inhibitor SCH79797. These bands had been observed in previous experiments on 
PGs. 
 Only thrombin application resulted in the appearance of PGs while the other GPCR 
agonist’s (angiotensin II and endothelin-1) did not. 
 In the PGs production experiments, optimal dose of thrombin addition was at 10 
U/ml which resulted in 70% increase in PGs associated 35S-sulfate released into the 
media. The SDS-PAGE gel showed the associated PGs with thrombin (10 U/ml) at 
24 hours had a more intense and wide band with a molecular weight of around 260-
340 kDa. 
 Thrombin addition resulted in a gradual increase in the release of 35S-sulfate labelled 
PGs from the cell surface until it reached 60% at 4 hours. However, the control 
showed no significant increase. The SDS-PAGE gel showed the PGs associated 35S-
sulfate released into the media with a peak time of 1 hour and a molecular weight 
around 260-340 kDa. 
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5.6 Discussion 
This study explored the role of growth factors on RPE cells and its impact on PGs 
and ECM. The findings in this study indicated that TGFβ, PDGF, IGF and VEGF did not 
stimulate the synthesis or release of 35S-sulfate labelled PGs from the surface of the RPE 
cells. Experiments confirmed that the cells were of retinal epithelial origin by comparing the 
marker genes described in the literature [259, 422, 423].  From our previous findings, the 
retinal choroidal endothelial cells TGFβ, PDGF and IGF stimulated PGs synthesis, 35S-
sulfate incorporation and GAGs elongation, but not VEGF (chapter 3) [13]. Also, the results 
in Chapter 3 showed that, VEGF did not stimulate sulfate incorporation and GAG elongation 
in retinal choroidal endothelial cells. A literature review also showed that there is a 
relationship between RPE and VEGF, in fact VEGF is secreted by RPE and most treatments 
of AMD target VEGF [2, 13, 299, 301]. 
Thrombin did not stimulate the synthesis of PGs in the RPE cell but caused an 
increase in the release of 35S-sulfate associated PGs from the cells with a size of around 260-
340 kDa, this suggested that thrombin did play a role in the generation of PGs but not in the 
synthesis of PGs as SCH 79797 (the thrombin receptor inhibitor) did not block its effect. 
The xyloside experiments showed the same bands around 260-340 kDa in addition to the 
xyloside bands. 
In the experiments aimed at detecting the GAGs elongation, the results confirmed 
that the cells were capable of GAGs elongation but not complete synthesis of PGs. The RPE 
cells did not synthesize complete PG under the influence of the growth factors tested [154, 
183, 316, 360]. The RPE cells need the GAGs for biological functions including the 
transportation of molecules across the cell with RPE cells being shown to elongate GAGs 
[425, 426].  
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Only thrombin application resulted in the release of 35S-sulfate associated PGs in 
the media while other GPCR agonists Angiotensin II and Endothelin-1 did not. This 
suggested that this property of PGs generation in the RPE was unique to thrombin. The 
optimal dose and time course experiments showed that 10U/ml at one hour was the optimal 
concentration and time while this also suggested there was PGs generation rather than 
synthesis (which required a time-frame longer than one hour) [170, 233, 427, 428]. 
These results reflect the role of RPE cells in AMD and its impact on the function of 
adjacent cells. As an example, RPE is reported to contribute significantly to the synthesis 
and degradation of PGs in the interphotoreceptor matrix [429]. RPE serves an important 
function in the transportation of molecules including PGs from surrounding cells to the 
photoreceptors cells [157]. This was why RPE did not synthesize PGs as it might possibly 
influence the stimulation of PGs synthesis in other cells. Many molecules in the 
interphotoreceptor matrix are synthesized in the systemic vasculature and delivered to the 
photoreceptors by the RPE [409]. 
The above results support the theory that RPE contributes to PGs synthesis in other 
cells. This contribution could be through paracrine and autocrine factors and any defect in 
the synthesis or degradation of GAGs by the RPE may be related to some forms of retinal 
degeneration [429]. This important function of the retina includes transporting molecules 
from and to adjacent cells. It has been reported that RPE constituted a main source of CS 
production in vivo, and so represented the main site of sub-retinal GAG synthesis [246]. CS 
could be transported from other cells and the only role of RPE was the delivery or trafficking 
of CS [430, 431]. 
PGs interact with many biologically active molecules via their core protein 
components, as well as their GAGs chains [157, 432]. The unique property of the HSPGs is 
their ability to bind potent neurotrophic growth factors such as basic fibroblast growth factor 
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(bFGF). This growth factor binds to HSPG in RPE cell ECM, as well as transforming growth 
factor-β, where it may act as an important regulator of growth factor delivery to target cells 
[246, 433].  
Treatment of RPE with these growth factors resulted in no PGs synthesis and this 
could be because these growth factors operate to drive PG synthesis in other cells [256, 259, 
280]. HSPG presence at the cell surface of cells have been shown to regulate the extracellular 
distribution of FGF1 because the addition of heparin prevented the binding of secreted FGF1 
to extracellular HSPG. Primary cultures of RPE cells have few PGs at the cell surface and 
very few FGF1 low-affinity binding sites related to HSPG [434]. Thus, secreted FGF1 may 
be preferentially located in the extracellular culture medium of SP-FGF RPE cells due to the 
small number of FGF1 low-affinity sites [405, 434]. 
Thrombin generated PGs in RPE-19 cells could be due to PAR-1 protease activity, 
proteolytic activity of thrombin, and these features were explored in the next chapter. These 
two observations suggest that, the appearance of PGs could be due to processes other than 
synthesis [2, 223, 412, 435]. 
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5.7 Conclusions 
This section set out to study effects of growth factors on PG synthesis- GAG 
elongation- but instead observed that RPE did not make nor secrete lipid binding CSPGs 
(100-200 kDa). Growth factors had no effects (except thrombin) on the release of 35S-sulfate 
associated PGs from the surface of cells. The question then is, “is this a receptor-mediated 
or protease mediated effect of thrombin?” 
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6. Chapter 6: The effects of thrombin that cause PG 
shedding in RPE cells 
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6.1 Abstract 
The aim of this work was to study PGs in RPE cells and assess the effect of 
thrombin on cell surface PGs. RPE cells were cultured, radiolabelled with 35S-sulfate for 24 
hours, washed carefully and new media added. Selected samples were treated with either 
thrombin, angiotensin II or endothelin-1 for one hour and desired inhibitors (E5555, SCH 
79797, GM6001, UBO-QIC, SB 431542 and imatinib) added 30 minutes before the addition 
of the agonists. An intracellular calcium assay was performed to determine whether GPCR 
activation led to the release of intracellular calcium in retinal epithelia. The results showed 
that only the GPCR agonist thrombin stimulated 35S-sulfate release and the peak production 
of shed PG was approximately 260-340 kDa at 1 hour with a concentration of 3 U/ml. 
Thrombin mediated shedding of PGs was due to thrombin proteolytic activity and not via 
receptor PAR-1 activation. In addition, the use of thrombin receptor agonist peptide (TRAP) 
did not lead to the appearance of a PGs band. 
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6.2 Introduction 
Thrombin is involved in many biological processes by acting through its GPCR or 
as a protease [436-438]. Thrombin binds to its cell surface GPCR receptor PAR-1 and is 
known to transactivate GPCR receptors PAR3 and PAR4 as these three receptors are the 
main targets for thrombin [439-442]. The PAR activation mechanism involves thrombin 
cleavage of the amino-terminal exodomain of PAR, which exposes a tethered peptide ligand. 
This ligand activates the receptor by binding to the heptahelical region of the receptor [201, 
232, 268, 276, 319, 437, 438]. The application of thrombin and other GPCR agonists such 
as angiotensin II and endothelin-1, can lead to the generation of phosphorylated Smad2 via 
time dependent process [98, 276, 349, 355] and [274, 276, 443]. Group Gα12/13, and Gαq 
have been implicated in the activation of PAR-1 via thrombin activities [443, 444]. PG 
shedding is one of the basic functions of the RPE [262] and part of a normal turnover process. 
However, thrombin induced PGs shedding requires the interaction of thrombin and the 
cellular thrombin receptor [445]. 
6.2.1 PGs in the RPE 
Retinal PGs are composed of core protein with covalently attached GAG chains 
[56, 368]. PGs can interact with other molecules either via their core protein or their GAG 
chains to form bigger molecules [56]. PGs can be classified into three major groups 
according to their GAG composition and the location of their core proteins. These are cell-
surface shed PGs, modular PGs and small leucin rich PGs  [2, 99, 446-448].  The cell-surface 
shed PGs are the focus of this study and the PGs in this group can be further divided into 
four major types based on the sulfation of their GAG chains. These are CSPGs, HSPGs, 
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KSPGs and DSPGs [449]. The ECM PGs include syndecans, phosphacan, versican, 
glypicans, betaglycans, hyalectans, perlecan and lecticans [154, 450]. 
The RPE is largely responsible for the transportation of molecules of different sizes 
and charges from the sub-retinal space to the underlying choroidal circulation [451, 452]. 
The RPE cells need the GAGs for their various biological functions such as the 
transportation of molecules across the cell (with the RPE cells modifying elongated GAGs) 
[425, 426, 453]. Tissue injury can result in changes to the matrix PG composition. One way 
of changing the concentration of PGs in the ECM is by cell-associated PG shedding. Shed 
PGs are heavy molecules and their accumulation can cause problems in their transportation 
through the BM. The accumulated PGs can interact with lipids, producing heavier molecules. 
This process leads to the development of drusen, blockage of BM and the loss of selective 
permeability of BM [154, 454]. 
6.2.2 Cell surface PG shedding 
Shedding is the release of cell surface components into the ECM as a consequence 
of cellular responses to tissue insult [455]. Cell surface PGs can function as receptor 
facilitators that catalyse the ligand receptor interaction [455, 456]. Shedding can be as simple 
as selective cleavage of HS or as complex as a major alteration or removal of the entire core 
protein with the attached GAG chain [457, 458]. HS can be linked to cell surface syndecans 
and HSPG is a cell surface receptor that plays important roles in lipid metabolism [221, 459]. 
Syndecans are a type of HSPG that regulate the activity of several growth factors [459, 460]. 
Thrombin mediated shedding can be due to PAR-1 activation via PAR-1 mediated shedding 
or to thrombin proteolytic activity. Both mechanisms will be investigated in this study [194, 
438, 461-463]. 
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6.2.3 Shedding due to thrombin cleavage proteolytic activity 
[464-466]. HSPGs are found on cell surfaces and are important participants in many cellular 
biological functions [221, 399, 445]. Thrombin belongs to proteases which are a group of 
enzymes that catalyse the cleavage reaction of peptide bonds in proteins and polypeptides 
[444, 467]. Proteases are involved in many biological processes and diseases and proteolytic 
activity has often been used as a marker for many diseases [438, 468, 469]. Thrombin is a 
dual function protease and like other coagulation proteases is activated by binding to its 
cofactor, thrombomodulin (TM) [194, 470]. This is a thrombin cofactor that in the presence 
of thrombin in a complex, causes thrombin to switch to its cleavage property and activate 
protein C which in turn generates the anticoagulant enzyme activated protein C [471-473]. 
Thrombin’s mode of action is similar to that of other members of the trypsin family of S1 
peptidases. Enzymes in this group are crucial mediators of many important processes such 
as blood coagulation and fibrinolysis [463, 474].  
Thrombin cleavage activity involves the thrombin receptor and the cleavage of 
arginine-lysine bonds and prothrombin at the N-terminal fragments [202-204]. Other 
proteases share similarities in action but not the thrombin unique properties of protease, 
hormone and growth factor. Thrombin action is also broader to that of other peptidases as it 
can change the substrate specificity based on cofactor reactions [463, 467, 475]. Some 
proteases can activate the signalling of PARs. For example, PAR-2 is known to be activated 
by trypsin and tryptase but the cellular response to trypsin is independent of PAR-1 which 
is activated by thrombin [463, 476]. Other molecules such as plasmin are also involved in 
the proteolytic cleavage of PGs. Plasmin can activate collagenase MMP-1 via the serine 
protease [445, 477]. The mechanism of thrombin proteolytic activity is shown in Figure 6.1. 
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Figure 6-1 Lepirudin blocking mechanism of PG shedding by inhibition 
of thrombin proteolytic activity  
 
Lepirudin inhition of thrombin multifunctional serine protease property that cleaves PGs 
between residues 15 and 16 on the core protein in PGs from the cell surface [220].  
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6.2.4 Thrombin proteolytic activity inhibition 
The actions of thrombin can be directly or indirectly inhibited by various molecules 
and these molecules differ in their mechanisms of inhibition [215, 217]. Direct thrombin 
inhibitors bind directly to thrombin and block the action of thrombin without the need for a 
cofactor such as antithrombin [217, 478]. Indirect thrombin inhibitors are low molecular 
weight heparins that block thrombin action by catalysing the function of antithrombin and 
form a complex by binding to exosite 2 in thrombin [215, 217, 436, 479].  
Hirudin and lepirudin are widely used as Direct thrombin inhibitors (DTIs). 
Lepirudin forms a 1:1 complex with thrombin to inhibit its protease activity [217, 480, 481]. 
Lepirudin is also known as the analogue of the peptide anticoagulant hirudin and is therefore 
a recombinant form of hirudins derived from yeast [480-482]. Hirudin and lepirudin react 
with thrombin to form a stoichiometric irreversible complex with thrombin [481-483]. 
However, there are some differences between hirudin and lepirudin namely the substitution 
of leucine for isoleucine at the N-terminal end and the absence of a sulfate group at position 
63 on the tyrosine of hirudin [480-482]. DTIs including hirudin and lepirudin and their 
modes of action are shown in Table 6.1 and Figure 6.3. 
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Table 6.1 DTIs classification 
 
 
Class 
 
Mode of action Example 
Bivalent 
bind both to the active site and 
exosite 1 
Hirudin, Bivalirudin, Lepirudin       
and Desirudin 
 
Univalent bind only to the active site 
Argatroban, Melagatran  
and Dabigatran 
Allosteric inhibitors 
bind exosite1, exosite2 and the 
sodium binding site 
DNA aptamers, Benzofuran 
dimers, Benzofuran trimers, 
Polymeric lignins and Sulfated 
β-O4 lignin (SbO4L) 
 
* DTIs are classified into three major groups based on their mode of action. Other classes of 
inhibitors include peptide based inhibitors and non-peptide based inhibitors [217]. 
 
 
Figure 6-2 The mode of action of DTIs on thrombin crystal structure 
 
 
Green active site, yellow Na binding loop, teal exosite1 and red exosite2. Adapted from 
[217].  
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6.2.5 PAR-1 mediated shedding 
Thrombin signalling is mediated through a family of PARs [222, 439, 466, 484]. 
PARs convert extracellular proteolytic cleavage within the N-terminus into a transmembrane 
signal consequently activating the cleaved receptor [222, 466, 484]. The PAR-1 is activated 
by thrombin, although other proteases such as plasmin and metalloproteinases (MMPs) can 
activate PAR-1 [439, 445, 477]. Shedding of PGs at the cell surface is accelerated by the 
activation of specific intracellular signalling pathways involving PAR-1 [12, 222, 461]. T 
cell immunoglobulin and mucin domain 3 (TIM-3)  are matrix-associated metalloproteinase 
inhibitors [485, 486]. The mechanism of PAR-1 mediated shedding and the cleavage of core 
protein in sulfated PGs can be inhibited by the action of TIM-3 [222, 486]. On the other 
hand, GM6001 is an MMP inhibitor which is not specific to individual members of the MMP 
family [477, 487-489]. PAR-1 mediated shedding  of PGs from the cell surface involves 
several intermediate signalling molecules and is affected by a variety of physiological 
effectors including the ERK MAP kinase pathway [222, 457, 466, 490]. PAR-1 mediated 
shedding of PGs is shown in Figure 6.3. 
6.2.6 Thrombin receptor inhibition 
Many other molecules can inhibit thrombin action, for example, PAR-1 inhibitor 
SCH 79797 dihydrochloride is a nonpeptide selective inhibitor of PAR1 [98, 232]. E5555 
(1-(3-tert-butyl-4-methoxy-5-morpholinophenyl)-2-(5,6-diethoxy-7-fluoro-1-imino-1,3-
dihydro-2H-isoindol-2-yl) ethanone hydrobromide) is a potent thrombin receptor antagonist 
[491-493]. Another thrombin inhibitor is UBO-QIC, an inhibitor specific for Gαq and 
selective against other G proteins [494-496]. Thrombin PAR-1 mediated inhibition is shown 
in Figure 6.3.  
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Figure 6-3 PAR-1 inhibition mechanism of thrombin shedding of PGs 
 
SCH 79797 and E5555, as examples of thrombin PAR-1 receptor specific inhibitors. 
Thrombin is a multifunctional serine protease generated at sites of tissue injury and 
inflammation. Thrombin cleaves the peptide bond between receptor residues Arg 41 and Ser 
42 at thrombin receptor PAR-1 N-terminus. This activates the receptor and leads to 
downstream activation of intracellular kinases MEK-1, ERK and PTK and matrix 
metalloproteinase (MMP) which then release shed PG (15 amino acids) from the cell surface 
[221-223]. 
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6.2.7 Types of shed PGs and their function 
The shedding of PGs at the cell surface is very important to membrane bound PGs 
because it reduces the ligand-binding GAGs while releasing soluble PGs that can act as 
effectors (autocrine and paracrine) [221, 457]. The shedding of PGs at the cell surface is a 
highly regulated cellular response to biological cues such as cell injury, tissue insults and 
inflammation. Shedding products act as regulators and effectors on many molecules and 
possibly the binding and carrying of growth factors [222, 497]. It has been reported that  
products from the shedding of PGs at the cell surface retain  their HS chain and hence  their 
biological HS activity and functions [221, 223].  
The aim of this chapter is to explore the role of thrombin on the PG shedding in the RPE and 
assess the implication of the shed PGs on AMD. In addition, the effect of thrombin 
proteolytic activity or PAR-1 mediated processes on shedding will be investigated. 
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6.3 Materials and methods 
6.3.1 Materials 
Dulbecco's Modified Eagle medium (DMEM) (0 and 25 mM glucose), 
trypsinversene and antibiotics (10,000 U/ml penicillin, 10,000μg/ml streptomycin) were 
purchased from GIBCO, (Grand Island, USA). Foetal bovine serum (FBS) was obtained 
from Invitro Technologies, Pty. Ltd. (VIC, Australia). PDGF, thrombin, SB431542, 
Dulbecco’s phosphate buffered saline (PBS) (10X), sodium dodecyl sulfate (SDS), 2-
mercaptoethanol, dimethyl sulfoxide (DMSO), GM6001 and chondroitin sulfate were 
purchased from Sigma-Aldrich (St Louis, MO, USA). UO126 was purchased from Promega 
(Madison, WI, USA). Human TGFβ and VEGF were purchased from Cell Signalling 
Technology (Danvers, MA, USA). Imatinib was obtained from (Alfred Hospital Pharmacy, 
Australia). The PAR-1 inhibitor SCH79797 was obtained from Tocris Biosciences. Human 
recombinant IGF-1 was obtained as a gift from Genentech Inc. (San Francisco, CA). Carrier-
free 35S-sulfate was obtained from MP Biomedical. CPC was obtained from Unilab 
Chemicals and Pharmaceuticals. Methyl b-D-xylopyranoside (xyloside), sepharose CL-6B, 
sodium borohydride, diethylaminoethyl-sephacel (DEAE-sephacel); Whatman 3MM 
chromatography paper were purchased from Biolab (Mulgrave, Australia). Absolute ethanol 
was purchased from LabServ (VIC, Australia). Insta-Gel Plus scintillation fluid was 
purchased from PerkinElmer Life Sciences. Rainbow™[14C] methylated protein molecular 
weight markers were purchased from GE Healthcare Bio-Sciences Corp. (Piscataway, NJ). 
TEMED, Tris Base and Glycine were obtained from Amresco (Solon, OH, USA). Tween 
20, 30% acrylamide/Bis Solution and APS were from BioRad Laboratories (CA, USA). All 
other chemicals were of the highest grade commercially available standard and were 
purchased from Sigma-Aldrich (Sydney, Australia). 
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6.3.2 Methods 
6.3.2.1 Cell culture 
RPE-19 (ATCC® CRL-2302™) cells used to study the impact of multiple retinal 
agonists on the synthesis and elongation of PGs were purchased from the American Type 
Culture Collection (ATCC). Samples were thawed during agitation in a water bath set at 
37°C. Cells were revitalized by DMEM (5mM glucose, 20% heat inactivated serum and 1% 
antibiotics at 37°C in 5% CO2) when growth became normal. Cells in wells were changed 
to low glucose and later 10% FBS. RPE-19 cells were seeded on 60 mm dishes and 24 well-
plates. When cells were at a confluent stage of growth and maturation, they were rendered 
quiescent and later subjected to serum deprivation for 48 hours. 
 
6.3.2.2 Quantitation of PGs associated radiolabel released into the media 
Cells were radiolabelled with 35S-sulfate (25m Ci/ml) for 24 hours. These cells in 
24-well plates were washed thoroughly and media was added with or without agonist or 
antagonist for 1-4 hours. Cell-associated PGs were collected from the media with protease 
inhibitors. Quantitative measurement of PGs associated radiolabel released into the media 
was performed utilizing CPC precipitation assay. 
6.3.2.3 SDS-PAGE analysis of PG size 
Equal aliquots of PGs were labelled with 35S-sulfate, eluted through DEAE-
Sephacel anionic exchange mini columns, sized by SDS-PAGE, added to pre-equilibrated 
columns and finally washed with low salt buffer. PGs were eluted with high salt buffer and 
fractions containing the highest levels of 35S-sulfate (cpm) were used. Equal aliquots of PGs 
were precipitated by ethanol solution (70%) after which chondroitin was added. Samples 
were re-constituted in buffer and an equal aliquot of buffer was added. Radio labelled 
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samples were separated on 4-13% PGs or 4-20% (xyloside-GAGs) acrylamide gels and 3% 
acrylamide stacking gel at 60 V overnight. Gels were fixed, dried and introduced to an 
imaging plate (Fujifilm BAS-MS 2040) for approximately 4-5 days. Images were developed 
on a Cyclone Plus Phosphor Imager (Perkin Elmer) [97, 253, 343]. In these experiments, 
equal aliquots were used instead of equal counts for loading count per sample on SDS-PAGE 
gel, because using this method it was possible to determine differences in the total amount 
of one or more PGs. 
6.3.2.4 Calcium assay  
A calcium assay was used to examine whether the use of agonists led to the release 
of intracellular calcium and whether inhibitors blocked the release of intracellular calcium 
in the cells by agonists. Cells were plated onto 96-well plates (10,000 cells/well), cultured 
to 80% confluence and then serum deprived for 48 hours (DMEM 5mM glucose 1% FBS). 
FURA-2AM ester (2µM, 30 minutes, 37ᵒC) was then added to the cells alongside 2µM  
probenecid and 0.01% pluronic F-127 to enhance the quantification of intracellular calcium 
as it binds to the calcium in the cell. Experiments were conducted in HANKS buffer (10mM 
HEPES, 5mM KCL, 140mM NaCl, 1mM MgCl2, 2mM CaCl2, 11mM Glucose). Cells were 
briefly incubated with antagonists for 15 minutes before stimulation with agonists. 
Fluorescence was quantified at 4 second intervals at 340nm and 380nm excitation and 
510nm emission wavelengths using a Flexstation 3 plate reader (Molecular Devices, 
Sunnyvale, CA). 
 
6.3.2.5 Statistical analysis 
Data was expressed as the mean± standard deviation (SD) of duplicate experiments, 
each with three replicates.   
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6.4 Results 
6.4.1 Effect of GPCR agonists thrombin, angiotensin II and endothelin-1 
on PG release in RPE-19 cells 
The results in chapter 5 (Figure 5.9) on the thrombin time course of action showed 
that one hour was the optimal time for thrombin action. Earlier findings suggested that the 
observed PG band was not due to synthesis which would normally require more than 20 
hours for complete synthesis of PG. RPE cells were treated with different compounds. This 
included the application of angiotensin II (1 uM) in the absence and presence of candesartan 
(10 μM) which is an angiotensin II AT1 receptor blocker [498, 499]. Endothelin-1 (100 nM) 
was added to RPE cells in the absence and presence of  (10 μM) the endothelin-1 mixed 
ETA/ETB receptor antagonist [332, 351, 500], and thrombin (10 U/ml) in the absence and 
presence of PAR-1 inhibitors SCH 79797 (10 μM) [98, 232] and E5555 (10 μM) [491, 492] 
for 1 hour. Figure 6.4 shows that thrombin increased the 35S-sulfate released into the media 
by 70% when compared to basal while the presence of SCH 79797 and E5555 did not show 
any effect on PGs associated 35S-sulfate released into the media. Both GPCR agonists 
angiotensin II and endothelin-1 did not show any stimulation of PGs 35S-sulfate released into 
the media. The SDS-PAGE gel showed the PGs isolated following thrombin (10 U/ml) 
application at 1 hour. There was a more intense and wide band of molecular weight around 
260-340 kDa which was also visible in the presence of PAR-1 inhibitors, SCH 79797 and 
E5555 (Figure 6.4).  
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(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) SDS-PAGE 
gel shows the sizing of the PGs in the medium.  
35S-sulfate radiolabel (25mCi/well) was added to RPE-19 cells and incubated for 24 hours 
and gently washed three times. Samples were treated with angiotensin II (1 uM) in the 
absence and presence of candesartan (10 μM) or endothelin-1 (100 nM) in the absence and 
presence of bosentan (10 μM) and thrombin (10 U/ml) in the absence and presence of SCH 
79797 (10 μM) and E5555 (10 μM) for 1 hour and (basal). Cells were also pre-treated with 
desired antagonists for 30 minutes. The experiments were repeated two times with similar 
results. 
A B   
Figure 6-4 Effect of GPCR agonists: thrombin, angiotensin II and 
endothelin-1 on RPE-19 cells PG. 
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6.4.2 Thrombin, angiotensin II and endothelin-1 impact on the release of 
intracellular calcium in RPE-19 cells 
The results obtained demonstrated that only the application of thrombin led to the 
generation of PGs while other GPCR agonists angiotensin II and endothelin-1 did not. 
Calcium release assays were performed to verify GPCR activity in RPE cells (Figure 6.5). 
Cells were incubated with Fura-2AM (2 µM) for 30 minutes, washed and incubated for a 
further 15 minutes in the presence or absence (basal) of different GPCR agonists: angiotensin 
II (30, 100, 300 and 1000 nM), endothelin-1 (3, 10, 30 and 100 nM), thrombin (1, 3, 10 
U/ml) and ionomycin (1 and 10 μM). Ionomycin is an ionophore that is capable of raising 
the intracellular calcium concentration and influencing the PGs associated 35S-sulfate 
released into the media [501, 502].  
The results in Figure 6.5 showed that only thrombin application led to the activation 
of GPCR and the release of intracellular calcium in RPE-19 cells. The increase in the 
fluorescence induced by thrombin (10 U/ml) was from 0.1 to 1.1 fluorescence ratio 
(340/380nm), while other GPCR agonists angiotensin II and endothelin-1 did not increase 
fluorescence levels (Figure 6.5).  
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Figure 6-5 thrombin, angiotensin II and endothelin-1 impact on the 
release of intracellular calcium in RPE-19 cells. 
 
RPE-19 cells were incubated with Fura-2AM (2 µM) for 30 minutes, washed and incubated 
for a further 15 minutes in the presence or absence of (basal), or with different GPCR 
agonists: angiotensin II (30, 100, 300 and 1000 nM), or endothelin-1 (3, 10, 30 and 100 nM), 
or thrombin (1, 3, 10 U/ml) or ionomycin (1 and 10 μM). The experiments were repeated 
twice with similar results. 
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6.4.3 The effects of thrombin receptor activating peptide (TRAP) 
activation of PAR-1 receptor on PG released into the media in RPE-19 
cells 
The results obtained from different experimental assays confirmed that thrombin 
was involved in the appearance of a PGs band as well as PGs associated 35S-sulfate released 
into the media. This raised the question, “what is the mechanism involved in the generation 
of this PGs band?” “Is the appearance of a PGs bands due to thrombin property of receptor 
PAR-1 activation in RPE-19?” [98, 462, 503]. TRAP mimics thrombin-mediated effects, so 
it should give similar results and this assertion was subsequently tested [98, 474]. To study 
the effects of specific PAR in thrombin activity, RPE-19 cells were treated with thrombin 
(10 U/ml) and in absence and presence of SCH 79797 (10 μM) or with TRAP (500 µM) in 
the absence and presence of SCH 79797 (10 μM) for 1 hour (Figure 6.6). Thrombin (10 
U/ml) application resulted in a 40% increase in PGs associated 35S-sulfate released into the 
media (Figure 6.6). TRAP did not stimulate PGs associated 35S-sulfate release into the media 
(Figure 6.6). PAR-1 inhibitor SCH 79797 had no effect on either thrombin or TRAP. This 
meant that the presence of a PG band was not related to PAR-1 activation. The SDS-PAGE 
gel showed cell-associated PGs with thrombin (10 U/ml) at 1 hour and a molecular weight 
of around 260-340 kDa. The presence of PAR-1 inhibitor SCH 79797 had no inhibitory 
effect on the PGs band. Therefore, TRAP application did not lead to the appearance of PGs 
bands in RPE-19.  
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(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) SDS-PAGE 
gel shows the sizing of the PGs in the medium. 
RPE-19 cells were treated with 35S-sulfate radiolabel (25mCi/well) for 24 hours. Cells were 
washed carefully, pre-treated with antagonists SCH 79797 (10 μM) for 30 minutes. New 
medium was added with or without (basal) GM6001 (2 μM), SB 431542 (10 μM) and 
imatinib (10μM), and with thrombin (10 U/ml) in absence or presence of SCH 79797 (10 
μM) and TRAP (500 µM) in absence or presence of SCH 79797 (10 μM) for 1 hour. The 
experiments were repeated twice with similar results. 
 
A B   
Figure 6-6 The production of PGs due to thrombin Receptor Activating 
Peptide (TRAP) activation of PAR-1 receptor in RPE-19 cells 
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6.4.4 Role of Gαq in thrombin stimulated cell surface PG shedding in 
RPE-19 cells 
To determine whether the PGs observed in thrombin activated RPE cells were due 
to the shedding of PGs mediated by PAR-1 activation, UBO-QIC was used as an inhibitor 
specific for Gαq [494, 495]. The results in Figure 6.7 show the 35S-sulfate exposed cells 
(basal) in the absence and presence of UBO-QIC (100 nM), with thrombin (10 U/ml) in the 
absence and presence of UBO-QIC (100 nM) and in the absence and presence of SCH 79797 
(10 μM) and TRAP (500 µM) in the absence and presence of UBO-QIC (100 nM) and in the 
absence and presence of SCH 79797 (10 μM) for 1 hour. Results showed that UBO-QIC 
without the agonist and compared to the basal there was no negative effect on basal cells. 
Therefore, the basal level of PGs associated 35S-sulfate released into the media was 
maintained. Thrombin application showed a 40% stimulation of PGs associated 35S-sulfate 
released into the media and UBO-QIC did not inhibit this PGs associated 35S-sulfate released 
(Figure 6.7). In the presence of SCH 79797, a partial inhibition of PGs associated 35S-sulfate 
released into the media was seen which could be due to the negative effect on cells (death) 
rather than the specific inhibition of PG generation (Figure 6.7). TRAP treatment showed no 
stimulation of PG and no inhibition by UBO-QIC or SCH 79797 (Figure 6.7). SCH 79797 
was observed to have a negative effect on the basal levels which was 30% lower. Therefore, 
TRAP did not have any stimulatory effect on PGs associated 35S-sulfate released into the 
media as verified by the absence of bands in the SDS-PAGE gel (Figure 6.7). Gαq inhibitor 
UBO-QIC and PAR-1inhibitor SCH 79797 also showed no inhibition of PG effects (Figure 
6.7).  
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(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) The SDS-
PAGE gel shows the sizing of the PGs in the medium. 
RPE-19 cells were labelled with 35S-sulfate radiolabel (25mCi/well) for 24 hours. Cells were 
washed, carefully pre-treated and incubated with antagonists for 30 minutes. New medium 
was added (basal) in the absence and presence of UBO-QIC (100 nM), with thrombin (10 
U/ml) in the absence and presence of UBO-QIC (100 nM), in the absence and presence of 
SCH 79797 (10 μM) and TRAP in the absence and presence of UBO-QIC (100 nM) and in 
the absence and presence of SCH 79797 (10 μM) for 1 hour. The experiments were repeated 
twice with similar results. 
Figure 6-7 Role of Gαq in thrombin stimulated PG shedding in RPE-19 cells 
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6.4.5 GM6001, SB 431542 and imatinib inhibitors as tools to determine 
the mechanism of PG release in RPE cells following thrombin stimulation 
To clarify the mechanism of PG generation in thrombin treated RPE cells, 
experiments were designed to use GM6001 MMPs inhibitor as a tool to evaluate the 
mechanism of PG generation in RPE cells following thrombin stimulation [486-489]. SB 
431542 is a potent and specific inhibitor of the transforming growth factor-beta superfamily 
and a specific inhibitor of a number of tyrosine kinase enzymes in RPE-19. RPE-19 cells 
were treated with 35S-sulfate radiolabel (25mCi/well) for 24 hours, incubated without 
(basal), with thrombin (10 U/ml) in the absence and presence of GM6001 (2 μM), SB 431542 
(10 μM) and imatinib (10μM) for 1 hour, and desired inhibitors were added 30 minutes 
before the agonist (Figure 6.8). Results showed that thrombin stimulated PGs associated 35S-
sulfate released into the media while GM6001, SB 431542 and imatinib did not inhibit PGs 
associated 35S-sulfate release into the media. The SDS-PAGE gel showed thrombin shed 
PGs band in the presence of PGs while GM6001, SB 431542 and imatinib showed no 
inhibitory effect on the PGs band. In conclusion, the shedding of PGs induced by thrombin 
in RPE-19 cells was not via PAR-1 and MMPs cleavage activity. 
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 (A) The histogram shows PGs associated 35S-sulfate released into the media. (B) SDS-
PAGE gel shows the sizing of PGs in the medium. 
RPE-19 Cells were labelled with 35S-sulfate radiolabel (25mCi/well) for 24 hours. Cells were 
washed carefully, pre-treated and incubated with antagonists for 30 minutes. New medium 
added without (basal), with thrombin (10 U/ml) in absence and presence of GM6001 (2 μM), 
SB 431542 (10 μM) and imatinib (10μM) for 1 hour. The experiments were repeated twice 
with similar results. 
 
  
A B   
Figure 6-8 Role of GM6001 metalloproteinase (MMP) in inhibition of 
PGs shedding in RPE-19 cells 
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6.4.6 Role of released intracellular calcium in the stimulation of the 
shedding of PGs in RPE-19 cells 
Our previous results in Figure 6.5 on calcium release following thrombin treatment 
of RPE, highlighted the potential relevance of calcium store release in retinal degenerative 
calcium mobilization. The calcium chelator BAPTA-AM regulates the calcium 
concentration and buffers any rise in the calcium concentration by acting as a calcium 
chelator [504, 505]. The hypothesis is that if the PG band was generated via a PAR-1 
mediated process, then BAPTA-AM would affect the PAR-1 pathway by mobilizing the 
intracellular calcium. This should affect PG sulfation and block the cell surface shedding of 
PG through MMPs [222, 501, 506]. If the PG band was due to thrombin activity, then 
BAPTA-AM would not have any effect as the thrombin enzymatic activity was the 
mechanism in operation on the cell surface [468, 501].  
Cells were treated with 35S-sulfate radiolabel (25mCi/well) for 24 hours and then incubated 
without ionomycin (basal) or with ionomycin (1, 10 and 100 uM) without thrombin for 30 
minutes. In other treatments, (i) 35S-sulfate radiolabelled cells were incubated with BAPTA-
AM (10 uM) for 30 minutes without thrombin or (ii) 35S-sulfate radiolabelled cells were 
incubated without BAPTA-AM (basal) and with thrombin (10 U/ml) for 1 hour or (iii) 35S-
sulfate radiolabelled cells were incubated in the presence of BAPTA-AM (1 and 10 uM) for 
30 minutes then treated with thrombin (10 U/ml) for 1 hour. The results obtained 
demonstrated that the PGs bands induced by thrombin in the presence of BAPTA-AM (10 
uM) were affected and became less intense. This meant that the calcium released by 
thrombin had been chelated by BAPTA-AM (Figure 6.9). The results showed that with 
ionomycin alone, shedding was not caused by the release of intracellular calcium. Even in 
the presence of thrombin and chelation of intracellular calcium by BAPTA-AM, shed PG 
bands were still detected.    
213 
 
 
 
 
(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) The SDS-
PAGE gel shows the sizing of PGs in the medium. 
RPE-19 cells were labelled with 35S-sulfate radiolabel (25mCi/well) for 24 hours, washed 
carefully, pre-treated and incubated with BAPTA-AM for 30 minutes. New medium was 
added with or without Ionomycin (1, 10 and 100 uM) and thrombin (10 U/ml) in absence 
and presence of BAPTA-AM (1 and 10 uM) for 1 hour. The experiments were repeated twice 
with similar results. 
 
  
A B   
Figure 6-9 Role of released intracellular calcium in stimulation 
of PGs shedding in RPE-19 cells. 
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6.4.7 Impact of lepirudin on thrombin release of intracellular calcium in 
RPE-19 cells. 
The results from the previous experiments in this chapter suggested that the 
shedding of PGs was not via receptor PAR-1 activation in RPE-19 cells. To investigate 
whether the generation of PGs mediated by thrombin occurred via the protease activity of 
thrombin, a bivalent DTIs lepirudin was used [217]. Using the calcium release assay as a 
readout of activation, cells were incubated with Fura-2/AM (2 µM) for 30 minutes, washed 
and incubated with new medium added for a further 15 minutes with the following 
treatments: (i) without thrombin and without lepirudin (blank), (ii) with thrombin (10 U/ml) 
alone (basal), or (iii) with  lepirudin (800 U/ml) without thrombin (control), or (iv) with 
thrombin (10 U/ml) in the presence of lepirudin (200, 400, 600 and 800 U/ml), or (v) with 
SCH 79797 (10 μM) without thrombin (control), or (vi) with  thrombin (10 U/ml) in presence 
of SCH 79797 (3 and 10 μM). 
 
Figure 6.10 shows that thrombin (10 U/ml) treatment caused an increase in release 
of intracellular calcium in RPE-19 cells from 0.1 to 1.3 fluorescence ratio (340/380nm). 
Thrombin (10 U/ml) application in the presence of lepirudin (200, 400, 600 and 800 U/ml), 
caused a gradual inhibition of the release of intracellular calcium in RPE-19 cells across 
lepirudin concentrations. Thrombin (10 U/ml) application in the presence of SCH 79797 (3 
and 10 μM) caused no inhibition of the release of intracellular calcium in RPE-19 cells. 
There was partial inhibition of the release of intracellular calcium in RPE-19 cells at high 
concentrations of lepirudin. Lepirudin (800 U/ml) and SCH 79797 (10 μM) applications did 
not have any effect on cell growth. Maximal inhibition of calcium release was observed at 
800 U/ml lepirudin and this concentration was used in subsequent experiments. A partial 
inhibition of the release of intracellular calcium in RPE-19 cells by SCH 79797 10μM 
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occurred. Figure 6.10 confirmed the inhibitory activities observed and provided validation 
of thrombin protease activity when RPE cells were treated with thrombin. This result showed 
that the process of the shedding of PGs induced by thrombin was not mediated via PAR-1. 
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Figure 6-10 Impact of lepirudin on thrombin induced the release of 
intracellular calcium in RPE-19 cells. 
 
RPE-19 cells were incubated with Fura-2/AM (2 µM) for 30 minutes, washed and incubated 
for a further 15 minutes without (blank), or with lepirudin (800 U/ml) and SCH 79797 (10 
μM), or with thrombin (10 U/ml) in the absence (basal) or presence of lepirudin (200, 400, 
600 and 800 U/ml) and SCH 79797 (3 and 10 μM). The experiments were repeated twice 
with similar results.  
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6.4.8 Lepirudin inhibits the shedding of PGs from RPE-19 cells 
The previous experiment demonstrated the impact of lepirudin on thrombin release 
of intracellular calcium and 800 U/ml was the optimal concentration for the highest 
inhibitory effect. The next experiments were designed with lower concentrations of lepirudin 
(500 U/ml) to examine the differences in inhibition at this concentration and at 
concentrations of lepirudin approximately 800 U/ml. This was to check whether PGs 
associated 35S-sulfate released into the media and cell surface PG bands were due to 
thrombin enzymatic protease cleavage activity or not. 
Thrombin (10 U/ml) application resulted in a 65% increase in PGs associated 35S-
sulfate released into the media (Figure 6.11). Lepirudin (800 U/ml) application in the 
presence of thrombin totally blocked PGs associated 35S-sulfate released into the media 
while lepirudin at 500 U/ml causing partial inhibition. Lepirudin (800 U/ml) alone did not 
change the basal level of PGs associated 35S-sulfate released into the media (Figure 6.11). 
The basal treatment showed no band on the SDS-PAGE gel and thrombin application (10 
U/ml) showed a clear band corresponding to PGs shed of around 260-340 kDa. The novel 
finding was that, lepirudin (800 U/ml) totally blocked thrombin PGs shedding property as 
no band appeared at the range of 260-340 kDa. Lepirudin (500 U/ml) application achieved 
up to 70% partial inhibition (determined from the band at the range of 260-340 kDa 
intensity). Lepirudin at 800 U/ml alone did not have any effect on basal. From these results, 
it can be concluded that PGs shedding was due to thrombin proteolytic activity (Figure 6.11). 
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(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) The SDS-
PAGE gel shows the sizing of PGs in the medium. 
RPE-19 cells were labelled with 35S-sulfate radiolabel (25mCi/well) for 24 hours, washed 
carefully, pre-treated and incubated with antagonists for 30 minutes. New medium was 
added without (blank), or with thrombin (10 U/ml) in the absence of Lepirudin (basal), or in 
the presence of Lepirudin (800 U/ml) without thrombin, or with thrombin (10 U/ml) in the 
presence of lepirudin (500 and 800 U/ml) for 1 hour. The histogram shows PGs associated 
with 35S-sulfate released into the media for cells. The experiments were repeated twice with 
similar results. 
A B   
Figure 6-11 Lepirudin inhibition of PGs shedding in RPE-19 cells 
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6.4.9 Hirudin inhibits PGs shedding from RPE-19 cells 
The previous experiment demonstrated that lepirudin (500 and 800 U/ml) blocked 
PGs associated 35S-sulfate released into the media and bands corresponding to the shedding 
of PGs on the SDS-PAGE gel. The finding from these results demonstrated that PGs 
associated 35S-sulfate released into the media and bands corresponding to the shedding of 
PGs was due to thrombin proteolytic activity (Figure 6.11). The next experiment tested 
another DTIs inhibitor which was hirudin as it is widely used as a direct thrombin inhibitor 
[98]. 
Cells were treated with 35S-sulfate radiolabel (25mCi/well) for 24 hours, washed 
and incubated for 1 hour with new medium  using the following treatments: (i) without 
hirudin and without thrombin (blank), or (ii) with thrombin (10 U/ml) alone (basal), or (iii) 
with hirudin (10 ATU) without thrombin for 30 minutes before the addition of the agonist 
(control), (iv) with SCH 79797 (3 μM) without thrombin for 30 minutes before the addition 
of the agonist (control), or (v) with thrombin (10 U/ml) in the presence of SCH 79797 (3 and 
10 μM) for 30 minutes before the addition of the agonist, or (vi) with thrombin (10 U/ml) in 
the presence of hirudin (10 and 30 ATU) for 30 minutes before the addition of the agonist.  
Thrombin (10 U/ml) application resulted in a 40% increase in PGs associated 35S-
sulfate released into the media (Figure 6.12). Hirudin (10 and 30 ATU) in the presence of 
thrombin did not block PGs associated 35S-sulfate released into the media as well SCH 79797 
(3 and 10 μM). On the SDS-PAGE gel, the blank control treatment showed no band but 
thrombin (10 U/ml) treatment showed clear PGs shed band of around 260-340 kDa. 
However, SCH 79797 (3 and 10 μM) did not block thrombin PGs associated 35S-sulfate 
released into the media bands at the range of 260-340 kDa (Figure 6.12).  
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(A) The histogram shows PGs associated 35S-sulfate released into the media. (B) The SDS-
PAGE gel shows the sizing of PGs in the medium. 
RPE-19 cells were labelled with 35S-sulfate radiolabel (25mCi/well) for 24 hours, washed 
carefully, pre-treated and incubated with antagonists for 30 minutes. New medium was 
added without (blank), or with thrombin (10 U/ml) in the absence (basal) and presence of 
SCH 79797 and in the presence of SCH 79797 (3 and 10 μM) for 1 hour, or with thrombin 
(10 U/ml) in the absence (basal) and presence of hirudin and in the presence of hirudin (10 
and 30 ATU) for 1 hour. The histogram shows the PGs associated 35S-sulfate released into 
the media for cells. The experiments were repeated twice with similar results. 
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Figure 6-12 Hirudin (DTIs) inhibition of PGs shedding in RPE-19 cells 
221 
 
6.4.10 Impact of hirudin on thrombin induced release of intracellular 
calcium in RPE-19 cells 
The calcium release assay was used to confirm the previous result in Figure 6.12. 
For activation, cells were incubated with Fura-2/AM (2 µM) for 30 minutes, washed and re-
incubated with new medium added for a further 15 minutes with the following treatments: 
(i) without thrombin and without hirudin (blank), (ii) with thrombin (10 U/ml) alone (basal), 
or (iii) with hirudin (10 ATU) without thrombin (control), or (iv) with thrombin (10 U/ml) 
in the presence of hirudin (10, 30, 50, 70 and 100 ATU), or (v) with SCH 79797 (1 μM) 
without thrombin (control), or (vi) with thrombin (10 U/ml) in the presence of SCH 79797 
(1, 3 and 10 μM), or (vii) with E5555 (100 nM) without thrombin (control), or (viii) with 
thrombin (10 U/ml) in the presence of E5555 (100, 300 and 1000 nM). 
Figure 6.13 showed that thrombin (10 U/ml) treatment caused increased release of 
intracellular calcium in RPE-19 cells from 0.1 to 1 fluorescence ratio (340/380nm). 
Thrombin (10 U/ml) in presence of hirudin (10, 30, 50, 70 and 100 ATU) did not cause any 
inhibition of the release of intracellular calcium in RPE-19 cells. Thrombin (10 U/ml) in the 
presence of SCH 79797 (1, 3 and 10 μM) caused a gradual inhibition of the release of 
intracellular calcium in RPE-19 cells. Thrombin (10 U/ml) in presence of E5555 (100, 300 
and 1000 nM) also caused a gradual inhibition of the release of intracellular calcium in RPE-
19 cells. Hirudin did not block thrombin from releasing intracellular calcium in RPE-19 cells 
(Figure 6.13). 
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RPE-19 Cells were incubated with Fura-2/AM (2 µM) for 30 minutes, washed and incubated 
for another further 15 minutes without additives (blank), or hirudin (10 ATU), SCH 79797 
(1 μM) and E5555 (100 nM), or with thrombin (10 U/ml) in absence (basal) and presence of 
hirudin (10, 30, 50, 70 and 100 ATU), SCH 79797 (1, 3 and 10 μM) and E5555 (100, 300 
and 1000 nM). The experiments were repeated twice with similar results. 
 
  
Figure 6-13 Impact of hirudin on thrombin released of intracellular 
calcium in RPE-19 cells. 
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6.5 Summary of results  
 Thrombin treatment of RPE cells resulted in the generation of PGs. Two other GPCR 
agonists’ angiotensin II and endothelin-1 did not generate PGs. 
 Thrombin activated its receptor and caused an increase in the release of intracellular 
calcium in RPE-19 cells. Angiotensin II and endothelin-1 receptors cells, as determined 
by the intracellular calcium release assay. 
 PGs generated after thrombin (10 U/ml) application for 1 hour had a molecular weight 
of approximately 260-340 kDa. PAR-1 inhibitor SCH 79797 showed no inhibition of the 
band corresponding to PGs on the SDS-PAGE gel of 35S-sulfate radiolabel cell surface 
PG associated assay.  
 TRAP did not lead to the appearance of 35S-sulfate radiolabel cell surface PG bands in 
RPE-19. 
 Gαq inhibitor UBO-QIC and PAR-1inhibitor SCH 79797 showed no inhibition of PGs 
associated 35S-sulfate released into the media and cell surface PG shedding bands. 
  GM6001, SB431542 and imatinib showed no inhibitory effects on PGs associated 35S-
sulfate released into the media and cell surface PG bands. 
 Thrombin PGs band in the presence of BAPTA-AM (10 uM) was less intense which 
meant that the calcium released by thrombin had been chelated by BAPTA-AM. 
 Thrombin activated its receptor and consequently there was an increase in the release of 
intracellular calcium in RPE-19 cells.  
 SCH 79797 (10 μM) did not inhibit thrombin release of intracellular calcium but 
lepirudin (800 U/ml) did inhibit thrombin release of intracellular calcium. 
 SCH 79797 (10 μM) did not inhibit thrombin induced PGs associated 35S-sulfate released 
into the media, while lepirudin (800 U/ml) did inhibit thrombin PGs associated 35S-
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sulfate released into the media. This confirmed that the process of shedding of PGs 
induced by thrombin was not mediated via PAR-1. 
 Hirudin did not block thrombin PGs associated 35S-sulfate released into the media bands 
at the range of 260-340 kDa. It also did not block thrombin mediated release of 
intracellular calcium in RPE-19 cells 
From these results, it can be concluded that the shedding of PGs on the 
surface of RPE cells was unique to thrombin cleavage via proteolytic activity. 
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6.6 Discussion 
RPE-19 cells have been implicated in the initiation, development, progression and 
advancement of AMD [507, 508]. Studying the role of growth factors in these cells and their 
impact on PGs should provide important knowledge about the development of AMD. In 
Chapter 5, the results showed that TGFβ (serine/threonine kinase receptor agonist) and 
VEGF (tyrosine kinase receptor agonist) did not stimulate PGs associated 35S-sulfate 
released into the media nor appearance of the band corresponding to PGs in SDS-PAGE. 
Thrombin stimulation of RPE cells generated a band of unknown PGs (260-340 kDa) and 
the band appeared 0-4 hours after thrombin treatment which was too short a time frame for 
new PG synthesis. PGs require more than 20 hours to be secreted while in these experiments 
the band corresponding to PGs appeared within one hour [170, 233, 427, 428]. In the 
literature, shedding is always referred to as a PAR-1 mediated process [455].  The findings 
presented in this chapter are in contrast to this because PAR-1 inhibitors such SCH 79797 
and E5555 did not block PGs shedding indicating it was not thrombin receptor driven. In 
addition, Gαq inhibitor UBO-QIC did not block the shedding of PGs induced by thrombin 
which was supported by the fact that PAR1 was not involved. Moreover, thrombin-receptor 
activating peptide TRAP treatment did not lead to the shedding of PGs, while thrombin 
treatment did lead to the shedding of PGs (Figure 6.14). Additionally, GM6001 did not block 
the shedding of PGs induced by thrombin. Therefore, shedding was not a PAR-1 mediated 
process. 
The findings in this chapter suggest that shedding was due to thrombin proteolytic 
activity and not a PAR-1 mediated process. This was confirmed by lepirudin experiments 
which totally blocked the shedding of PGs induced by thrombin in Figure 6.11.  
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Figure 6-14 Utilizing TRAP as a tool to investigate whether thrombin 
induced shedding of PGs in RPE-19 involves PAR-1 or not 
 
TRAP is a thrombin-receptor activating peptide that is linked to PAR-1 and stimulates its 
activation [98, 462, 503]. GPCR receptor PAR-1 activation leads to intermediate processes 
and activates MMP which shed PG (at 15 amino acids) from the cell surface [223, 457, 509]. 
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Hirudin did not block thrombin shedding action, while lepirudin completely 
blocked thrombin shedding action. This was due to hirudin inefficiency in totally blocking 
thrombin as it has been reported that thrombin could be partially active in the presence of 
free hirudin [481-483, 510]. Another possibility could be related to the mechanism or mode 
of actions of lepirudin and hirudin on thrombin as lepirudin is effective in blocking thrombin 
protease activity while hirudin acts as an anticoagulant [217, 480-482]. 
The shedding of PGs at the cell surface is a process that is induced by many factors 
such as inflammation, cell injury and tissue insult [222, 497]. Shedding products play an 
important role in changing the cell surface ligands and affect  the function and mobility of 
other molecules [221, 457]. Shedding products are soluble molecules with HS characteristics 
[221, 223]. Breakdown of the BRB results in rapid conversion towards wet AMD, as 
thrombin interacts with RPE leading to the shedding of the PGs on the surface of the RPE 
[300]. From these results, it can be concluded that the shedding of PGs was due to thrombin 
cleavage via proteolytic activity [454]. This study was limited to the scope of thrombin and 
the relationship of PGs. Future research should focus on characterization of shed PGs and 
the trapping of other growth factors. 
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6.7 Conclusions 
The finding that shedding was due to thrombin proteolytic activity and not a PAR-
1 mediated process in the RPE cells is novel. This finding also provides a clearer clarification 
of the role of thrombin in the shedding of PGs which may contribute to the development of 
retinal disease, especially in early AMD. These contributions can result in the thickening of 
the BM and deposition of drusen. The findings in this chapter have also increased the 
scientific understanding of the shedding process to be due to the proteolytic property of 
thrombin. This property is unique to thrombin and different from the action of other 
proteases[160]. 
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7. Chapter 7: General discussion and future perspectives 
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7.1 Introduction 
AMD is one of the most important eye diseases with a high prevalence and serious 
health implications in some parts of the world [511, 512]. In its simplest manifestation, AMD 
has two major forms potentially representing its natural history [100, 513]. In the earliest dry 
stage, there are changes in endothelial cells, epithelial cells and photoreceptor cells leading 
to thickening of the BM and a loss of central vision [512, 514, 515]. BM constitutes the 
boundary between the retina and the choroid and the thickening of BM is associated with 
the deposition of serum-derived lipoproteins in the tissue [326, 514, 516]. As the disease 
progresses, there is a breakdown of the barrier function of BM allowing migration and 
proliferation of endothelial cells and the penetration of micro vessels into the retina in the 
wet phase of the disease [42, 93]. The wet phase of the disease is the more aggressive and 
the target of most medical therapies. However, the dry phase is more prevalent, most likely 
representing the chronological progression of the disease [31, 512]. The pathophysiology 
underlying the early dry phase of AMD is not fully understood and there are currently no 
therapies targeting the early dry phase of AMD [119, 131, 452, 517, 518]. 
The retinal endothelial and epithelial cells are particularly important due to their 
location in neighbouring BM [515].These cells secrete and release PGs as a result of the 
actions of growth factors. [2, 48, 117, 515, 516, 519]. The retinal endothelial cells are also 
important in providing protection to tissues critical to vision through the supply of nutrients 
and secretion of growth factors [13, 520, 521]. Understanding the processes and mechanisms 
involved in the regulation of PG expression is critical to understanding the various functions 
of endothelial cells [522].  
 
There are three steps in growth factor dependent signalling which elicits cellular 
responses, in particular PG synthesis. The three steps involved are, (i) binding of growth 
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factors to the trans membrane receptor, (ii) activation of receptor kinase activity and (iii) 
activation and recruitment of cellular enzymes [523]. Growth factors are released in the 
ECM which affects the function of other surrounding cells [524, 525]. Several growth factors 
such as TGFβ, thrombin, PDGF, IGF and VEGF from different receptor groups have been 
reported to play a role in PGs synthesis and GAG elongation [2, 13]. Therefore, these growth 
factors contribute to AMD progression and the morphological changes  of cells [2, 13, 60, 
106, 264, 297, 299, 310]. Growth factors are involved in the process of GAG hyper-
elongation and GAG elongation is involved in BM thickening [2, 48, 49, 515]. Genes 
reportedly involved in PG synthesis and GAG elongation, include XT-1, ChGn-2, ChPF, 
ChSy-1, C4ST-1 and C4ST-2 [13, 170, 232, 236]. 
The RPE forms a single layer surrounded by 2 other layers, BM basally and the 
photoreceptor apically. The photoreceptor layer is important for the integrity of retina [424, 
452, 515, 526]. The RPE cells serve several functions which include the formation of the 
BRB by tight junctions and transportation of nutrients [262, 263, 527]. The growth factors 
in the RPE are up regulated by thrombin whose functions also include enhancing cell to cell 
contact [203, 211, 270, 383]. PGs are found on the surface of the RPE and HSPGs are the 
most prominent types of PGs susceptible to thrombin shedding [189, 221, 399, 528]. 
Shedding occurs via the cleavage of PGs matrix ectodomain from its membrane associated 
domain which causes RPE to lose its PGs attachment to the ECM [222, 457, 528, 529]. PG 
shedding is highly regulated and an important cellular response to specific conditions and 
biological cues, such as inflammation and cell injury [221, 222, 457, 497]. The products of 
the shedding process are particularly important. The shed products retain their HS moiety 
growth factors because they are soluble and reactive. The shed PG product also causes 
changes in the cell surface ligand and cell bound PGs [221-223, 293, 497, 530]. There are 
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two common processes possible that can result in the shedding of PGs and these are, receptor 
mediated shedding and enzyme catalysed cleavage [12, 194, 202-204, 221-223, 461].  
The hypothesis tested in this study focused on early AMD and alterations to ECM 
composition. The specific hypothesis was that “growth factors impact PG synthesis and 
GAG elongation in RF/6A retinal endothelial cells and RPE-19 epithelial cells  that surround 
BM  and undergo thickening during early AMD” [2, 13, 48]. This research which focused 
on early AMD might yield new treatment targets [2, 13]. 
7.1.1 Impact of growth factors on the synthesis of PGs and GAGs 
elongation in RF/6A cells 
The first aim of this project was to investigate the effects of TGFβ, thrombin, 
PDGF, IGF and VEGF on PG synthesis and GAG elongation in RF/6A cells (covered in 
Chapter 3) [2, 13]. The growth factors explored in this section were from three different 
receptor families; serine/threonine receptor agonist, tyrosine kinase receptor agonist and 
GPCR agonist. The application of all the growth factors, TGFβ, thrombin, tyrosine kinase 
receptor agonists PDGF and IGF (except VEGF) resulted in increases in PG synthesis and 
GAG elongation as measured by the amount of 35S-sulfate incorporated into PGs [13]. 
Figures 3.8 and 3.9 generated from the xyloside initiated GAG synthesis experiments clearly 
showed that TGFβ, thrombin, PDGF and IGF stimulated xyloside initiated GAG 35S-sulfate 
incorporation and elongation while VEGF did not [13]. The endothelial cells showed no 
response to VEGF and this was a surprising result that warranted further investigations. 
Consequently, the two main signalling pathways known to be activated by VEGF were 
subject to further scientific investigations [97, 235].  
This study therefore investigated the effect of VEGF on both the phosphorylation 
of the poly functional ERK and ubiquitous serine/threonine protein kinase AKT [235, 253, 
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345, 346]. There are several pathways involving ERK to GAG hyperelongation which are 
activated by VEGF [353]. Figure 3.11 showed that VEGF stimulated pERK 
(Thr202/Tyr204) in RF/6A cells but not pAKT (Ser473) [13]. These results showed that the 
signalling pathway for VEGF was present and active in endothelial cells. The results also 
supported the hypothesis that TGFβ, thrombin, PDGF, IGF but not VEGF dose dependently 
stimulated PG synthesis and GAG elongation [13]. It is important to mention that most 
therapies used anti-VEGF but the findings from this study showed that VEGF had no effect 
on the synthesis of PGs or GAG elongation [13, 76, 81, 95, 135, 137]. Thrombin and TGFβ 
application on the other hand resulted in the highest cellular response of PGs synthesis and 
GAG elongation. Therefore based on this finding it is recommended that anti-thrombin and 
anti-TGFβ (or genes  encoding these growth factors) be targeted in future studies in other 
cell types [13].  
There are not many published scientific reports on the impact of growth factors on 
the synthesis of PG and elongation of GAG in retinal endothelial cells with reference to early 
AMD [2, 13]. The observed effects of TGFβ, thrombin, PDGF and IGF on PG synthesis and 
GAG elongation reported in this thesis were similar to other closely related studies [96-98, 
233, 235, 253, 337, 355, 368, 531]. However, the lack of response from the retinal 
endothelial cells to VEGF could have been due to the role of VEGF in late AMD rather than 
in early stages of the disease. This is because many scientific publications have reported 
roles of VEGF in late AMD and as a therapeutic target for late AMD [46, 63, 94, 95, 131, 
132, 134, 532]. The limitation of this study is that the core protein cleavage technique which 
could have provided more scientific clarity, was not used in this research due to time and 
experimental constraints [234, 289, 533, 534]. It is recommended that this technique be used 
in future studies. Having established the effect of growth factors on PG synthesis and GAG 
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elongation, it was important to explore the role of these growth factors on the genes (mRNA 
expression of enzymes) involved in PG synthesis and GAG elongation [170, 183, 190, 357]. 
7.1.2 Impact of growth factors on gene mRNA expression of PG and 
GAGs elongation enzymes in RF/6A cells 
Chapter 4 experimental procedures were designed to investigate the second aim of 
this study which was “to assess the effect of selected growth factors TGFβ, thrombin, PDGF 
and VEGF on mRNA expression of XT-1, ChPF, ChSy-1, ChGn-2, C4ST-1 and C4ST-2 
genes involved in PG synthesis and GAG elongation” [13, 170, 183, 314, 316, 360-366]”. 
The aim was to check whether growth factors stimulated the RF/6A cells  by measuring 
mRNA expression of genes responsible for PG synthesis and GAG elongation [13]. All the 
growth factors (TGFβ, thrombin and PDGF) except VEGF stimulated the mRNA expression 
of XT-1, ChPF, ChSy-1, ChGn-2, C4ST-1 and C4ST-2 genes at 4 hours in RF/6A cells [13]. 
The results of the mRNA expressions of the genesin Figure 4.8 were well correlated with 
the results from Chapter 3 in that VEGF showed no effect on PG synthesis or GAG 
elongation. Also the results showed similar trends  with TGFβ and thrombin resulting in the 
highest stimulation of PG synthesis and GAG elongation [13]. The findings in this section 
supported the study hypothesis; growth factors affect PG synthesis and GAG elongation and 
consequently may impact on early changes in AMD by altering ECM composition of RF/6A 
cells [13]. In addition, the results provided clarity on the role of genetic factors in PG 
synthesis and GAG elongation  during cell responses to the growth factors studied [13]. The 
findings in this study are consistent with other published data, although some were not 
conducted specifically in retinal endothelial cells but in VSMC [168, 170, 178, 232, 236, 
290, 358, 361]. The limitation of this study was that the growth factor IGF could have been 
studied here on the RPE cell but wasn’t studied due to experimental constraints [13]. The 
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previous results on the retinal endothelial cells led to the generation of a question about 
whether these growth factors (TGFβ, thrombin, PDGF, IGF and VEGF) could have had the 
same effect on the RPE cells which is the other layer adjacent to BM, the key site for early 
AMD [2, 31, 42, 93, 515].  
7.1.3 Effects of growth factors on PGs in RPE-19 cells 
The third aim of this thesis was investigated in chapter five and this was on studying 
the effects of TGFβ, thrombin, PDGF, IGF and VEGF on the release of PGs in the culture 
media of RPE-19 cells [2, 13]. The results showed that none of the growth factors TGFβ, 
PDGF, IGF and VEGF, stimulated 35S-sulfate labelled PGs release from the RPE-19 cells. 
The SDS-PAGE gel result of experiments conducted with these growth factors showed no 
appearance of bands of interest (PGs) (100-200 kDa). Only thrombin in Figure 5.5, 
stimulated the release of 35S-sulfate labelled PGs from the cell surfaces showing two bands 
of unknown PGs, approximately 260-340 kDa on SDS-PAGE gel. Thrombin time course 
studies showed that in 4-hour experiments, the peak band of PGs was reached at 1 hour 
(Figure 5.9). The observation that there was a lack of response of the RPE-19 cells to the 
growth factors TGFβ, PDGF, IGF and VEGF was unexpected. This could be due to the 
nature and role of the RPE, in that RPE-19 cells can transport these molecules to other cells 
without the need to use the molecules inside the cells [154, 183, 256, 259, 280, 316, 360, 
425, 426, 535]. The band corresponding to PGs that resulted from the thrombin treatment 
was due to a mechanism other than the stimulation of the RPE to synthesize PGs. This was 
because cells need approximately 20 hours for complete PG synthesis [170, 233, 427, 428]. 
The limitation of this study was that the characterization of released PGs which was out of 
the scope of this study. The results of thrombin mediated release of PGs from the cell surface, 
which is termed PGs shedding, raised questions on whether the mechanism of the shedding 
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of PGs was a receptor-mediated or protease mediated effect of thrombin [194, 223, 435, 438, 
461-463]. 
7.1.4 Mechanism of shed PGs released from RPE-19 cells 
The fourth aim of this thesis was investigated in Chapter 6 and this was to study the 
effect of thrombin on the shedding of PGs in RPE-19 cells and to explore the mechanisms 
underpinning the shedding process. Was the shedding of PGs due to thrombin proteolytic 
activity or a PAR-1 mediated process? [222, 439, 444, 466, 467, 484]. The results showed 
that only thrombin stimulated PG associated 35S-sulfate release and the peak production of 
shed PG of approximately 260-340 kDa was at 1 hour and 3 U/ml concentrations. The other 
GPCR agonists angiotensin II and endothelin-1 did not generate shed PGs (Figure 6.4). None 
of the PAR-1 mechanism related substances used (E5555, SCH 79797, GM6001, UBO-QIC 
and TRAP were able to block thrombin action. Only lepirudin (800 U/ml) the DTI in Figure 
6.11 resulted in blockage of thrombin PGs associated 35S-sulfate released into the media. 
This confirmed that the process of thrombin induced shedding of PGs was not mediated via 
PAR-1, but rather due to the unique thrombin cleavage property of proteolytic activity [215, 
217, 436, 479-482]. Most studies reported PG shedding as a process mediated via PAR-1, 
which the finding of this study contradicts [12, 222, 461]. Some other studies agree with our 
finding in that they described the shedding as a body defence mechanism with sulfated PGs 
scavenging unwanted, harmful pro-inflammation substances such as chemokines and 
proteases [530, 536]. Another study had reported that PG shedding was due to thrombin 
proteolytic activity. This study indicated that the role of HSPGs was to present the growth 
factors to their receptors and that HSPGs were involved in the accumulation of growth 
factors in the ECM [222, 497, 530]. The limitation of this section is that it would have been 
more informative in terms of getting better clarity on a shedding mechanism This would 
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have provided the necessary information to carry out trials with other proteases such as 
pepsin, trypsin and plasmin [445, 476, 537]. This was not possible due to time constraints. 
The novel results obtained in this study were surprising and unexpected considering 
the information currently available in the scientific literature. VEGF for example, did not 
show any effect on the synthesis of PGs or GAG elongation despite that fact that it is targeted 
in AMD treatments and therapy [2, 13]. The results obtained from the RPE cells in which 
cell surface PG shedding occurred due to thrombin proteolytic activity was interesting. These 
results were totally different to what was expected in with PG synthesis and GAG elongation 
in retinal endothelial cells. The results were very exciting and it could shift the therapy 
research focus to new areas. 
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7.2 Significance and importance of the findings to AMD  
Growth factors such as TGFβ, thrombin, PDGF and IGF stimulated retinal 
endothelial cells to secrete PGs, as evident by an increase in incorporation of 35S-sulfate and 
the appearance of a band corresponding to PGs around 100-120 kDa [13, 190, 538]. These 
secreted PGs constitute a major component of the ECM [149, 450, 539]. PGs with elongated 
GAG are larger and may have some difficulties passing through BM which could result in 
accumulation of elongated GAG and the formation of drusen [2, 3, 48, 49, 60, 106, 107, 112, 
532]. It has been reported that PGs are found in fluid of AMD eye [396, 540]. The PGs 
secreted by the retinal endothelial cells in this study could have varying degrees of sulfation 
and sulfated GAG are very reactive, binding to many components of the ECM including 
lipids [154, 190, 357, 399, 515, 541, 542]. Considering these findings, the hypothesis that 
growth factors play an important role in early AMD is supported, as PGs are part of the 
drusen components and part of the cellular materials that cause BM thickening [53, 93, 310, 
515]. In addition, the interrelation of PGs, GAG elongation and growth factors observed in 
this study is an important link leading to early changes in AMD [2, 13, 452]. This is the stage 
where if the above-mentioned interrelation was controlled, the progression of the disease 
could be limited or reversed [2, 13, 452]. The accumulation of PGs is a manifestation of the 
alteration of the ECM matrix and an indication of early morphological changes in the AMD 
site in BM [53, 93, 310, 432]. The morphological changes involve retinal endothelial and 
epithelial cells as evident by the formation of drusen and GA [60, 106, 114, 310].  
VEGF has been targeted in many treatments and therapy strategies [130, 543, 544]. 
However, VEGF as shown by the results in this thesis, had no effect on PGs which are one 
of the most important constituents implicated in the early stages of waste accumulation [11, 
68, 94, 295, 448]. Since VEGF has no effect on the secretion of PGs or GAG elongation, 
itmay only be involved in the late stages of AMD.The role of VEGF is in CNV and blood 
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vessel formation and penetration [13, 42, 532]. Although VEGF may not have affected the 
secretion of PGs, VEGF secretion might be affected by the accumulation of sulfated PGs 
[94, 545]. It has been reported that, these sulfated PGs at a certain level can trigger the cells 
to secret VEGF and the growth of blood vessels to open channels for waste movement [94, 
544]. The role of VEGF in AMD can represent the mile stone change that takes the disease 
to the late stage [94, 385, 546].  
The PGs secreted in the retinal endothelial cells in response to the stimulation 
driven by TGFβ, thrombin and PDGF application require the participation of many genes 
and expression of enzymes involve in PGs synthesis and GAG elongation [13, 170, 232, 
236]. This study explored the effect of TGFβ, thrombin, PDGF and IGF individually with 
six major genes mRNA expression of XT-1, ChPF, ChSy-1, ChGn-2, C4ST-1 and C4ST-2. 
These genes are thought to be important for the expression of enzymes required in PGs 
synthesis, GAG synthesis and elongation [13, 170, 183, 190, 232, 236, 365].  
TGFβ application resulted in the highest mRNA expression of all the four-
glycosyltransferase gene, XT-1, ChPF, ChSy-1 and ChGn-2. Thrombin also stimulated the 
mRNA expression of these four genes but to a lesser extent [13]. Interestingly, thrombin 
application resulted in the highest mRNA expression of the two sulfotransferase gene C4ST-
1 and C4ST-2 among all the other growth factors [358, 365]. This showed that thrombin 
treatment stimulated the synthesis of highly sulfated PGs which consequently became highly 
negatively charged and more susceptible to lipid binding and GAGs elongation [188, 315, 
362, 515]. 
 PDGF stimulated the mRNA expression of only XT-1, ChPF, ChSy-1 genes but 
not the ChGn-2 gene. With the sulfotransferases, it only stimulated the mRNA expression 
of the C4ST-1 gene but not the C4ST-2 gene. This could lead to a PDGF driven low level 
production of PGs with less sulfation with these kind of PGs having lower effects on the 
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development of early AMD [287]. PDGF stimulated the mRNA expression of genes 
encoding less sulfated, less reactive PGs which were less susceptible to GAG elongation and 
lipid binding [232, 236, 515]. It is possible that these PGs synthesised by the effect of PDGF, 
are different in their type in comparison to the type that have TGFβ binding affinity and 
inhibit its activity [547]. PDGF can compete with angiogenesis on HS depriving 
angiogenesis access to HS. Reduced angiogenesis access to HS leads to less adhesion to the 
cells with a lethal outcome in contrast to an observed CNS development when access to HS 
was not impeded [288, 293, 548]. The imbalance in growth factor production is often first 
initiated by AMD risk factors such as aging, genetics and smoking [124, 390, 549, 550]. 
This leads to tissue insult and an increase in the production of PGs. This increase can later 
cause the thickening of the BM because of elongated GAGs in PGs and enhanced binding to 
LDL [2, 52, 117, 390, 515]. HS presence is probably due to its synthesis in the choroidal 
endothelial cells.  
VEGF application did not stimulate mRNA expression of any genes which was in 
agreement with the trend observed in earlier results. HS plays a crucial role in blood vessel 
formation [390, 551]. Nevertheless, HS is involved in angiogenesis and it interacts with 
growth factors involved in the angiogenesis process [545, 552]. Alterations of the balance 
between the positive and negative regulators of angiogenesis result in over-proliferation of 
capillary endothelial cells leading to neovascularization [543, 550, 552]. The retina is known 
to exert a biochemical effect via diffusion of compounds which causes vascular growth with 
the production of these compounds being linked to retinal ECM [550, 553, 554]. HS is 
responsible for the diffusion and in turn the availability of PDGF, which affects pericyte 
growth around the newly formed capillaries [293, 550].  HS serves as a maintenance factor 
for neuronal parts of the eye in addition to its role as regulator of the growth of ocular blood 
vessels [547, 552]. HS anti-angiogenic property is selective because it is effective against 
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newly formed vessels but has no effect on the already formed vessels that prevent vessel 
damage [293, 555, 556]. HS also has some influence at the cellular, tissue and organismal 
level due to its action as core receptors for various tyrosine kinase-type growth factor 
receptors which occur in two ways. Firstly, it changes the duration of their signals and 
secondly, it lowers their activation thresholds [399, 557]. PDGF receptors are stabilized and 
up regulated by HS with an age-related reduction in the production of the gene encoding 
PDGF in many types of cells [558, 559].  
The angiogenesis and micro vascular permeability can be affected by a synergistic 
effect or an imbalance of growth factors including FGF, EGF, IGF, PDGF, TGFβ and 
thrombin. [475, 547, 550, 559]. This could be indirectly through the up regulation or down 
regulation of VEGF expression in different cells type including smooth muscle cells and 
fibroblasts [383-385, 553, 560]. The newly synthesised PGs contain 75% CS/DS and 25% 
HS. Results from this study have revealed the roles of these molecules in the early and late 
stages of AMD, and the involvement of growth factors and and ECM in these two stages 
[47, 550, 561, 562]. Targeting mRNA expression of specific genes could be useful in 
manipulating and controlling the composition of the ECM [547, 563].    
Although the results of the growth factor application in the RPE experiments were 
unexpected, they reflected the differences in the functions of the retinal endothelial and 
epithelial cells [262]. None of the growth factors explored in this study resulted in the 
synthesis of PGs except thrombin, whose application resulted in the appearance of a band 
corresponding to PGs. It was therefore important to investigate the thrombin-related 
mechanisms responsible for the generation of this PGs band; whether the shedding of PG 
was via PAR-1 or the proteolytic activity of thrombin. This investigation would also provide 
useful information on the importance of the products of this process to ECM composition, 
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the functionality of other molecules including growth factors and the possible effect on 
inflammation or tissue injury [550, 563]. 
The absence of PG synthesis response from RPE interactions with selected growth 
factors is interesting and can be interpreted considering the circumstances under which the 
RPE shed PGs [262, 263, 310]. Shedding is a defence mechanism by the RPE in response to 
inflammation or tissue injury [222, 497, 550] and the RPE needs a fast mechanism to shed 
cell surface PG for defensive purposes. As the synthesis of PG is a process that needs more 
than 20 hours to be fully completed [170, 233, 427, 428], this cannot be the appropriate 
mechanism needed for a fast response [263]. The results in this study showed that thrombin 
can shed the cell surface PGs in a very fast manner, more rapidly than synthesizing new 
sulfated PG [263]. The RPE also needs the shed highly sulfated PGs as a binder and carrier 
of growth factors to locations where the RPE requires their functions [549, 563]. The HSPGs 
shed products are soluble short molecules that can move fast and permeate between cells 
because of their solubility and size [221, 457, 519, 564].  
Shedding is an important mechanism that affects both the early stage of AMD as 
explained above or in the late stage when the BRB breaks down and thrombin comes in 
direct contact with the cell surface PGs [58, 300, 565-567]. The likely excessive shedding 
of PGs and mass transport of growth factors can affect the functions of various surrounding 
cells and consequently speed up disease progression with total blindness being a possible 
final outcome [300, 519, 544, 565, 568]. Taking into consideration the RPE need for a fast 
process to shed PGs, thrombin proteolytic activity is a faster mechanism than the thrombin 
PAR-1 mediated mechanism. The location of the RPE could also be contributed to RPE’s 
inability to synthesise PGs. This is because the only possible waste discharge route is through 
BM and production of PGs in the RPE might constitute a problem for BM and hence the 
AMD disease [90, 385, 515, 519]. The cell surface PG shed products can bind to growth 
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factors utilizing their HS property thereby playing key roles in their transportation, possibly 
having some impacts on their availability, functionality and the progression of AMD [293, 
547, 563]. 
The findings in this study shed light on the role of growth factors on AMD as growth 
factors impact on the synthesis and release of sulphated GAGs that capable of bind to lipids 
to further cause BM thickening before it a advance to late stages. Thrombin shedding results 
in active sulphated GAGs that capable of bind to lipids and also contribute to the 
accumulation of waste and may be the formation of other longer molecules.   
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7.3 Future perspectives  
The synergistic effect of growth factors has the potential to open new areas of 
research and therapy. Therefore, future research approaches should focus on the 
harmonization of the actions of the following growth factors; TGFβ, thrombin, PDGF and 
IGF. This does not mean that the individual effect is not important. It is important, especially 
in the case of thrombin when it affects the synthesis of PGs and GAGs elongation in retinal 
endothelial cells and shed PGs are released in retinal epithelial cells. However, assays 
combining the growth factors would allow for a better qualification of any synergistic benefit 
of this approach. It should be a promising approach to utilize both thrombin activity and anti-
thrombin in future research in addition to studying the genes involved in thrombin secretion. 
7.3.1 PGs synthesis and GAGs elongation in retinal endothelial cells 
 The results from this study showed that TGFβ and thrombin were involved in PG 
synthesis and GAG elongation and their application resulted in the highest response in 
retinal endothelial cells. Future research should focus on ways to stop or reduce TGFβ 
and thrombin such as anti-TGFβ and anti-thrombin.  
 TGFβ, thrombin, PDGF and IGF all stimulated PG synthesis and GAG elongation at 
varying levels. Conducting characterization of PGs in future research is important as it 
would allow for the correlation of these PGs to lipid binding capacity and BM thickening. 
 The unexpected result from the application of VEGF indicates that future research should 
validate our findings in trials with other growth factors related to AMD or found in the 
eye. mRNA expression of XT-1, ChPF, ChSy-1, ChGn-2, C4ST-1 and C4ST-2 genes, 
enzyme protein assays and gene knock out in real intact fresh tissue including that of 
humans should also be explored. 
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 Other genes involved or related to the synthesis of PGs and GAG elongation should also 
be investigated in future studies, as well as the GAG synthesizing enzyme protein 
expression experiments for all the growth factors and genes used in this study. 
7.3.2 Thrombin induced the release of shed PGs in RPE cells 
 The results showed that thrombin induced the release of shed cell surface PGs and it 
might yield soluble molecules that have the HSPGs property and could possibly bind to 
growth factors. PGs characterization of these molecules would provide greater insight 
into the changes in the RPE that are related to AMD disease.  
 The possible role of PGs shed product in binding to lipids warrants further investigation 
with respect to the lipid binding capacity of these molecules and drusen composition. 
 The mRNA expression of GAG synthesis and elongation enzyme encoding genes should 
be investigated with thrombin in order to explore the ability of the RPE to mediate GAG 
synthesis and elongation.  
 Other DTIs from other inhibitor classes should be studied with thrombin as a target for 
future therapy research. 
These experiments should be conducted in both in vivo and in vitro. From a 
scientific point of view, the PGs synthesized in the early stage of AMD in the retinal 
endothelial cells and/or the PGs released from the retinal epithelial cells (especially HSPGs), 
should be characterized and the possibility of their use as tools to diagnose the stages of the 
disease should be evaluated. The levels of growth factors in the ECM can also be used as 
indication for the stages of the disease.  
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